
<html lang="en"     class="pb-page"  data-request-id="9a652f04-988f-4d5f-9beb-edbea7da97b1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-14;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b00393;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections" /></meta><meta name="dc.Creator" content="Yahui  Huang" /></meta><meta name="dc.Creator" content="Guoqiang  Dong" /></meta><meta name="dc.Creator" content="Huanqiu  Li" /></meta><meta name="dc.Creator" content="Na  Liu" /></meta><meta name="dc.Creator" content="Wannian  Zhang" /></meta><meta name="dc.Creator" content="Chunquan  Sheng" /></meta><meta name="dc.Description" content="Clinically, leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens. Herein, a novel therapeutic strategy was developed in ..." /></meta><meta name="Description" content="Clinically, leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens. Herein, a novel therapeutic strategy was developed in ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 25, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00393" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2018 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00393" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00393" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00393" /></link>
        
    
    

<title>Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00393" /></meta><meta property="og:title" content="Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0020.jpeg" /></meta><meta property="og:description" content="Clinically, leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens. Herein, a novel therapeutic strategy was developed in which a small molecule can simultaneously treat leukemia and invasive fungal infections (IFIs). Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematological cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections. In particular, compound 20a, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections. This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Clinically, leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens. Herein, a novel therapeutic strategy was developed in which a small molecule can simultaneously treat leukemia and invasive fungal infections (IFIs). Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematological cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections. In particular, compound 20a, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections. This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0020.jpeg" /></meta><meta name="twitter:title" content="Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00393"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00393">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00393&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00393&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00393&amp;href=/doi/10.1021/acs.jmedchem.8b00393" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6056-6074</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00373" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00403" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yahui Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yahui Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yahui++Huang">Yahui Huang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Guoqiang Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guoqiang Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guoqiang++Dong">Guoqiang Dong</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Huanqiu Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huanqiu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmaceutical Science, Soochow University, Suzhou 215123, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huanqiu++Li">Huanqiu Li</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Na Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Na Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Na++Liu">Na Liu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Wannian Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wannian Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wannian++Zhang">Wannian Zhang</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Chunquan Sheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunquan Sheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#24574c414a43475564574949510a4140510a474a"><span class="__cf_email__" data-cfemail="12617a777c75716352617f7f673c7776673c717c">[emailÂ protected]</span></a>. Phone/Fax: +86-21-81871239.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunquan++Sheng">Chunquan Sheng</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9489-804X" title="Orcid link">http://orcid.org/0000-0001-9489-804X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00393&amp;href=/doi/10.1021%2Facs.jmedchem.8b00393" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6056â6074</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 25, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 March 2018</li><li><span class="item_label"><b>Published</b> online</span>25 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 July 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editorsâ Choice" /></img><span>ACS Editorsâ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00393"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5877</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">46</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00393" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yahui&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Guoqiang&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Huanqiu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Na&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Wannian&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Chunquan&quot;,&quot;last_name&quot;:&quot;Sheng&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;6056-6074&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00393&quot;},&quot;abstract&quot;:&quot;Clinically, leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens. Herein, a novel therapeutic strategy was developed in which a small molecule can simultaneously treat leukemia and invasive fungal infections (IFIs). Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematological cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections. In particular, compound 20a, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections. This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00393&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00393" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00393&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00393" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00393&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00393" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00393&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00393&amp;href=/doi/10.1021/acs.jmedchem.8b00393" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00393" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00393" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26pmid%3D29940115%26genre%3Darticle%26aulast%3DHuang%26date%3D2018%26atitle%3DDiscovery%2Bof%2BJanus%2BKinase%2B2%2B%2528JAK2%2529%2Band%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BDual%2BInhibitors%2Bas%2Ba%2BNovel%2BStrategy%2Bfor%2Bthe%2BCombinational%2BTreatment%2Bof%2BLeukemia%2Band%2BInvasive%2BFungal%2BInfections%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290677" title="Toxicological synergy">Toxicological synergy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/14" title="Go to Volume 61, Issue 14"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/jmcmar.2018.61.issue-14/20180726/jmcmar.2018.61.issue-14.largecover.jpg" alt="Go to Volume 61, Issue 14"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Clinically, leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens. Herein, a novel therapeutic strategy was developed in which a small molecule can simultaneously treat leukemia and invasive fungal infections (IFIs). Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematological cell lines and excellent synergistic effects with fluconazole to treat resistant <i>Candida albicans</i> infections. In particular, compound <b>20a</b>, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant <i>C. albicans</i> infections. This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Invasive fungal infections (IFIs) are life-threatening and often occur in immunocompromised hosts. Leukemia patients undergoing chemotherapy, hematopoietic stem cell transplantation (HSCT), or immunosuppressive therapy are highly vulnerable to IFIs.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> According to National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology, primary antifungal prophylaxis (azoles, amphotericin B, or echinocandins) should be used in high-risk patients, especially those with acute myeloid leukemia (AML) and graft versus host disease (GVHD). However, severe drug resistance has been observed for antifungal agents. In recipients of HSCT, the mortality associated with IFIs still remains high. Tyrosine kinase inhibitors have been widely used in the targeted therapy of leukemia.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Despite the success, clinically available therapeutics generally suffered from limited efficacy and drug resistance. Thus, developing new generation of kinase inhibitors for targeted therapy remains an active research area. In particular, a kinase inhibitor that can synergize with antifungal agents and improve their potency to treat resistant IFIs is highly desirable. However, the discovery of such a difunctional molecule is challenging.</div><div class="NLM_p">The Janus kinases (JAK1, JAK2, JAK3, and TYK2) belong to the family of intracellular protein tyrosine kinases, which play essential roles in the signaling of a variety of cytokines.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Activation of JAKs by different cytokines results in phosphorylation and dimerization of the STAT (signal transducers and activators of transcription) proteins, which further translocate to the nucleus and activate gene transcription.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The JAK/STAT signaling axis is associated with diverse biological functions including inflammation, immune function, and hematopoiesis.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> JAK inhibitors have been extensively investigated as new therapeutics for the treatment of immune-inflammatory diseases (e.g., rheumatoid arthritis, RA) and cancer (e.g., leukemia, lymphoma, and solid tumor).<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6â8)</a> Currently, a number of pan-JAK and selective JAK inhibitors have been discovered.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Pan-JAK inhibitor tofacitinib<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> was approved for the treatment of RA, and JAK1/2 inhibitor ruxolitinib (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> was marketed to treat myelofibrosis and polycythemia vera. Among the four JAK subtypes, JAK2 was proven to be critical for the growth and progression tumor. JAK2 inhibitors have been evaluated in clinical trials for the treatment of a wide spectrum of hematological malignancies as well as solid tumors.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, resistance of JAK2 inhibitors has been observed.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> To improve the therapeutic effects and reduce the risk of resistance, combinational drug therapy<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14â16)</a> or the development of JAK2-based multitargeting antitumor agents<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> offer new opportunities.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Chemical structures and pharmacophore of JAK2 inhibitors; (B) chemical structure and pharmacophore of HDAC inhibitors; (C) design of JAK2-HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a family of epigenetic enzymes, histone deacetylases (HDACs) remove acetyl groups from lysine on histones and other proteins, which play an essential role on various cellular functions including gene regulation; transcription; and cell proliferation, differentiation, and death. The over-expression of HDACs are observed in different human cancers, and thus, they are regarded as promising antitumor drug targets.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Up to now, four HDAC inhibitors, namely vorinostat (SAHA, <b>2</b>), romidepsin, belinostat, and panobinostat, have been approved for the treatment of hematologic cancer.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23">(20â23)</a> Similar to JAK2, HDAC-based multitargeting antitumor agents have achieved great success in achieving higher efficacy, broader antitumor spectrum, and better safety profiles.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">Clinically, specific drug combinations have been widely used in cancer therapy. However, drug cocktails often suffer from complicated dose (or schedule) design as well as poor patient compliance.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In contrast, a single multitargeting molecule has obvious advantages in terms of synergistic antitumor effects, more-predictable and -favorable pharmacokinetic (PK) profiles, and reduced compliance difficulties and drugâdrug interactions.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Recent evidence suggested that the design of dual JAK2/HDAC inhibitors could be a promising strategy for the treatment of leukemia, solid tumor, and other related indications.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Both JAK2 and HDAC inhibitors demonstrated similar clinical efficacy, have synergistic effects, and can be used in combination therapy.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Dymockâs group further confirmed that dual JAK-HDAC pathway inhibition was achieved with a single molecule.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Despite these advancements, the therapeutic value of dual JAK-HADC inhibitors remains to be further explored. In particular, in vivo potency has not been achieved by the reported dual JAK2-HDAC inhibitors due to unfavorable PK properties.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a></div><div class="NLM_p last">Herein, in vivo therapeutic values of JAK2-HADC dual inhibitors were confirmed for the first time. Novel JAK2-HADC dual inhibitors were identified, which showed excellent potency in combinational treatment of AML and resistant <i>Candida albicans</i> infections, providing a new strategy for the clinical therapy of leukemia along with IFIs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure-Based Design of JAK2/HDAC Dual Inhibitors</h3><div class="NLM_p last">Inspired by our previous efforts in multitargeting drug design,<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30â32)</a> a series of novel JAK2-HADC inhibitors were designed according to synergistic effect between the two targets.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Generally, the pharmacophore of JAK2 inhibitors consists of a hinge-region binder (typically an aminopyrimidine), two hydrophobic groups (phenyl group), and a solvent-exposed part (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> that serves as a template in designing dual inhibitors. Because the aminopyrimidine of JAK2 inhibitor CYT-387 (<b>1</b>) has been proven to be responsible for the JAK2 inhibitory activity, the motif was maintained in designing the dual inhibitors. HDAC inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B) generally consist of a hydrophobic cap group, a linker (alkyl, alkenyl, or aryl), and a zinc-binding group (ZBG, hydroxamic acid or benzamide).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Given that the cap group is flexible and can be replaced by other moieties to generate HDAC inhibitors, the first series of dual inhibitors (<b>8</b>, <b>10</b>, and <b>12a</b>,<b>b</b>) were designed by merging the core group of <b>1</b> with the ZBG motif (hydroxamic acid or benzamide) through various linkers (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C). Moreover, on the basis of the fact that <i>N-</i>phenylmethanesulfonamide derivatives of compound <b>1</b> exhibited similar JAK2 inhibition,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> the second series of JAK2-HDAC inhibitors (compounds <b>16</b>, <b>18</b>, and <b>20a</b>â<b>h</b>) were designed with the <i>N</i>-cyanomethylbenzamide/<i>N</i>-phenylmethanesulfonamide replacement. Finally, considering that a minor substitution in the hydrophobic domain of JAK2 inhibitor <b>1</b> would be tolerated, hydroxamic acid or benzamide was introduced at this position to achieve dual inhibition toward both targets (compounds <b>24</b> and <b>26</b>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Chemical synthesis of JAK2-HDAC dual inhibitors are depicted in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a><named-content content-type="anchor" rid="sch2" type="simple"></named-content>â<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Starting from 2,4-dichloropyrimidine (<b>3</b>), intermediate <b>7</b> was prepared via a regioselective Suzuki reaction and an aniline displacement reaction according to the reported methods<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The treatment of compound <b>7</b> with freshly prepared hydroxylamine methanol solution gave target compound <b>8</b> or, with LiOH, yielded acid <b>9</b>. The condensation of <b>9</b> with <i>o</i>-phenylenediamine afforded target compound <b>10</b> or, with different amino-esters, yielded esters <b>11a</b>,<b>b</b>, which were subsequently reacted with hydroxylamine methanol solution to give target compounds <b>12a</b>,<b>b</b>. Using a similar protocol, <i>N</i>-phenylmethanesulfonamide analogues (<b>16</b>, <b>18</b>, and <b>20a</b>â<b>h</b>) were obtained according to the procedures outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. As shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, target compounds <b>24</b> and <b>26</b> were prepared using the conditions similar to those for compounds <b>8</b> and <b>10</b>, respectively.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Toluene/<i>n-</i>PrOH, 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 100 Â°C, 55%; (b) <b>6</b>, TsOHÂ·H<sub>2</sub>O, 120 Â°C, 3 Days, 82%; (c) NH<sub>2</sub>OK, Anhydrous CH<sub>3</sub>OH, 4 h, 56%; (d) LiOH, THF/H<sub>2</sub>O, Reflux, 4 h, 85%; (e) <i>o</i>-Phenylenediamine, HATU, DIPEA, DMF, RT, 4 h, 63%; (f) Various Amino-Esters, HATU, DIPEA, DMF, RT, 4 h, 58%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Toluene/<i>n-</i>PrOH, 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 100 Â°C, 51%; (b) <b>6</b>, TsOHÂ·H<sub>2</sub>O, 120 Â°C, 3 Days, 77%; (c) NH<sub>2</sub>OK, Anhydrous CH<sub>3</sub>OH, 4 h, 48%; (d) LiOH, THF/H<sub>2</sub>O, Reflux, 4 h, 82%; (e) <i>o</i>-Phenylenediamine, HATU, DIPEA, DMF, RT, 4 h, 56%; (f) Various Amino-Esters, HATU, DIPEA, DMF, RT, 4 h, 57%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Toluene/<i>n-</i>PrOH, 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 100 Â°C, 48%; (b) 4-Morpholinoaniline, TsOHÂ·H<sub>2</sub>O, 120 Â°C, 3 Days, 73%; (c) NH<sub>2</sub>OK, Anhydrous CH<sub>3</sub>OH, 4 h, 62%; (d) LiOH, THF/H<sub>2</sub>O, Reflux, 4 h, 86%; (e) <i>o</i>-Phenylenediamine, HATU, DIPEA, DMF, RT, 4 h, 51%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Enzyme Inhibitory Activities and in Vitro Antitumor Potency of JAK2-HDAC Dual Inhibitors</h3><div class="NLM_p">Initially, the JAK-HDAC dual inhibitors were assayed against JAK2 and HDAC1 using compounds <b>1</b> and <b>2</b> as reference drugs. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the first series of dual inhibitors (compounds <b>8</b>, <b>10</b>, and <b>12a</b>,<b>b</b>) exhibited excellent inhibitory activity against JAK2 (IC<sub>50</sub> range: 4â16 nM), which were better than compound <b>1</b> (IC<sub>50</sub> = 41 nM). However, their activity against HDAC1 was moderate (IC<sub>50</sub> range: 1.7â23.6 Î¼M). Then, their inhibitory activities against three human leukemia cell lines HL60, K562, and HEL were evaluated using the CCK-8 assay. However, only compound <b>10</b> demonstrated moderate inhibitory activity against the HEL cell line (IC<sub>50</sub> = 6.6 Î¼M).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzyme Inhibition and in Vitro Antitumor Activity of Target Compounds <b>8</b>, <b>10</b>, and <b>12a</b>,<b>b</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0014.gif" alt="" id="GRAPHIC-d7e664-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">NT, not tested.</p></div></div><div></div></div><div class="NLM_p">Next, the nitrile carboxamide group of the first series of compounds was replaced by <i>N</i>-phenylmethanesulfonamide. As a result, compounds <b>16</b>, <b>18</b>, and <b>20a</b>â<b>c</b> generally displayed improved HDAC1 inhibitory activity (IC<sub>50</sub> range: 0.25â2.9 Î¼M), while excellent JAK2 inhibitory activity was retained. More importantly, their antitumor activities were also increased. For the ZBG, hydroxamic acid derivative <b>20a</b> showed better antitumor activity than benzamide derivative <b>18</b>. Thus, more derivatives containing various alkyl linkers were investigated (compounds <b>20d</b>â<b>h</b>). Enzyme assays showed that their JAK2 and HDAC1 inhibitory activities were further improved (JAK2 IC<sub>50</sub> range: 1â3 nM; HDAC1 IC<sub>50</sub> range: 0.018â9 Î¼M). SAR studies indicated that the HDAC1 inhibitory activity increased along with the elongation of the linker (<b>20h</b> > <b>20g</b> > <b>20f</b> > <b>20e</b> > <b>20d</b>). Among the second series of dual inhibitors, compound <b>20a</b> exhibited the best inhibitory activity against HEL cells (IC<sub>50</sub> = 0.34 Î¼M), which was more potent than JAK2 inhibitor <b>1</b> (IC<sub>50</sub> = 2.3 Î¼M) and HDAC inhibitor <b>2</b> (IC<sub>50</sub> = 0.86 Î¼M), although its JAK2 and HDAC inhibitory activities were less potent than the two inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The combination of <b>1</b> and <b>2</b> were also evaluated to investigate the synergic effect between JAK and HDAC inhibitors. Compounds <b>1</b> and <b>2</b> (1:1) showed improved antitumor potency than that of <b>1</b> and <b>2</b> dosed alone against HL60 and K562 cells. Thus, JAK and HDAC inhibitors showed synergic effect in cancer cells. Moreover, compound <b>20a</b> showed better HEL inhibitory activities than the combination of <b>1</b> and <b>2</b> (IC<sub>50</sub> = 1.51 Î¼M). These results indicated that the cytotoxicity might be the consequence of the synergism of the JAK2 and HDAC inhibition.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzyme Inhibition and in Vitro Antitumor Activity of Target Compounds <b>16</b>, <b>18</b>, and <b>20a</b>â<b>h</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0016.gif" alt="" id="GRAPHIC-d7e800-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0017.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">NT, not tested.</p></div></div><div></div></div><div class="NLM_p">Finally, ZBGs (hydroxamic acid or benzamide) were used to replace the <i>N</i>-cyanomethylbenzamide group in JAK2 inhibitor <b>1</b> (compounds <b>24</b> and <b>26</b>). As listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the ZBGs were important for the inhibition of enzyme and leukemia cell lines. Compound <b>24</b> containing hydroxamic acid as the ZBG displayed good inhibitory activity toward HDAC1 (IC<sub>50</sub> = 0.16 Î¼M) and JAK2 (IC<sub>50</sub> = 0.085 Î¼M), and the antitumor activities were comparable with lead compounds <b>1</b> and <b>2</b>. In contrast, benzamide derivative <b>26</b> only exhibited moderate JAK2 inhibitory activity (IC<sub>50</sub> = 0.11 Î¼M) and was totally inactive in inhibiting HDAC1 and cell proliferation.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Enzyme Inhibition and in Vitro Antitumor Activity of the Target Compounds <b>24</b> and <b>26</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0018.gif" alt="" id="GRAPHIC-d7e861-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0019.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">NT, not tested.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> JAK2/HDAC1 Dual Inhibitors and Excellent Synergistic Effect with FLC against Resistant <i>C. albicans</i> Isolates</h3><div class="NLM_p">HDACs are important regulators of heat shock protein 90 (Hsp90), which is essential for fungal survival and is associated with antifungal drug resistance.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> HDAC inhibitors were reported to enhance the potency of antifungal agents (e.g., azoles and echinocandins) against various fungal pathogens including resistant isolates.<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37â39)</a> Thus, the antifungal activity and synergistic effects of JAK2/HDAC dual inhibitors were evaluated against FLC-resistant <i>C. albicans</i> isolates 0304103, 100, and 071922. The antifungal activity was expressed as the minimum inhibitory concentration that achieves 50% of inhibition (MIC<sub>50</sub>) using the checkerboard microdilution assay according to the methods of the CLSI (formerly NCCLS)(M27-A).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The synergistic effects were evaluated by the fractional inhibitory concentration (FIC) index, and the synergism was defined by FIC index of â¤0.5.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, most of the target compounds were inactive to three FLC-resistant <i>C. albicans</i> isolates when used alone (MIC<sub>50</sub> > 64 Î¼g/mL). Only compounds <b>20d</b>â<b>f</b> showed moderate antifungal activity against FLC-resistant <i>C. albicans</i> 0304103 (MIC<sub>50</sub> = 32 Î¼g/mL). When used in combination with FLC, a majority of compounds (<b>8</b>, <b>12a</b>, <b>16</b>, <b>20a</b>, <b>20c</b>â<b>h</b>, and <b>24</b>) exhibited excellent synergistic effects against the FLC-resistant <i>C. albicans</i> strain 0304103 with the FIC index ranging from 0.078 to 0.50. SAR studies indicated that compounds containing the benzamide ZBG (e.g., compounds <b>10</b>, <b>18</b>, and <b>26</b>) were devoid of the synergistic antifungal effects. HDAC inhibitor <b>2</b> and the combination of <b>1</b> and <b>2</b> also showed synergistic effects against <i>C. albicans</i> 0304103 strain, whereas the synergism was lost for strains 100 and 0710922. In contrast, obvious synergistic effect (FIC range: 0.039 to 0.5) was retained for dual inhibitors <b>8</b>, <b>16</b>, <b>20a</b>, <b>20c</b>â<b>e</b>, <b>20g</b>,<b>h</b>, and <b>24</b> against these resistant strains. Compounds <b>12a</b>, <b>20a</b>, <b>20g</b>,<b>h</b>, and <b>24</b> exhibited good synergism (FIC index range: 0.14 to 0.5). Considering the potent antitumor activity and promising antifungal profile of compounds <b>20a</b>, <b>20h</b>, and <b>24</b>, they were subjected for further evaluations.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antifungal Activity and Synergistic Effects of Target Compounds with FLC against Resistant <i>C. albicans</i> Isolates by the Microdilution Assay</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">strains</th><th class="rowsep1 colsep0" colspan="5" align="center">0304103 (MIC<sub>50</sub>, Î¼g/mL)</th><th class="rowsep1 colsep0" colspan="5" align="center">100 (MIC<sub>50</sub>, Î¼g/mL)</th><th class="rowsep1 colsep0" colspan="5" align="center">0710922 (MIC<sub>50</sub>, Î¼g/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">used alone</th><th class="rowsep1 colsep0" colspan="2" align="center">used in combination</th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">used alone</th><th class="rowsep1 colsep0" colspan="2" align="center">used in combination</th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">used alone</th><th class="rowsep1 colsep0" colspan="2" align="center">used in combination</th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">FLC</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">FLC</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">FIC index<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">FLC</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">FLC</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">FIC index</th><th class="colsep0 rowsep0" align="center">FLC</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">FLC</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">FIC index</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.039</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.078</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.02</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.01</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.03</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.25</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20c</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.078</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20d</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20e</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.50</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.26</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.50</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.50</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20h</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.01</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">0.51</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1 + 2</b> (1:1)</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.26</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.01</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">>64</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">1.06</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">FIC index is defined as the sum of MIC of each drug used in combination divided by the MIC of the drug used alone. Synergy and antagonism were defined by FIC indices of â¤0.5 and >4, respectively. An FIC index between 0.5 and 4 was considered indifferent.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Binding Mode of the JAK2-HDAC Dual Inhibitors</h3><div class="NLM_p">To investigate the binding mode of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> with JAK2 and HDAC1, molecular docking studies were performed. Compound <b>20a</b> bound with HDAC1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>, mainly through the linker and ZBG (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The hydroxamic acid of <b>20a</b> coordinated to the catalytic Zn<sup>2+</sup> of HDAC1 and formed two hydrogen bonds with Gly146 and His178, respectively. The hydrophobic cinnamamide group formed ÏâÏ stacking interactions with His178, Phe150, and Phe205. Moreover, the <i>N</i>-phenylmethanesulfonamide moiety formed three additional hydrogen bonds with Glu146, Lys143, and Ser148. Similarly, the ZBG of compound <b>20h</b> was engaged with a hydrogen boding network with Gly138, Asp176, and Tyr303 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). The <i>N</i>-phenylmethanesulfonamide group interacted with Glu146 through a hydrogen bond. For compound <b>24</b>, the hydroxamic acid moiety formed a coordination interaction and a hydrogen bond with Zn<sup>2+</sup> and Gly149, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). In addition, its aromatic linker and phenyl group in the cap formed ÏâÏ stacking interactions with Phe205. In contrast, the terminal <i>N</i>-(2-aminophenyl)benzamide of compound <b>26</b> forced the whole molecule located at the outside of the active site, which might be the reason why <b>26</b> was totally inactive toward HDAC1 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Figure S1</a>).</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed binding mode of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> in the active site of HDAC1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>, <b>AâC</b>) and in the ATP-binding site of JAK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AQC">4AQC</a>, <b>DâF</b>). The carbons of <b>20a</b>, <b>20h</b>, and <b>24</b> are colored in yellow, pink and orange, respectively. Oxygen atoms are colored in red and nitrogen atoms in blue. Hydrogen bonds are indicated with dashed lines. The figure was generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In JAK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AQC">4AQC</a><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>), the aminopyrimidine scaffold of compound <b>20a</b> formed hydrogen bonds to the backbone of Leu932 in the hinge region (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D). Its <i>N</i>-phenylmethanesulfonamide group formed an additional hydrogen bond with Asp994. Moreover, the linker and ZBG extended out of the binding site and formed hydrogen bonds with Asp939 and Arg980, respectively. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E,F, the binding modes of compounds <b>20h</b> and <b>24</b> with JAK2 were similar to that of <b>20a</b>, where hydrogen bonds between animopyrimidine and the backbone of Leu932 were observed. The <i>N</i>-phenylmethanesulfonamide and hydroxamic acid moiety of compound <b>20h</b> formed hydrogen bonds with Asp994 and Lys857, respectively. Moreover, an additional hydrogen bond was found between the hydroxamic acid group of compound <b>24</b> and Asn981.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell apoptosis induced by compounds <b>20a</b>, <b>20h</b>, and <b>24</b>. HEL cells were incubated with the indicated concentrations of <b>1</b>, <b>20a</b>, <b>20h</b>, and <b>24</b> for 48 h. Cells treated with DMSO were used for comparison. Data were represented as mean Â± standard deviation from three independent experiments. A single asterisks indicates <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001, as determined with a Studentâs <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vitro JAK and HDAC Isoform Selectivity of Compounds <b>20a</b>, <b>20h</b>, and <b>24</b></h3><div class="NLM_p">To obtain evidence for the JAK and HDAC isoform selectivity, compounds <b>20a</b>, <b>20h</b>, and <b>24</b> were evaluated against four JAK isoforms (JAK1, JAK2, JAK3, and TYK2) and five HDAC isoforms (HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8). As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, three compounds exhibited remarkable selectivity for JAK2 over other isoforms. For HDACs, surprisingly, three compounds displayed different selective profiles (Tables <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">S1</a>, and <a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">S2</a>). Compound <b>20a</b> showed good selectivity for HDAC6 (IC<sub>50</sub> = 46 nM), whereas compound <b>24</b> was observed to be a HDAC3-selective inhibitor (IC<sub>50</sub> = 45 nM). In contrast, compound <b>20h</b> showed similar inhibitory activity for HDAC1 and HDAC3 with an IC<sub>50</sub> value of 18 and 17 nM, respectively.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. JAK Isoform Profiling of Compounds <b>20a</b>, <b>20h</b>, and <b>24</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char="."><b>20a</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20h</b></th><th class="colsep0 rowsep0" align="center" char="."><b>24</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JAK1</b></td><td class="colsep0 rowsep0" align="char" char=".">359Â Â±Â 22</td><td class="colsep0 rowsep0" align="char" char=".">76Â Â±Â 3.5</td><td class="colsep0 rowsep0" align="char" char=".">69Â Â±Â 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JAK2</b></td><td class="colsep0 rowsep0" align="char" char=".">8.4Â Â±Â 0.7</td><td class="colsep0 rowsep0" align="char" char=".">2.2Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="char" char=".">85Â Â±Â 6.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JAK3</b></td><td class="colsep0 rowsep0" align="char" char=".">121Â Â±Â 13</td><td class="colsep0 rowsep0" align="char" char=".">144Â Â±Â 14</td><td class="colsep0 rowsep0" align="char" char=".">517Â Â±Â 27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>TYK2</b></td><td class="colsep0 rowsep0" align="char" char=".">46Â Â±Â 1.7</td><td class="colsep0 rowsep0" align="char" char=".">74Â Â±Â 6.4</td><td class="colsep0 rowsep0" align="char" char=".">419Â Â±Â 71</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. HDAC Isoform Profiling of Compounds <b>20a</b>, <b>20h</b>, and <b>24</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char="."><b>20a</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20h</b></th><th class="colsep0 rowsep0" align="center" char="."><b>24</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HDAC1</b></td><td class="colsep0 rowsep0" align="char" char=".">1100Â Â±Â 140</td><td class="colsep0 rowsep0" align="char" char=".">18Â Â±Â 6.0</td><td class="colsep0 rowsep0" align="char" char=".">160Â Â±Â 32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HDAC2</b></td><td class="colsep0 rowsep0" align="char" char=".">7472Â Â±Â 856</td><td class="colsep0 rowsep0" align="char" char=".">132Â Â±Â 28</td><td class="colsep0 rowsep0" align="char" char=".">1704Â Â±Â 115</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HDAC3</b></td><td class="colsep0 rowsep0" align="char" char=".">234Â Â±Â 31</td><td class="colsep0 rowsep0" align="char" char=".">17Â Â±Â 1.2</td><td class="colsep0 rowsep0" align="char" char=".">45Â Â±Â 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HDAC6</b></td><td class="colsep0 rowsep0" align="char" char=".">46Â Â±Â 1.7</td><td class="colsep0 rowsep0" align="char" char=".">74Â Â±Â 6.4</td><td class="colsep0 rowsep0" align="char" char=".">419Â Â±Â 71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HDAC8</b></td><td class="colsep0 rowsep0" align="char" char=".">6065Â Â±Â 529</td><td class="colsep0 rowsep0" align="char" char=".">572Â Â±Â 49</td><td class="colsep0 rowsep0" align="char" char=".">609Â Â±Â 85</td></tr></tbody></table></div></div><div class="NLM_p last">Due to HDAC selective profile of compounds <b>20a</b> and <b>24</b>, selective HDAC6 inhibitors Tubastatin A (<b>27</b>)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and ACY1215 (<b>28</b>)<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and selective HDAC3 inhibitor RGFP966 (<b>29</b>)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> were further assayed (for chemical structures, see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Figure S4</a>). As listed in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Table S3</a>, HDAC6 inhibitors <b>27</b> and <b>28</b> exhibited moderate inhibitory activities against HL60, K562, and HEL cell lines (IC<sub>50</sub> range: 3.75â23.88 Î¼M), which were less active than compound <b>20a</b>. For HDAC3 inhibitor <b>29</b>, it only showed marginal activity (IC<sub>50</sub> range: 21.71â33.58 Î¼M). The combinations of JAK2 inhibitor <b>1</b> with three selected HDAC inhibitors were also investigated for antiproliferative activities. When compound <b>1</b> was used in combination with HDAC6 inhibitor <b>27</b> or <b>28</b>, the inhibitory activities were not significantly changed (IC<sub>50</sub> range: 2.54â8.55 Î¼M), indicating that there was no synergistic effect between them. In contrast, when compound <b>1</b> was used in combination with HDAC3 inhibitor <b>29</b>, improved antitumor activity was observed (IC<sub>50</sub> range: 1.64â4.19 Î¼M). For the antifungal activity, compounds <b>27</b>â<b>29</b> were inactive to three FLC-resistant <i>C. albicans</i> isolates (MIC<sub>50</sub> > 64 Î¼g/mL). When used in combination, only compound <b>28</b> showed synergistic effects with FLC against <i>C. albicans</i> 0304103 strain (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Table S4</a>).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Compounds <b>20a</b>, <b>20h</b>, and <b>24</b> and Induction of Apoptosis and Cell-Cycle Arrest</h3><div class="NLM_p">To investigate the effect of the selected dual inhibitors on the induction of apoptosis, compounds <b>20a</b>, <b>20h</b>, and <b>24</b> were evaluated by annexin VFTIC/propidium iodide (PI) assay. HEL cells were incubated with vehicle alone or tested compounds at 5 and 10 Î¼M for 48 h. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compounds <b>20a</b>, <b>20h</b>, and <b>24</b> caused a dose-dependent induction of apoptosis in HEL cells. The percentages of apoptotic cells for compounds <b>20a</b>, <b>20h</b>, and <b>24</b> at the concentration of 10 Î¼M were 70.62%, 89.2%, and 86.2%, respectively, which were significantly higher than JAK2 inhibitor <b>1</b> (25.9% apoptotic cells at 10 Î¼M, <i>P</i> < 0.001).</div><div class="NLM_p">To probe the effect of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> on various phases of cell cycle progression, flow cytometry method was performed. HEL cells were treated with vehicle alone or compound <b>20a</b>, <b>20h</b>, and <b>24</b> at different concentrations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). After treatment with compound <b>20a</b> at 1 and 5 Î¼M for 48 h, the ratios of the G<sub>2</sub>/M phase of the cell cycle were 11.75% and 28.14%, respectively. The ratios of cells untreated in the G<sub>2</sub>/M phase of the cell cycle were 9.32% and 9.31%, respectively. Interestingly, the ratios of cells incubated with compound <b>20h</b> at 1 and 5 Î¼M in the G<sub>2</sub>/M phase of cell cycle were not dramatically changed (8.23% and 8.12%, respectively), but the ratios in the S phase of the cell cycle were 25.56% and 34.37%, respectively. Similarly, the ratios of cells treated with compound <b>24</b> at 5 and 10 Î¼M in the S phase of the cell cycle were 18.90% and 48.68%, respectively. Taken together, compounds <b>20a</b> arrested HEL cells mainly at the G<sub>2</sub>/M phase (<i>P</i> < 0.001), and compounds <b>20h</b> and <b>24</b> could significantly arrest HEL cells at the S phase (<i>P</i> < 0.001).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cell cycle analysis after 48 h of treatment. HEL cells treated with <b>20a</b>, <b>20h</b>, and <b>24</b> at different concentrations for 48 h were assayed by flow cytometry after staining with PI. Data were represented as mean Â± standard deviation from three independent experiments. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001, as determined with Studentâs <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>2</b> arrested HEL cells mainly in the G<sub>1</sub> phase,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> while JAK2 inhibitors induced cell cycle arrest at the G<sub>2</sub>/M phase in HEL cells.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> HDAC6-selective inhibitors (<b>27</b> and <b>28</b>) and HDAC3-selective inhibitor <b>29</b> were further evaluated on the various phases of cell cycle progression (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Figure S5</a>). Surprisingly, all the three compounds arrested HEL cells at the G<sub>1</sub> phase (<i>P</i> < 0.05), which was different with compounds <b>20a</b>, <b>20h</b>, and <b>24</b>. These data suggest that compound <b>20a</b> arrested HEL cells at the G<sub>2</sub>/M phase, possibly because of the inhibition of JAK2. The underlying mechanisms why compounds <b>20h</b> and <b>24</b> arrested HEL cells at the S phase remains to be investigated further.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Compounds <b>20a</b>, <b>20h</b>, and <b>24</b> and Inhibition of JAK and HDAC in HEL Cells</h3><div class="NLM_p">To determine whether the three selected compounds inhibited both the JAK-STAT and HDAC pathway in cells, Western blot assay was performed to evaluate the effect of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> on the acetylation level of histone 3 and histone 4 and the phosphorylation of STAT5. HEL cells were exposed to them at 0.2, 1, and 5 Î¼M for 24 h. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, all the three compounds caused a dramatic increase in acetyl-histone 3 and acetyl-histone 4 in a dose-dependent manner. However, exposure of HEL cells to compounds <b>20a</b>, <b>20h</b>, and <b>24</b> resulted in dose-dependent decreases in STAT5 phosphorylation. Taken together, the results clearly confirmed that the designed JAK2/HDAC inhibitors inhibited both targets in HEL cells.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> on the levels of acetyl-H3, acetyl-H4, and STAT5 phosphorylation in HEL cells. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 versus the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synergistic DoseâResponse Relationships against FLC-Resistant <i>C. albicans</i> Cells</h3><div class="NLM_p">The synergistic doseâresponse relationship of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> against FLC-resistant <i>C. albicans</i> strain 0304103 was further investigated. The cells were treated with different concentrations of FLC (1 to 32 Î¼g/mL) and compounds <b>20a</b>, <b>20h</b>, and <b>24</b> (2 to 32 Î¼g/mL) using the growth curves assay (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). A high dosage of target compounds (32 Î¼g/mL) or 1 Î¼g/mL of FLC alone exhibited no antifungal effect, but the antifungal effect was significantly improved when they were used together (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>AâC). Interestingly, the results also indicated that the synergistic effect mainly depended on the concentration of the dual inhibitors instead of FLC (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>DâF).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Synergistic doseâresponse relationships of the drug combination. Growth curves of <i>C. albicans</i> 0304103 cells incubated with 1 Î¼g/mL of FLC and different concentration of compounds (A) <b>20a</b>, (B) <b>20h</b>, and (C) <b>24</b> for 24 h. Growth curves of <i>C. albicans</i> 0304103 cells treated with 32 Î¼g/mL of compounds (D) <b>20a</b>, (E) <b>20h</b>, and (F) <b>24</b> and different concentration of FLC for 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Compounds <b>20a</b> and <b>24</b> and Inhibition of the Biofilm Formation of FLC-Resistant <i>C. albicans</i> Cells</h3><div class="NLM_p"><i>C. albicans</i> biofilms are complex communities that form on tissues and implanted medical devices, causing drug resistance and repeated infections in clinics.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> The effect of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> on FLC-resistant <i>C. albicans</i> (strain no. 0304103) biofilm formation was evaluated by the XTT reduction assay.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> A total of 1 Ã 10<sup>6</sup> cells of FLC-resistant <i>C. albicans</i> strain and 64 Î¼g/mL of FLC were incubated in a 96-well plate for 90 min and then treated with different concentrations of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> for 24 h. An equivalent volume of DMSO was added as the control. Interestingly, they inhibited the biofilm formation in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). More specifically, 16 Î¼g/mL of compound <b>20a</b> or <b>24</b> inhibited biofilm formation by about 30% (<i>P</i> < 0.05), and the antibiofilm effect increased with the increasing of the concentration. However, compound <b>20h</b> was less active.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of FLC-resistant <i>C. albicans</i> biofilm formation by (A) DMSO and compounds (B) <b>20a</b>, (C) <b>20h</b>, and (D) <b>24</b> using the XTT reduction assay. The results were presented as a percentage compared with the control biofilms formed without compound treatment. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 versus the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Compounds <b>20a</b>, <b>20h</b>, and <b>24</b> and Potent in Vivo Anti-tumor Activity in AML Xenograft Models</h3><div class="NLM_p">To investigate the in vivo antitumor effect, xenograft models of AML were prepared. First, compounds <b>20a</b>, <b>20h</b>, and <b>24</b> were tested in the HEL xenograft model. HEL cells (5 Ã 10<sup>6</sup>) were subcutaneously implanted in the right flanks of the female nude mice. When the implanted tumor reached a volume of 100â300 mm<sup>3</sup>, compounds <b>20a</b>, <b>20h</b>, and <b>24</b> were administered intraperitoneally at 10 mg/kg twice a day for 21 consecutive days. Compounds <b>1</b> and <b>2</b> were used as the positive controls. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B, treatment with three compounds caused significantly reduction in tumor growth. Moreover, all of them were observed to be well tolerated during the test and no significant loss of body weight was observed (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Figure S2</a>), indicating that their toxicity is low. Particularly, compound <b>24</b> revealed the best in vivo antitumor activity, which showed higher TGI value (59.9%) and lower <i>T</i>/<i>C</i> value (41.1%) than positive drugs <b>1</b> (TGI = 40.2%; <i>T</i>/<i>C</i> = 68.3%) and <b>2</b> (TGI = 13.8%; <i>T</i>/<i>C</i> = 87.9%). In contrast, selective HDAC6 inhibitors (<b>27</b> and <b>28</b>) and selective HDAC3 inhibitor <b>29</b> only exhibited weak antitumor activity in the xenograft HEL model with a TGI value of 18.8%, 14.1%, and 16.4, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Figure S6</a>).</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compounds <b>20a</b>, <b>20h</b>, and <b>24</b> suppress tumor growth and improve survival of leukemic mice in vivo. (A) The efficacy of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> in the HEL xenograft model. Data were represented as mean Â± standard deviation. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 versus the control group, as determined with Studentâs <i>t</i> test. (B) Tumor weight of dissected HEL tumor tissues. (C) The KaplanâMeier curves of leukemic mice in control (vehicle), <b>1</b>, <b>2</b>, <b>20a</b>, <b>20h</b>, and <b>24</b> treatment groups. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 by log-rank test for significance. (D) The spleen weight of the killed leukemic mice. Single asterisks indicate <i>P</i> < 0.05 and double asterisks indicate <i>P</i> < 0.01, as determined with Studentâs <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Furthermore, the three compounds were evaluated on the HEL AML xenograft model. HEL cells (5 Ã 10<sup>6</sup>) were injected via tail vein to sublethally irradiated female 5 week old SCID mice. At the dose of 10 mg/kg (once daily), compounds <b>20a</b>, <b>20h</b>, and <b>24</b> resulted in a significant increase in the survival rate (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). More specifically, after about 10 days, mice in vehicle group, positive drug <b>1</b>- or <b>2</b>-treated group died off sharply. In contrast, the lifetime of mice lasted as long as 27 days when treated with compounds <b>20h</b> and <b>24</b>. On the day 32, the survival percentage in <b>20a</b>-treated group was 37.5%. KaplanâMeier analysis indicated that the three tested compounds significantly extended the lifetime and survival of leukemic mice. A total of three mice were picked from each group and sacrificed for histological analysis. Meanwhile, spleens in leukemic mice were dissected and weighted (Figures <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>D and <a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">S3</a>). Enlarged spleens were found notably in vehicle-treated mice, which could be alleviated when treated with compounds <b>20a</b>, <b>20h</b>, and <b>24</b>. This can be regarded as positive effect in AML therapies, because enlarged spleens are usually considered as a symbol of pathological tissue infiltration.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> In contrast, positive drugs <b>1</b> and <b>2</b> showed no effect in the reduction of spleen enlargement. Similarly, selective HDAC6 (<b>27</b> and <b>28</b>) and HDAC3 (<b>29</b>) inhibitors also could not extend the lifetime of leukemic mice (<i>P</i> > 0.05) and reduce the enlargement of the spleen (<i>P</i> > 0.05).</div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Compounds <b>20a</b>, <b>20h</b>, and <b>24</b> and Effective Synergy with FLC to Treat Resistant <i>C. albicans</i> Infections in Disseminated Candidiasis Models</h3><div class="NLM_p">Given the potent synergistic effects between FLC and compounds <b>20a</b>, <b>20h</b>, and <b>24</b>, their therapeutic efficacy in resistant <i>C. albicans</i> models were investigated. Immunocompromised ICR mice were injected via tail vein with 15 Ã 10<sup>4</sup> cells of FLC-resistant <i>C. albicans</i> (strain no. 0304103) and were treated daily with vehicle, compounds <b>20a</b>, <b>20h</b>, and <b>24</b> (5 mg/kg), FLC (1 mg/kg), or a drug combination (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The median survival time (MST) of the vehicle mice was 4.5 days, and the FLC-treated group only resulted in a minor increase of survival time (MST = 7.5 days). In combination-therapy groups, the MST of the FLC/<b>1</b>-combination- and FLC/<b>2</b>-combination-treated group is 5.5 and 10 days, respectively. In contrast, the MST of mice treated with combination of FLC and compounds <b>20a</b>, <b>20h</b>, and <b>24</b> were significantly increased (MST = 11.5, 13, and 11 days, respectively). When used alone, selective HDAC6 (<b>27</b> and <b>28</b>) and HDAC3 (<b>29</b>) inhibitors had no effect on the extension of mice survival time (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Figure S7</a>). In the combination-therapy groups, the MST of the FLC/<b>27</b>-combination-, FLC/<b>28</b>-combination-, and FLC/<b>29</b>-combination -treated group is 4.5, 5, and 5 days, respectively. These results indicated three selective HDAC inhibitors had no therapeutic effect on IFI mice (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">Figure S6</a>). The results highlighted the advantages of JAK2/HDAC dual inhibitors in the combinational treatment of resistant <i>C. albicans</i> infections.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Therapeutic efficacy of compounds and FLC in FLC-resistant <i>C. albicans</i> disseminated infection model. Mice were infected with <i>C. albicans</i> isolate 0304103 and treated with vehicle, (A) compounds <b>1</b> and <b>2</b>, (B) <b>20a</b>, (C) <b>20h</b>, (D) <b>24</b>, or FLC or a combination. Triple asterisks indicate <i>P</i> < 0.001 vs the FLC group by log-rank test for significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Preliminary PK Profiles</h3><div class="NLM_p">In vitro metabolic stability of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> was evaluated using the liver microsome assay. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, compounds <b>20a</b>, <b>20h</b>, and <b>24</b> exhibited similar metabolic properties with half-lives of 19.4, 15.7, and 16.5 min, respectively. Furthermore, PK profiles of compound <b>20a</b> were evaluated in Sprague Dawley (SD) rats. When it was administered intraperitoneally at 10 mg/kg, the half-life was approximately 5.14 h. The peak concentration <i>C</i><sub>max</sub> and plasma clearance (CL) was 1603.41 ng/mL and 2246.64 mL/h/mg, respectively (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Mice Microsomal Stability of Compounds <b>20a</b>, <b>20h</b>, and <b>24</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a>(min)</th><th class="colsep0 rowsep0" align="center" char=".">CL<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> (mL/min/mg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="char" char=".">19.4</td><td class="colsep0 rowsep0" align="char" char=".">0.0716</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20h</b></td><td class="colsep0 rowsep0" align="char" char=".">15.7</td><td class="colsep0 rowsep0" align="char" char=".">0.0881</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">16.5</td><td class="colsep0 rowsep0" align="char" char=".">0.0838</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Half-life.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Clearance.</p></div></div></div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmacokinetics of compound <b>20a</b> in rats. (A) Mean (Â± standard deviation) plasma concentrationâtime profiles of compound <b>20a</b> in SD rats. (B) PK parameters of compound <b>20a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, this study provided a novel strategy of for the combinational treatment of leukemia and IFIs by designing novel JAK2-HDAC dual inhibitors. In particular, compound <b>20a</b> was a highly active and selective JAK2/HDAC6 dual inhibitor that showed potent antiproliferative activity toward hematological cell lines and excellent synergistic effects with FLC to treat resistant <i>C. albicans</i>. Importantly, the therapeutic potential of compound <b>20a</b> was validated in several in vivo models. It showed good in vivo antitumor efficacy in the HEL xenograft model, significantly prolonged the survival of leukemic mice in the AML model, reduced leukemic infiltration to spleen, and extended the survival of mice infected with resistant <i>C. albicans</i> in combination with FLC. To the best of our knowledge, this is the first example that a small molecule can simultaneously treat AML and synergize with FLC to treat resistant fungal infections. Further mechanism and lead-optimization studies are in progress.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Methods</h4><div class="NLM_p last"><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on Bruker AVANCE300 or AVANCE600 spectrometers (Bruker Company, Germany), using TMS as an internal standard and CDCl<sub>3</sub> or DMSO-<i>d6</i> as solvents. Chemical shifts are given in parts per million (Î´). Elemental analyses were performed with a MOD-1106 instrument and were consistent with theoretical values within 0.4%. The mass spectra were recorded on an Esquire 3000 liquid chromatographyâmass spectrometry (LCâMS) instrument. Silica gel thin-layer chromatography was performed on precoated plates GF-254 (Qingdao Haiyang Chemical, China). All solvents and reagents were analytically pure, and no further purification was needed. All starting materials were commercially available. The purities of the compounds were determined by HPLC (Agilent 1260), and all final compounds exhibited purities greater than 95%.</div></div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 1-(4-((4-(4-((Cyanomethyl)carbamoyl)phenyl)pyrimidin-2-yl)amino)phenyl)-<i>N</i>-hydroxypiperidine-4-carboxamide (<b>8</b>)</h4><div class="NLM_p last">To a stirred solution of hydroxylamine hydrochloride (4.67 g, 67 mmol) in MeOH (24 mL) was added drop-wise a solution of potassium hydroxide (5.61 g, 100 mmol) in MeOH (12 mL) at 0 Â°C. After this addition, the mixture was stirred for 30 min at room temperature. The precipitate was filtered and the filtrate formed a solution of free hydroxylamine in MeOH. Then, compound <b>7</b> (0.1 g, 0.20 mmol) was dissolved in above freshly prepared solution of hydroxylamine in MeOH (15 mL). The mixture was stirred at room temperature for 45 min, and then adjusted to pH 7 with acetic acid. The mixture was concentrated and the residue was washed with water to afford compound <b>8</b> (0.05 g, 53%) as a yellow solid. Mp: 213-215 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.43 (s, 1H), 9.42 (s, 1H), 9.04 (s, 1H), 8.81 (t, <i>J</i> = 5.67 Hz, 1H), 8.68 (s, 1H), 8.50 (d, <i>J</i> = 5.21 Hz, 1H), 8.22 (d, <i>J</i> = 8.51 Hz, 2H), 8.00 (d, <i>J</i> = 8.51 Hz, 2H), 7.62 (d, <i>J</i> = 9.16 Hz, 2H), 7.36â7.38 (m, 1H), 6.91 (d, <i>J</i> = 8.76 Hz, 2H), 5.37 (s, 1H), 3.88 (d, <i>J</i> = 6.07 Hz, 1H), 3.62 (d, <i>J</i> = 12.57 Hz, 2H), 2.56â2.61 (m, 2H), 2.09â2.13 (m, 1H), 1.67â1.72 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>, TMS, Î´): 171.51, 166.27, 162.58, 160.34, 159.21, 150.47, 146.44, 139.36, 135.36, 132.35, 127.83, 127.77, 126.73, 126.68, 120.44, 116.45, 107.49, 49.16, 42.39, 28.03. MS (ESI negative) <i>m</i>/<i>z</i> [M â H]<sup>+</sup>: 470.52.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(2-Aminophenyl)-1-(4-((4-(4-((cyanomethyl)carbamoyl)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>10</b>)</h4><div class="NLM_p last">To a solution of compound <b>9</b> (0.11 g, 0.24 mmol), HATU (0.11 g, 0.29 mmol) and DIPEA (50 Î¼L, 0.48 mmol) in DMF (5 mL) was added <i>o</i>-phenylenediamine (0.03 mg, 0.29 mmol), and the mixture was stirred at room temperature for 4 h. The reaction solution was diluted with water (40 mL) and filtered. The precipitate was dried and purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>: MeOH = 100:3) to give target compound <b>10</b> (0.07 g, 51%) as a yellow solid. Mp: 154â156 Â°C.<sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.00 (s, 4H), 9.47 (s, 1H), 9.41 (t, <i>J</i> = 5.41 Hz, 1H), 9.19 (s, 1H), 8.54 (d, <i>J</i> = 5.41 Hz, 1H), 8.27 (d, <i>J</i> = 8.50 Hz, 2H), 8.04 (d, <i>J</i> = 8.50 Hz, 2H), 7.66 (d, <i>J</i> = 8.50 Hz, 2H), 7.40 (d, <i>J</i> = 5.41 Hz, 1H), 7.19 (d, <i>J</i> = 6.96 Hz, 1H), 6.97 (s, 2H), 6.89 (t, <i>J</i> = 6.96 Hz, 1H), 6.72 (d, <i>J</i> = 6.96 Hz, 1H), 6.54 (t, <i>J</i> = 6.96 Hz, 1H), 4.88 (s, 1H), 4.35 (d, <i>J</i> = 5.22 Hz, 2H), 3.68 (d, <i>J</i> = 11.48 Hz, 2H), 2.69 (s, 2H), 2.56 (s, 1H), 1.92 (d, <i>J</i> = 12.01, 2H), 1.80 (d, <i>J</i> = 12.01 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 166.17, 162.42, 160.30, 159.28, 139.92, 134.50, 127.90, 126.94, 125.75, 125.35, 123.03, 120.34, 117.54, 116.83, 116.40, 116.03, 111.10, 107.67, 62.72, 49.45, 28.20, 27.73. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 547.55.</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>E</i>)-1-(4-((4-(4-((Cyanomethyl)carbamoyl)phenyl)pyrimidin-2-yl)amino)phenyl)-<i>N</i>-(4-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)piperidine-4-carboxamide (<b>12a</b>)</h4><div class="NLM_p">To a stirred solution of compound <b>9</b> (0.12 g, 0.26 mmol), HATU (0.12 g, 0.32 mmol) and DIPEA (84 Î¼L, 0.52 mmol) in DMF (5 mL) was added (<i>E</i>)<i>-</i>methyl 3-(4-aminophenyl)acrylate (0.04 mg, 0.32 mmol), and the mixture was stirred at room temperature for 4 h. The reaction solution was diluted with water (40 mL) and filtered. The precipitate was dried and purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>: MeOH = 100:4) to give intermediate <b>11a</b> (0.097 g, 61%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.16 (s, 1H), 9.49 (s, 1H), 9.35 (t, <i>J</i> = 5.22 Hz, 1H), 8.56 (d, <i>J</i> = 5.32 Hz, 1H), 8.29 (d, <i>J</i> = 8.40 Hz, 2H), 8.05 (d, <i>J</i> = 8.40 Hz, 2H), 7.70 (d, <i>J</i> = 6.67 Hz, 3H), 7.67 (d, <i>J</i> = 5.32 Hz, 1H), 7.62 (d, <i>J</i> = 16.08 Hz, 1H), 7.42 (d, <i>J</i> = 5.14 Hz, 1H), 6.98 (d, <i>J</i> = 8.46 Hz, 2H), 6.54 (d, <i>J</i> = 16.08 Hz, 1H), 4.38 (d, <i>J</i> = 5.32 Hz, 2H), 3.73 (s, 3H), 3.71 (d, <i>J</i> = 13.18 Hz, 2H), 2.69 (t, <i>J</i> = 10.01 Hz, 2H), 1.92 (d, <i>J</i> = 11.26 Hz, 2H), 1.79â1.83 (m, 2H). MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 616.23.</div><div class="NLM_p">Compound <b>11a</b> (0.08 g, 0.13 mmol) was dissolved in above freshly prepared solution of hydroxylamine in MeOH (15 mL). The mixture was stirred at room temperature for 45 min, and then adjusted to pH 7 with acetic acid. The mixture was concentrated and the residue was washed with water to afford target compound <b>12a</b> (0.05 g, 62%) as a yellow solid. Mp: 244â246 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.10 (s, 1H), 9.45 (s, 1H), 8.52 (d, <i>J</i> = 4.84 Hz, 1H), 8.24 (d, <i>J</i> = 7.87 Hz, 2H), 8.03 (t, <i>J</i> = 7.87 Hz, 2H), 7.68 (t, <i>J</i> = 8.48 Hz, 4H), 7.50 (d, <i>J</i> = 8.48 Hz, 1H), 7.39 (d, <i>J</i> = 5.45 Hz, 2H), 6.96 (d, J = 8.48 Hz, 2H), 6.38 (t, <i>J</i> = 15.74 Hz, 1H), 5.39 (s, 1H), 3.90 (d, <i>J</i> = 6.01 Hz, 1H), 3.68â3.71 (m, 2H), 2.67 (t, <i>J</i> = 10.58 Hz, 2H), 1.90 (d, <i>J</i> = 11.90 Hz, 2H), 1.78â1.82 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 173.69, 166.20, 166.01, 162.54, 160.33, 159.19, 150.44, 146.45, 139.35, 135.77, 132.45, 129.06, 128.13, 127.85, 127.77, 126.73, 126.67, 120.40, 119.16, 119.05, 117.19, 116.51, 107.50, 49.18, 42.74, 28.91, 28.14. MS (ESI positive) <i>m</i>/<i>z</i> [M+MeOH]<sup>+</sup>: 650.61.</div><div class="NLM_p last">Compound <b>12b</b> was synthesized according to a similar protocol as that described for <b>12a</b>.</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(4-(Hydroxycarbamoyl)phenyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>12b</b>)</h4><div class="NLM_p">Yield 58%, yellow solid. Mp: 276â278 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 11.11 (s, 1H), 10.30 (s, 1H), 9.43 (d, <i>J</i> = 8.61 Hz, 1H), 8.52 (t, <i>J</i> = 6.40 Hz, 1H), 8.26 (d, <i>J</i> = 8.54 Hz, 1H), 8.23 (d, <i>J</i> = 8.54 Hz, 1H), 8.01â8.03 (m, 2H), 7.91 (d, <i>J</i> = 8.54 Hz, 1H), 7.76 (d, <i>J</i> = 8.54 Hz, 1H), 7.69 (d, <i>J</i> = 8.54 Hz, 1H), 7.64 (d, <i>J</i> = 8.54 Hz, 2H), 7.37â7.42 (m, 1H), 6.96 (d, <i>J</i> = 8.54 Hz, 2H), 5.39 (s, 1H), 4.34 (d, <i>J</i> = 4.00 Hz, 1H), 3.82 (s, 3H), 3.69 (d, <i>J</i> = 12.00 Hz, 2H), 2.67 (t, <i>J</i> = 12.00 Hz, 2H), 1.91 (d, <i>J</i> = 12.00 Hz, 2H), 1.75â1.81 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 174.02, 170.87, 166.12, 165.80, 162.59, 162.40, 160.35, 159.25, 159.17, 150.40, 146.44, 143.75, 139.96, 139.35, 135.81, 134.51, 132.53, 130.30, 130.20, 127.88, 127.78, 127.61, 126.93, 126.71, 126.66, 123.70, 120.37, 118.45, 118.34, 117.56, 116.52, 107.55, 107.49, 51.81, 49.17, 42.79, 28.93, 28.12, 27.75. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 590.52.</div><div class="NLM_p last">Compounds <b>16</b>, <b>18</b>, <b>20a</b>â<b>h</b> were synthesized according to similar protocol to those described for compounds <b>8</b>, <b>10</b>, and <b>12a</b>, respectively.</div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-Hydroxy-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>16</b>)</h4><div class="NLM_p last">Yield 72%, light yellow solid. Mp: 213â215 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 11.35 (s, 1H), 10.28 (s, 1H), 8.62 (s, 1H), 7.98 (t, <i>J</i> = 5.47 Hz, 1H), 7.92 (d, <i>J</i> = 7.75 Hz, 1H), 7.56 (t, <i>J</i> = 7.75 Hz, 1H), 7.49 (d, <i>J</i> = 7.75 Hz, 1H), 7.37 (d, <i>J</i> = 7.75 Hz, 1H), 7.24 (d, <i>J</i> = 7.75 Hz, 1H), 7.17 (t, <i>J</i> = 7.29 Hz, 1H), 7.13 (t, <i>J</i> = 7.29 Hz, 1H), 7.03 (t, <i>J</i> = 7.29 Hz, 1H), 6.18 (s, 1H), 5.34 (d, <i>J</i> = 5.93 Hz, 1H), 3.37 (d, <i>J</i> = 15.50 Hz, 1H), 3.17 (s, 1H), 3.09â3.12 (m, 1H), 2.87â2.91 (m, 2H), 2.51 (s, 3H), 1.84 (t, <i>J</i> = 7.33 Hz, 2H), 1.28â1.34 (m, 2H), 1.18â1.24 (m, 2H), 1.00â1.04 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 171.50, 162.78, 160.24, 128.77, 146.28, 140.79, 132.59, 131.68, 128.02, 120.26, 118.75, 116.51, 106.59, 49.23, 45.72, 28.05, 8.53. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 483.51.</div></div><div id="sec4_1_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(2-Aminophenyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>18</b>)</h4><div class="NLM_p last">Yield 63%, yellow solid. Mp: 220â222 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.12 (s, 1H), 9.34 (s, 1H), 9.11 (s, 1H), 8.42 (d, <i>J</i> = 5.24 Hz, 1H), 8.11 (d, <i>J</i> = 8.64 Hz, 2H), 7.64 (d, <i>J</i> = 8.64 Hz, 2H), 7.31 (d, <i>J</i> = 8.64 Hz, 2H), 7.24 (d, <i>J</i> = 5.55 Hz, 1H), 7.16 (d, <i>J</i> = 8.02 Hz, 1H), 6.94 (d, <i>J</i> = 9.26 Hz, 2H), 6.88 (t, <i>J</i> = 7.40 Hz, 1H), 6.70 (d, <i>J</i> = 8.02 Hz, 1H), 4.80 (s, 2H), 3.67 (d, <i>J</i> = 12.34 Hz, 2H), 3.05 (s, 3H), 2.64 (t, <i>J</i> = 13.57 Hz, 2H), 1.89 (d, <i>J</i> = 12.34 Hz, 2H), 1.73â1.80 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 173.38, 162.82, 160.26, 158.74, 146.37, 141.88, 141.15, 132.64, 131.48, 128.01, 125.71, 125.32, 123.44, 120.20, 118.68, 116.51, 116.17, 115.88, 106.53, 49.29, 42.11, 28.43. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 558.48.</div></div><div id="sec4_1_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>E</i>)-<i>N</i>-(4-(3-(Hydroxyamino)-3-oxoprop-1-en-1-yl)phenyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20a</b>)</h4><div class="NLM_p last">Yield 58%, yellow solid. Mp: 239â241 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.70 (s, 1H), 10.13 (s, 1H), 9.33 (s, 1H), 8.43 (d, <i>J</i> = 5.29 Hz, 1H), 8.11 (d, <i>J</i> = 9.07 Hz, 3H), 7.63â7.39 (m, 5H), 7.48 (d, <i>J</i> = 8.66 Hz, 2H), 7.37 (d, <i>J</i> = 15.24 Hz, 1H), 7.33 (d, <i>J</i> = 9.70 Hz, 2H), 7.25 (d, <i>J</i> = 4.94 Hz, 1H), 6.94 (d, <i>J</i> = 8.95 Hz, 2H), 6.35 (d, <i>J</i> = 15.68 Hz, 1H), 3.67 (d, <i>J</i> = 13.10 Hz, 3H), 3.07 (s, 3H), 2.64 (t, <i>J</i> = 12.08 Hz, 2H), 1.88 (d, <i>J</i> = 11.72 Hz, 2H), 1.73â1.79 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 173.71, 163.15, 162.81, 160.28, 158.76, 146.25, 140.79, 140.52, 132.69, 131.75, 128.13, 128.01, 120.25, 119.17, 118.75, 117.16, 116.54, 106.59, 49.20, 42.71, 28.91, 28.15. HRMS (ESI, negative) <i>m</i>/<i>z</i>: [M â H] calcd for C<sub>32</sub>H<sub>32</sub>N<sub>7</sub>O<sub>5</sub>S, 626.2191; found, 626.2202. HPLC purity: 97.0%.</div></div><div id="sec4_1_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(4-(Hydroxycarbamoyl)phenyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20b</b>)</h4><div class="NLM_p last">Yield 62%, yellow solid. Mp: 229â231 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.17 (s, 1H), 9.37 (s, 1H), 8.46 (d, <i>J</i> = 4.92 Hz, 1H), 8.14 (d, <i>J</i> = 8.85 Hz, 2H), 7.67â7.74 (m, 5H), 7.33 (d, <i>J</i> = 8.36 Hz, 2H), 7.28 (d, <i>J</i> = 5.01 Hz, 1H), 6.98 (d, <i>J</i> = 8.36 Hz, 2H), 3.71 (d, <i>J</i> = 11.70 Hz, 2H), 3.08 (s, 3H), 2.68 (t, <i>J</i> = 11.87 Hz, 2H), 1.92 (d, <i>J</i> = 11.82 Hz, 2H), 1.78â1.84 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 173.79, 163.83, 162.85, 160.25, 158.69, 146.30, 141.86, 141.55, 132.72, 131.21, 127.99, 127.59, 126.99, 120.18, 118.69, 118.36, 116.55, 106.50, 49.23, 42.76, 28.19. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 602.46.</div></div><div id="sec4_1_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(4-(Hydroxycarbamoyl)benzyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20c</b>)</h4><div class="NLM_p last">Yield 57%, light yellow solid. Mp: 207â209 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 11.17 (s, 1H), 9.35 (s, 1H), 9.03 (s, 1H), 8.46 (d, <i>J</i> = 5.72 Hz, 1H), 8.42 (t, <i>J</i> = 5.72 Hz, 1H), 8.14 (d, <i>J</i> = 8.57 Hz, 2H), 7.72 (d, <i>J</i> = 8.57 Hz, 2H), 7.67 (d, <i>J</i> = 8.57 Hz, 2H), 7.32â7.40 (m, 4H), 7.28 (d, <i>J</i> = 5.72 Hz, 1H), 6.96 (d, <i>J</i> = 8.57 Hz, 2H), 4.39 (d, <i>J</i> = 5.72 Hz, 2H), 3.67 (d, <i>J</i> = 11.68 Hz, 2H), 3.10 (s, 3H), 2.65 (t, <i>J</i> = 10.99 Hz, 2H), 2.34â2.36H (m, 1H), 1.85 (d, <i>J</i> = 13.19 Hz, 2H), 1.73â1.80 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 174.13, 169.12, 162.78, 160.25, 158.75, 146.39, 140.87, 132.56, 131.63, 128.01, 126.83, 120.19, 118.68, 116.46, 106.54, 49.29, 41.82, 38.28, 32.20, 29.03, 28.48, 28.37, 26.20, 25.01. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 616.52.</div></div><div id="sec4_1_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(4-(Hydroxyamino)-4-oxobutyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20d</b>)</h4><div class="NLM_p last">Yield 68%, yellow solid. Mp: 221â223 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.33 (s, 1H), 10.11 (s, 1H), 9.31 (s, 1H), 8.65 (s, 1H), 8.43 (d, <i>J</i> = 4.41 Hz, 1H), 8.11 (d, <i>J</i> = 8.81 Hz, 2H), 7.79 (t, <i>J</i> = 5.32 Hz, 1H), 7.63 (d, <i>J</i> = 8.65 Hz, 2H), 7.32 (d, <i>J</i> = 8.65 Hz, 2H), 7.24 (d, <i>J</i> = 4.66 Hz, 1H), 6.91 (d, <i>J</i> = 8.65 Hz, 2H), 3.61 (d, <i>J</i> = 12.64 Hz, 2H), 3.07 (s, 3H), 3.00â3.03 (m, 2H), 2.58 (t, <i>J</i> = 10.64 Hz, 2H), 2.17â2.21 (m, 1H), 1.93 (t, <i>J</i> = 7.98 Hz, 2H), 1.74 (d, <i>J</i> = 10.64 Hz, 2H), 1.68 (t, <i>J</i> = 9.31 Hz, 2H), 1.58â1.64 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 174.27, 168.85, 162.78, 160.25, 158.76, 146.38, 140.83, 132.58, 131.66, 128.02, 120.19, 118.67, 116.48, 106.55, 49.29, 41.82, 38.03, 29.84, 28.32, 25.32. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 568.50.</div></div><div id="sec4_1_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(5-(Hydroxyamino)-5-oxopentyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20e</b>)</h4><div class="NLM_p last">Yield 56%, light yellow solid. Mp: 204â206 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.32 (s, 1H), 10.16 (s, 1H), 9.32 (s, 1H), 8.65 (s, 1H), 8.43 (d, <i>J</i> = 4.55 Hz, 1H), 8.11 (d, <i>J</i> = 7.96 Hz, 2H), 7.78 (s, 1H), 7.64 (d, <i>J</i> = 8.53 Hz, 2H), 7.31 (d, <i>J</i> = 7.96 Hz, 2H), 7.25 (d, <i>J</i> = 4.55 Hz, 1H), 6.92 (d, <i>J</i> = 8.53 Hz, 2H), 3.62 (d, <i>J</i> = 10.23 Hz, 2H), 3.06 (s, 3H), 3.02â3.04 (m, 2H), 2.59 (t, <i>J</i> = 10.23 Hz, 2H), 2.21 (t, <i>J</i> = 11.37 Hz, 2H), 1.94 (t, <i>J</i> = 6.82 Hz, 2H), 1.67â1.73 (m, 4H), 1.47 (t, <i>J</i> = 6.82 Hz, 2H), 1.36 (t, <i>J</i> = 6.82 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 174.12, 169.12, 162.78, 160.25, 158.75, 146.35, 140.84, 132.61, 131.66, 128.01, 120.19, 118.68, 116.49, 106.55, 49.32, 41.79, 38.28, 32.20, 29.03, 28.48, 28.35, 26.20, 25.01.MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 582.51.</div></div><div id="sec4_1_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(6-(Hydroxyamino)-6-oxohexyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20f</b>)</h4><div class="NLM_p last">Yield 65%, yellow solid. Mp: 170â172 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.32 (s, 1H), 9.27 (s, 1H), 8.39 (d, <i>J</i> = 4.75 Hz, 1H), 8.05 (d, <i>J</i> = 7.92 Hz, 2H), 7.65 (s, 1H), 7.45 (d, <i>J</i> = 7.92 Hz, 2H), 7.33 (d, <i>J</i> = 7.92 Hz, 2H), 7.20 (d, <i>J</i> = 4.75 Hz, 1H), 6.92 (d, <i>J</i> = 7.92 Hz, 2H), 3.62 (d, <i>J</i> = 10.57 Hz, 2H), 3.00â3.03 (m, 4H), 2.96 (t, <i>J</i> = 10.23 Hz, 2H), 2.69 (s, 1H), 2.59 (t, <i>J</i> = 10.57 Hz, 2H), 2.21 (s, 1H), 1.93 (t, <i>J</i> = 5.28 Hz, 2H), 1.68â1.73 (m, 4H), 1.49 (t, <i>J</i> = 7.92 2H), 1.35â1.39 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 174.07, 168.97, 163.09, 160.22, 158.42, 146.31, 133.05, 132.74, 132.37, 131.47, 131.41, 128.75, 128.67, 127.85, 127.08, 120.09, 118.81, 116.48, 106.22, 49.35, 41.82, 38.22, 32.18, 28.85, 28.28, 25.96, 24.83. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 596.94.</div></div><div id="sec4_1_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(7-(Hydroxyamino)-7-oxoheptyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20g</b>)</h4><div class="NLM_p last">Yield 63%, yellow solid. Mp: 183â185 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.33 (s, 1H), 10.14 (s, 1H), 9.35 (s, 1H), 8.65 (s, 1H), 8.47 (d, <i>J</i> = 5.19 Hz, 1H), 8.15 (d, <i>J</i> = 8.30 Hz, 2H), 7.73 (t, <i>J</i> = 5.19 Hz, 1H), 7.66 (d, <i>J</i> = 8.30 Hz, 2H), 7.36 (d, <i>J</i> = 8.30 Hz, 2H), 7.28 (d, <i>J</i> = 5.19 Hz, 1H), 6.95 (d, <i>J</i> = 8.30 Hz, 2H), 3.64 (d, <i>J</i> = 11.41 Hz, 2H), 3.11 (s, 3H), 3.03â3.07 (m, 2H), 2.62 (t, <i>J</i> = 9.34 Hz, 2H), 2.23 (s, 1H), 1.95 (t, <i>J</i> = 8.35 Hz, 2H), 1.76 (t, <i>J</i> = 10.31 Hz, 2H), 1.71 (d, <i>J</i> = 10.31 Hz, 2H), 1.50 (t, <i>J</i> = 8.25 Hz, 2H), 1.39â1.51 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 174.11, 169.10, 160.26, 146.39, 140.84, 132.57, 131.66, 128.02, 120.19, 118.67, 116.47, 106.55, 49.31, 41.82, 38.27, 32.19, 28.97, 28.36, 28.26, 26.04, 25.04. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 610.83.</div></div><div id="sec4_1_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(8-(Hydroxyamino)-8-oxooctyl)-1-(4-((4-(4-(methylsulfonamido)phenyl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide (<b>20h</b>)</h4><div class="NLM_p">Yield 65%, yellow solid. Mp: 199â201 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 10.33 (s, 1H), 9.35 (s, 1H), 8.65 (s, 1H), 8.46 (d, <i>J</i> = 5.48 Hz, 1H), 8.14 (d, <i>J</i> = 8.22 Hz, 2H), 7.77 (t, <i>J</i> = 5.48 Hz, 1H), 7.66 (d, J = 8.22 Hz, 2H), 7.35 (d, <i>J</i> = 8.22 Hz, 2H), 7.27 (d, <i>J</i> = 5.48 Hz, 1H), 6.95 (d, <i>J</i> = 8.22 Hz, 2H), 3.64 (d, <i>J</i> = 12.33 Hz, 2H), 3.09 (s, 3H), 3.03â3.07 (m, 3H), 2.61 (t, <i>J</i> = 9.59 Hz, 2H), 2.21 (s, 1H), 1.95 (t, <i>J</i> = 7.85 Hz, 2H), 1.69â1.77 (m, 4H), 1.50 (t, <i>J</i> = 7.85 Hz, 2H), 1.36â1.40 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 174.08, 169.09, 162.77, 160.25, 158.74, 146.37, 140.84, 132.58, 131.65, 128.01, 120.17, 118.66, 116.46, 106.54, 49.30, 41.81, 38.28, 32.21, 29.05, 28.49, 28.37, 26.21, 25.02. HRMS (ESI, negative) <i>m</i>/<i>z</i>: [M â H] calcd for C<sub>31</sub>H<sub>40</sub>N<sub>7</sub>O<sub>5</sub>S, 622.2817; found, 622.2821. HPLC purity: 99.4%.</div><div class="NLM_p last">Compounds <b>24</b> and <b>26</b> were synthesized according to a similar protocol to those described for compounds <b>8</b> and <b>10</b>, respectively.</div></div><div id="sec4_1_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N-</i>Hydroxy-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide (<b>24</b>)</h4><div class="NLM_p last">Yield 72%, light yellow solid. Mp: 176â178 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 11.32 (s, 1H), 8.50 (d, <i>J</i> = 5.17 Hz, 1H), 8.19 (d, <i>J</i> = 8.05 Hz, 2H), 7.88 (d, <i>J</i> = 8.05 Hz, 2H), 7.64 (d, <i>J</i> = 8.62 Hz, 2H), 7.35 (d, <i>J</i> = 5.17 Hz, 1H), 6.91 (d, <i>J</i> = 9.05 Hz, 2H), 3.72 (t, <i>J</i> = 4.67 Hz, 4H), 3.03 (t, <i>J</i> = 4.67 Hz, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 162.59, 160.33, 159.17, 146.20, 139.19, 134.59, 132.83, 132.00, 131.47, 131.41, 129.61, 128.75, 128.68, 127.34, 126.79, 120.32, 115.60, 107.49, 66.15, 49.25. HRMS (ESI, negative) <i>m</i>/<i>z</i>: [M â H] calcd for C<sub>21</sub>H<sub>20</sub>N<sub>5</sub>O<sub>3</sub>, 390.1572; found, 390.1567. HPLC purity: 99.5%.</div></div><div id="sec4_1_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(2-Aminophenyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide (<b>26</b>)</h4><div class="NLM_p last">Yield 60%, yellow solid. Mp: 206â208 Â°C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz, Î´): 9.76 (s, 1H), 9.49 (s, 1H), 8.52 (d, <i>J</i> = 4.81 Hz, 1H), 8.26 (d, <i>J</i> = 8.17 Hz, 2H), 8.12 (d, <i>J</i> = 8.17 Hz, 2H), 7.66 (d, <i>J</i> = 9.13 Hz, 2H), 7.41 (d, <i>J</i> = 4.81 Hz, 1H), 7.18 (d, <i>J</i> = 7.21 Hz, 1H), 6.97 (t, <i>J</i> = 7.21 Hz, 1H), 6.92 (d, <i>J</i> = 9.13 Hz, 2H), 6.78 (d, <i>J</i> = 8.17 Hz, 1H), 6.59 (t, <i>J</i> = 7.21 Hz, 1H), 4.93 (s, 2H), 3.73 (t, <i>J</i> = 4.74 Hz, 4H), 3.04 (t, <i>J</i> = 4.74 Hz, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 150 MHz, Î´): 164.77, 162.59, 160.35, 159.21, 146.21, 143.18, 139.38, 136.44, 132.85, 128.27, 126.67, 123.10, 120.33, 116.20, 116.07, 115.60, 107.56, 66.15, 49.25. MS (ESI positive) <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 483.33.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> In Vitro JAK Inhibition Assay</h3><div class="NLM_p last">The kinase assay was performed in the buffer (50 mM HEPES, pH of 7.5, 0.015% Brij-35, 10 mM MgCl<sub>2</sub>, 10 mM MnCl<sub>2</sub>, and 2 mM DTT). A 5 mL volume of tested compounds (3-fold dilution, 10 concentrations) were pre-diluted for dose response in 384-well plates in duplicates. A 10 mL volume of diluted enzyme solution was sequentially added, and the assay plates were incubated at room temperature for 10 min. Then, a 10 mL volume of a mixture of peptide solution containing FAM-labeled peptide (GL Biochem, catalog no. 112393,lot no. P130408-ZB112393) and ATP (Sigma, catalog no. A7699-1G, CAS no. 987-65-5) was incubated at 28 Â°C for 25 min. The reaction was stopped with the addition of 50 mM EDTA containing 25 mL of 100 mM HEPES, pH of 7.5, 0.015% Brij-35, and 0.2% coating reagent no. 3, and the data were collected on Caliper. Half maximal inhibition (IC<sub>50</sub>) values were calculated using a nonlinear curve fit with XLfit software.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> In Vitro HDAC Inhibition Assay</h3><div class="NLM_p last">The HDAC1 (no. AB101661) and HDAC6 (no. AB42632) enzymes were purchased from Abcam. HDAC3 (no. BML-SE515-0050) was purchased from ENZO Inc. HDAC4 (no. H86-31G) and HDAC8 (no. H90-30H) was purchased from SignalChem. The reaction mixture contained 25 mM Tris (pH 8.0), 1 mM MgCl<sub>2</sub>, 0.1 mg/mL BSA, 137 mM NaCl, 2.7 mM KCl, HDAC (HDAC1, 7.2 ng per well; HDAC2, 7.5 ng per well; HDAC3, 3.4 ng per well; HDAC4, 0.3 ng per well; HDAC6, 15 ng per well; HDAC8, 22 ng per well) in a total volume of 40 Î¼L. The test compounds (3-fold dilution, 10 concentrations) were diluted in 10% DMSO, and 5 Î¼L of the dilution was added and pre-incubated with purified recombinant HDAC at room temperature for 5 min before substrate addition. Finally, the enzyme substrate (Ac-Leu-Gly-Lys(Ac)-AMC, 10 Î¼M for HDAC1, 2, 3, 6; Ac-Leu-Gly-Lys(Tfa)-AMC, 2 Î¼M for HDAC4 and HDAC8) was added, and the plate was incubated at 37 Â°C for 30 min in a final volume of 50 Î¼L. The reaction was quenched with 50 Î¼L of HDAC assay developer (1 mg/mL trypsin and 2 Î¼M TSA in assay buffer) for 30 min at room temperature. The assay was performed by quantitating the fluorescent product amount of in solution following an enzyme reaction. Fluorescence was then analyzed with an excitation of 350â360 nm and an emission wavelength of 450â460 nm at Spectra Max M5 microtiter plate reader. The IC<sub>50</sub> values were calculated using nonlinear regression with normalized doseâresponse fit using Prism GraphPad software. All experiments were independently performed at least three times.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> In Vitro Anti-proliferative Assay</h3><div class="NLM_p last">A total of three human leukemic cell lines (HL60, K562, and HEL), which were in the logarithmic phase, were harvested and plated in cells were plated in 96-well transparent plates at a density of 7 Ã 10<sup>3</sup> cells per well and incubated in a humidified atmosphere with 5% CO<sub>2</sub> at 37 Â°C for 24 h. Test compounds were added onto triplicate wells with different concentrations and 0.1% DMSO for control. After they had been incubated for 48 h, 10 Î¼L of cell counting kit-8 (CCK8) solution was added to each well and the plate was incubated for additional 1â4 h. The absorbance (OD) was read on a Biotek Synergy H2 (Lab systems) at 450 nm. The concentration causing 50% inhibition of cell growth (IC<sub>50</sub>) was determined by the Logit method. All experiments were performed three times.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Checkerboard Microdilution Assay</h3><div class="NLM_p last">Assays were performed according to the methods of the CLSI (formerly NCCLS) (M27-A). Briefly, RPMI 1640 medium was adjusted to pH 7 at 25 Â°C using 3-[<i>N</i>-morpholino]-propanesulfonic acid (MOPS). The initial concentration of the fungal suspension in RPMI 1640 medium was 10<sup>3</sup> CFU/mL, and the final concentrations ranged from 0.125 to 64 Î¼g/mL for FLC and 1 to 32 Î¼g/mL for target compounds in the 96-well microtiter plates. A drug-free medium with fungi and a fungus-free medium were used as the positive and negative controls, respectively. Plates were incubated at 35 Â°C for 48 h. OD was measured at 630 nm, and the background OD was subtracted from that of each well. MIC<sub>50</sub> was determined as the lowest concentration of the drugs (alone or in combination) that inhibited cell growth by 50%, compared to the cell growth of the drug-free wells. The fractional inhibitory concentration (FIC) index is defined as the sum of the MIC of each drug used in combination divided by the MIC of the drug used alone. Synergy and antagonism were defined by FIC index of â¤0.5 and >4, respectively. An FIC index of >0.5 but â¤4 was considered indifferent.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Apoptosis Detection Assay</h3><div class="NLM_p last">HEL cells (3 Ã 10<sup>5</sup> cells/mL) were seeded in 6-well plates and treated with compounds <b>20a</b>, <b>20h</b>, and <b>24</b> at concentration of 5 and 10 Î¼M for 48 h. The cells were then harvested by trypsinization and washed twice with cold PBS. After the centrifugation and removal of the supernatants, cells were resuspended in 400 Î¼L of a 1Ã binding buffer, which was then added to 5 Î¼L of annexin V-FITC and incubated at room temperature for 15 min. After the addition of 10 Î¼L of PI, the cells were incubated at room temperature for another 15 min in the dark. The stained cells were analyzed by a flow cytometer (BD Accuri C6).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Cell Cycle Analysis by Flow Cytometry</h3><div class="NLM_p last">HEL cells (3 Ã 10<sup>5</sup> cells per well) were treated with compounds <b>20a</b>, <b>20h</b>, and <b>24</b> at different concentration for 48 h. The treated cells were collected, resuspended, and then incubated for 30 min at 37 Â°C with 25 Î¼g/mL PI and 10 Î¼g/mL RNase buffer. For each sample, at least 1 Ã 10<sup>4</sup> cells were analyzed using flow cytometry (BD Accuri C6).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Western Blotting</h3><div class="NLM_p last">HEL cells were seeded (5 Ã 10<sup>5</sup> cells per well) on 6-well transparent plates (Corning). HEL cells were exposed to compounds <b>20a</b>, <b>20h</b>, and <b>24</b> at 0.2, 1, and 5 Î¼M for 24 h and then harvested and washed with PBS three times. Then the cells were lysed with RIPA cell lysis buffer on ice for 30 min. The cell lysates were centrifuged at 12000<i>g</i> for 15 min at 4 Â°C. Supernatant was collected, and BCA protein assay was used for determined protein concentration. Equal amounts of protein (30 Î¼g) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Next, the proteins were transferred to polyvinylidene fluoride membranes and were blocked with 5% bovine serum albumin for 2 h. The membranes were incubated with the primary antibody overnight at 4 Â°C and were washed with Tris-buffered saline and Tween 20 (TBST) three times. Then the mixture was incubated with the secondary antibody for 1.5 h. The membranes were washed with TBST three times. The immunoblots were visualized by Odyssey infrared imaging. The antibodies including anti-histone H3 (no. ab1791, Abcam), anti-histone H4 (no. ab9051, Abcam), and anti-STAT5 (phosphor Y694, no. ab32364, Abcam) were purchased from Abcam.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Growth Curve Assay</h3><div class="NLM_p last">Growth curve assay was performed according to the reported protocol,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> with a few modifications. Briefly, exponentially growing <i>C. albicans</i> cells were harvested and resuspended in fresh YPD (yeast peptone dextrose) medium to a concentration of 5 Ã 10<sup>4</sup> cells per milliliter. Various concentrations of FLC and compounds <b>20a</b>, <b>20h</b>, and <b>24</b> were added. The cells were cultured at 30 Â°C with constant shaking (20 rpm) and counted at designated time points after culture (0, 4, 8, 12, and 24 h). No FLC or selected compounds were added in the control group. A total of three independent experiments were performed.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> In Vitro Biofilm Formation Assay</h3><div class="NLM_p last">Biofilm formation assay was performed in a 96-well tissue culture plate (Corning, catalog no. 3599) by seeding with 100 Î¼L cell suspensions (1 Ã 10<sup>6</sup> cells per milliliter) in RPMI 1640 medium and incubating them with 64 Î¼g/mL of FLC statically at 37 Â°C. After 90 min of adhesion, the medium was aspirated; non-adherent cells were removed; and different concentration of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> was added. The plate was further incubated at 37 Â°C for 24 h. A semiquantitative measure of the formed biofilms was calculated using an XTT reduction assay.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> HEL Xenograft Tumor Mouse Model</h3><div class="NLM_p last">The experimental procedures and the animal use and care protocols were approved by the Committee on Ethical Use of Animals of Second military medical university. BALB/C nude female mice (certificate SCXK-2007-0005, weighing 18 to 20 g) were obtained from Shanghai Experimental Animal Center, Chinese Academy of Sciences. HEL cell suspensions were implanted subcutaneously into the right axilla region of mice. Treatment was begun when implanted tumors had reached a volume of about 100â300 mm<sup>3</sup>. The animals were randomized into appropriate groups (5 animals per group) for the testing of compounds <b>20a</b>, <b>20h</b>, and <b>24</b>, and control mice received vehicle (0.5% carboxymethyl cellulose). Compounds were suspended in the 0.5% carboxymethyl cellulose and administered intraperitoneally at the dose of 10 mg/kg/day for 21 consecutive days. Tumor volumes were monitored by caliper measurement of the length and width and calculated using the formula of TV = <sup>1</sup>/<sub>2</sub> Ã <i>a</i> Ã <i>b</i>,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> where <i>a</i> is the tumor length and <i>b</i> is the width. Tumor volumes and body weights were monitored every 2 days over the course of treatment. Mice were sacrificed on day 30 to 33 after implantation of cells and tumors were removed and recorded for analysis.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> AML Mouse Model</h3><div class="NLM_p last">A total of 5 Ã10<sup>6</sup> HEL cells were injected via tail vein to sublethally irradiated female 5-week SCID mice. The leukemic mice were randomized into appropriate groups (ten animals). Compounds were injected intraperitoneally at dose of 10 mg/kg every day. The leukemic mice became moribund and then were killed, and the enlarged spleens were picked for histological assessments.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> In Vivo Antifungal Potency</h3><div class="NLM_p last">Female ICR mice 4 to 6 weeks old and weighing 20 to 25 g were housed and fed. After acclimating for 1 week, mice were infected through the tail vein with 0.2 mL of yeast suspension, which corresponded to 15 Ã 10<sup>4</sup> CFU per mouse. FLC (at dose of 1 mg/kg), and compounds <b>20a</b>, <b>20h</b>, and <b>24</b> (at dose of 5 mg/kg) were injected intraperitoneally alone or combination every day after the infection. The control group consisted of mice treated with placebo consisting of 0.5% carboxymethyl cellulose. Survival was monitored daily, and moribund mice were sacrificed and considered deceased at the time of sacrifice.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00393" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54752" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54752" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00393" class="ext-link">10.1021/acs.jmedchem.8b00393</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figures showing the proposed binding mode, the change of body weight, a picture of dissected spleens, experimental structures, cell cycle analysis, selective HDAC inhibitors, therapeutic efficacy, and HPLC spectra. Tables showing inhibitory analysis, anti-cancer activities, antifungal activities, and synergistic effects. Experimental protocols, structural characterization, molecular docking, determination of metabolic stability, and pharmacokinetic studies. (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the target compounds. (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf">jm8b00393_si_001.pdf (1.27 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_002.csv">jm8b00393_si_002.csv (1.66 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00393" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunquan Sheng</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9489-804X" title="Orcid link">http://orcid.org/0000-0001-9489-804X</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2c5f4449424b4f5d6c5f41415902494859024f42"><span class="__cf_email__" data-cfemail="f5869d909b929684b586989880db909180db969b">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yahui Huang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guoqiang Dong</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huanqiu Li</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmaceutical Science, Soochow University, Suzhou 215123, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Na Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wannian Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.H., G.D., and H.L. contributed equally to this work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Key R&D Program of China (grant no. 2017YFA0506000 to C.S.), National Natural Science Foundation of China (grant no. 81725020 to C.S.), and Science and Technology Commission of Shanghai Municipality (grant no. 17XD1404700 to C.S.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations List</td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HSCT</td><td class="NLM_def"><p class="first last">hematopoietic stem-cell transplantation</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">GVHD</td><td class="NLM_def"><p class="first last">graft versus host disease</p></td></tr><tr><td class="NLM_term">IFIs</td><td class="NLM_def"><p class="first last">invasive fungal infections</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc-binding group</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N,N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimum inhibitory concentration</p></td></tr><tr><td class="NLM_term">FIC</td><td class="NLM_def"><p class="first last">fractional inhibitory concentration</p></td></tr><tr><td class="NLM_term">FLC</td><td class="NLM_def"><p class="first last">fluconazole</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immune deficiency</p></td></tr><tr><td class="NLM_term">ICR</td><td class="NLM_def"><p class="first last">Institute of Cancer Research</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">Sprague-Dawley</p></td></tr><tr><td class="NLM_term">CFU</td><td class="NLM_def"><p class="first last">colony-forming units</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">MST</td><td class="NLM_def"><p class="first last">median survival time</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57878" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57878" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offidani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invernizzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lint, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentini, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girmenia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosari, A.</span></span> <span> </span><span class="NLM_article-title">The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1068</span>â <span class="NLM_lpage">1075</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=1068-1075&author=L.+Paganoauthor=M.+Cairaauthor=A.+Candoniauthor=M.+Offidaniauthor=L.+Fianchiauthor=B.+Martinoauthor=D.+Pastoreauthor=M.+Picardiauthor=A.+Boniniauthor=A.+Chierichiniauthor=R.+Fanciauthor=C.+Caramattiauthor=R.+Invernizziauthor=D.+Matteiauthor=M.+E.+Mitraauthor=L.+Melilloauthor=F.+Aversaauthor=M.+T.+Van+Lintauthor=P.+Falcucciauthor=C.+G.+Valentiniauthor=C.+Girmeniaauthor=A.+Nosari&title=The+epidemiology+of+fungal+infections+in+patients+with+hematologic+malignancies%3A+the+SEIFEM-2004+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DL.%26aulast%3DCaira%26aufirst%3DM.%26aulast%3DCandoni%26aufirst%3DA.%26aulast%3DOffidani%26aufirst%3DM.%26aulast%3DFianchi%26aufirst%3DL.%26aulast%3DMartino%26aufirst%3DB.%26aulast%3DPastore%26aufirst%3DD.%26aulast%3DPicardi%26aufirst%3DM.%26aulast%3DBonini%26aufirst%3DA.%26aulast%3DChierichini%26aufirst%3DA.%26aulast%3DFanci%26aufirst%3DR.%26aulast%3DCaramatti%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DR.%26aulast%3DMattei%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DM.%2BE.%26aulast%3DMelillo%26aufirst%3DL.%26aulast%3DAversa%26aufirst%3DF.%26aulast%3DVan%2BLint%26aufirst%3DM.%2BT.%26aulast%3DFalcucci%26aufirst%3DP.%26aulast%3DValentini%26aufirst%3DC.%2BG.%26aulast%3DGirmenia%26aufirst%3DC.%26aulast%3DNosari%26aufirst%3DA.%26atitle%3DThe%2520epidemiology%2520of%2520fungal%2520infections%2520in%2520patients%2520with%2520hematologic%2520malignancies%253A%2520the%2520SEIFEM-2004%2520study%26jtitle%3DHaematologica%26date%3D2006%26volume%3D91%26spage%3D1068%26epage%3D1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pophali, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, M. M.</span></span> <span> </span><span class="NLM_article-title">The role of new tyrosine kinase inhibitors in chronic myeloid leukemia</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">40</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1097/PPO.0000000000000165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1097%2FPPO.0000000000000165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26841016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit12msrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=40-50&author=P.+A.+Pophaliauthor=M.+M.+Patnaik&title=The+role+of+new+tyrosine+kinase+inhibitors+in+chronic+myeloid+leukemia&doi=10.1097%2FPPO.0000000000000165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia</span></div><div class="casAuthors">Pophali, Priyanka A.; Patnaik, Mrinal M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-50</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia.  Imatinib produces acceptable responses in approx. 60% of patients, with approx. 20% discontinuing therapy because of intolerance and approx. 20% developing drug resistance.  The advent of newer TKIs, such as nilotinib, dasatinib, bosutinib, and ponatinib, has provided multiple options for patients.  These agents are more potent, have unique adverse effect profiles, and are more likely to achieve relevant milestones, such as early mol. responses (3-6 mo) and optimal mol. responses (12 mo).  The acquisition of BCR-ABL kinase domain mutations is also reportedly lower with these drugs.  Thus far, none of the randomized phase III clin. trials have shown a clin. significant survival difference between frontline imatinib vs. newer TKIs.  Cost and safety issues with the newer TKIs, such as vascular disease with nilotinib and ponatinib and pulmonary hypertension with dasatinib, have dampened the enthusiasm of using these drugs as frontline options.  While the utility of new TKIs in the setting of imatinib failure or intolerance is clear, their use as frontline agents should factor in the age of the patient, addnl. comorbidities, risk stratification (Sokal score), and cost.  Combination therapies and newer agents with potential to eradicate quiescent chronic myeloid leukemia stem cells offers future hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouJ68ImNbrpbVg90H21EOLACvtfcHk0lhqmkJsTPWBSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit12msrs%253D&md5=ad246db34c96901d74a5f33cdefdf88f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000165%26sid%3Dliteratum%253Aachs%26aulast%3DPophali%26aufirst%3DP.%2BA.%26aulast%3DPatnaik%26aufirst%3DM.%2BM.%26atitle%3DThe%2520role%2520of%2520new%2520tyrosine%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520J.%26date%3D2016%26volume%3D22%26spage%3D40%26epage%3D50%26doi%3D10.1097%2FPPO.0000000000000165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J.</span></span> <span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>â <span class="NLM_lpage">244</span>, <span class="refDoi">Â DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0lhqmkJsTPWBSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">550</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lhqmkJsTPWBSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>â <span class="NLM_lpage">911</span>, <span class="refDoi">Â DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lhSqdWmsCMxiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>â <span class="NLM_lpage">5038</span>, <span class="refDoi">Â DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lhSqdWmsCMxiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontzias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotlyar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">464</span>â <span class="NLM_lpage">470</span>, <span class="refDoi">Â DOI: 10.1016/j.coph.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease&doi=10.1016%2Fj.coph.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0lhSqdWmsCMxiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470%26doi%3D10.1016%2Fj.coph.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2601</span>â <span class="NLM_lpage">2613</span>, <span class="refDoi">Â DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0lgjFPD5bMSXxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushal, S.</span></span> <span> </span><span class="NLM_article-title">Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1074</span>â <span class="NLM_lpage">1086</span>, <span class="refDoi">Â DOI: 10.1016/j.clinthera.2014.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.clinthera.2014.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=25047498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=1074-1086&author=K.+Kaurauthor=S.+Kalraauthor=S.+Kaushal&title=Systematic+review+of+tofacitinib%3A+a+new+drug+for+the+management+of+rheumatoid+arthritis&doi=10.1016%2Fj.clinthera.2014.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis</span></div><div class="casAuthors">Kaur, Kirandeep; Kalra, Sonesh; Kaushal, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1074-1086</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The goal of this study was to review and summarize the efficacy and safety of use of tofacitinib for treating rheumatoid arthritis (RA).  A systematic literature review was conducted to identify English-language articles published through May 2013 within PubMed, ClinicalTrials.gov, and Cochrane Library reporting results from Phase II and Phase III tofacitinib randomized clin. trials.  Tofacitinib must have been used as monotherapy or in combination therapy with disease-modifying antirheumatic drugs (DMARDs) in the treatment of RA.  Study outcomes had to include at least 1 of the following: American College of Rheumatol. (ACR) 20%, 50%, or 70% response rates; tender/swollen joint count; health assessment questionnaire of disability; radiog. outcomes; and drug persistence.  Eight studies (4 Phase II and 4 Phase III trials) were included in the review.  Patients with active RA and who were nonresponders to a biol. agent or the nonbiol. DMARD methotrexate were included in these studies.  The results of the Phase II trials show that tofacitinib at doses â¥3 mg BID was efficacious among the nonresponders.  The results of the Phase III trials, comparing tofacitinib 5 and 10 mg with placebo, show that tofacitinib led to a significant improvement in ACR20 response (P < 0.0001), Health Assessment Questionnaire-Disability Index (P < 0.0001) scores, and ACR50 response (P < 0.0001) after 3 mo.  The efficacy of tofacitinib was numerically similar to adalimumab.  The most common adverse events were infections, infestations, increases in LDL-C and HDL-C levels, and a decrease in neutrophil counts.  Tofacitinib is an efficacious drug for the management of moderate to severe RA among patients with an inadequate response to methotrexate and tumor necrosis factor inhibitors.  Long-term studies can help in understanding the risk/benefit profile of tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNhogMT16YO7Vg90H21EOLACvtfcHk0lgjFPD5bMSXxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI&md5=8ffd0a6e85f9b9880cc80462337ddc7f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2014.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2014.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DS.%26atitle%3DSystematic%2520review%2520of%2520tofacitinib%253A%2520a%2520new%2520drug%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DClin.%2520Ther.%26date%3D2014%26volume%3D36%26spage%3D1074%26epage%3D1086%26doi%3D10.1016%2Fj.clinthera.2014.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plosker, G. L.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a review of its use in patients with myelofibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">308</span>, <span class="refDoi">Â DOI: 10.1007/s40265-015-0351-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1007%2Fs40265-015-0351-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=25601187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=297-308&author=G.+L.+Plosker&title=Ruxolitinib%3A+a+review+of+its+use+in+patients+with+myelofibrosis&doi=10.1007%2Fs40265-015-0351-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis</span></div><div class="casAuthors">Plosker, Greg L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (Jakavi, Jakafi) is an orally administered inhibitor of Janus kinases (JAK) 1 and 2 used in the management of patients with myelofibrosis.  Clin. trials with ruxolitinib, notably the phase III COMFORT-I and -II studies and their extensions, have demonstrated marked and durable clin. benefits in terms of redns. in splenomegaly and disease-related symptoms in patients with intermediate-2 or high-risk myelofibrosis.  Ruxolitinib was also assocd. with improvements in health-related quality of life and functioning.  Despite the crossover of patients in control groups to ruxolitinib, results of the COMFORT studies and their extensions indicate a survival advantage for patients randomized to ruxolitinib.  The beneficial effects of ruxolitinib were obsd. across subgroups of myelofibrosis patients, including those not harbouring the JAK2V617F mutation.  Improvements in splenomegaly and disease-related symptoms were also obsd. in a trial in Japanese/Asian patients with myelofibrosis and in myelofibrosis patients with a low baseline platelet count.  Dose-related anemia and thrombocytopenia were common in clin. trials with ruxolitinib, but rarely led to discontinuation of therapy and were managed with dosage modifications and/or transfusions of packed red blood cells.  In addn. to the USA and EU, ruxolitinib is now approved in a no. of other countries, including Japan, and remains the only approved drug for the treatment of myelofibrosis, although various other agents are undergoing investigation.  Appropriate monitoring and dosage titrn. are important to achieve optimal clin. benefits of ruxolitinib.  Further research, including studies evaluating ruxolitinib-based combination therapy, may also help to optimize treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqinnNMi_PLVg90H21EOLACvtfcHk0lgjFPD5bMSXxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D&md5=58970b22ffdaab2e4a3d8ee7dffdb72f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0351-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0351-8%26sid%3Dliteratum%253Aachs%26aulast%3DPlosker%26aufirst%3DG.%2BL.%26atitle%3DRuxolitinib%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D297%26epage%3D308%26doi%3D10.1007%2Fs40265-015-0351-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK kinase in solid tumors: emerging opportunities and challenges</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">939</span>â <span class="NLM_lpage">951</span>, <span class="refDoi">Â DOI: 10.1038/onc.2015.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fonc.2015.150" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=939-951&author=M.+Buchertauthor=C.+J.+Burnsauthor=M.+Ernst&title=Targeting+JAK+kinase+in+solid+tumors%3A+emerging+opportunities+and+challenges&doi=10.1038%2Fonc.2015.150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.150%26sid%3Dliteratum%253Aachs%26aulast%3DBuchert%26aufirst%3DM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DErnst%26aufirst%3DM.%26atitle%3DTargeting%2520JAK%2520kinase%2520in%2520solid%2520tumors%253A%2520emerging%2520opportunities%2520and%2520challenges%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D939%26epage%3D951%26doi%3D10.1038%2Fonc.2015.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms</span>. <i>Hematol. Oncol. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">627</span>â <span class="NLM_lpage">642</span>, <span class="refDoi">Â DOI: 10.1016/j.hoc.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.hoc.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=28673392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=627-642&author=S.+C.+Meyer&title=Mechanisms+of+resistance+to+JAK2+inhibitors+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.hoc.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms</span></div><div class="casAuthors">Meyer Sara C</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-642</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myeloproliferative neoplasms are driven by activated JAK2 signaling due to somatic mutations in JAK2, the thrombopoietin receptor MPL or the chaperone calreticulin in hematopoietic stem/progenitor cells.  JAK2 inhibitors have been developed, but despite clinical benefits, they do not signficantly reduce the mutant clone.  Loss of response to JAK2 inhibitors occurs and several mechanisms of resistance, genetic and functional, have been identified.  Resistance mutations have not been reported in MPN patients suggesting incomplete target inhibition.  Alternative targeting of JAK2 by HSP90 inhibitors or type II JAK2 inhibition overcomes resistance to current JAK2 inhibitors.  Additional combined therapy approaches are currently being evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsWLFM_lbR1VmfW6udTcc2eYVYkVqGc-zUbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D&md5=195db657c3d8a32ffc83932047d37595</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520JAK2%2520inhibitors%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D31%26spage%3D627%26epage%3D642%26doi%3D10.1016%2Fj.hoc.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span> <span> </span><span class="NLM_article-title">Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms</span>. <i>Int. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">695</span>â <span class="NLM_lpage">702</span>, <span class="refDoi">Â DOI: 10.1007/s12185-013-1353-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1007%2Fs12185-013-1353-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23670175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1yntLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=695-702&author=N.+Bhagwatauthor=R.+L.+Levineauthor=P.+Koppikar&title=Sensitivity+and+resistance+of+JAK2+inhibitors+to+myeloproliferative+neoplasms&doi=10.1007%2Fs12185-013-1353-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms</span></div><div class="casAuthors">Bhagwat, Neha; Levine, Ross L.; Koppikar, Priya</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-702</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  The discovery of activating mutations in JAK2 and MPL in a majority of patients with myeloproliferative neoplasms (MPN) has led to the rapid clin. development of several JAK kinase inhibitors.  Of these, the JAK1/2 inhibitor, ruxolitinib (INCB018424, Incyte Corporation) was recently approved for the treatment of patients with myelofibrosis (MF).  JAK inhibitors have effectively reduced splenomegaly and high cytokine levels in patients leading to improvements in quality of life.  However, they have not been successful in eliminating the mutant clone in a majority of patients.  In vitro studies using satn. mutagenesis screens have revealed several mutations in JAK2 that confer resistance to JAK inhibitors.  Nevertheless, these mutations have not been identified so far in JAK inhibitor-treated patients.  A recent study from our lab. demonstrated that chronic JAK kinase inhibition leads to JAK inhibitor persistence via transphosphorylation of JAK2 through other JAK kinase family members.  This phenomenon is seen in cell lines, mouse models and patient samples.  The JAK inhibitor persistent cells, however, still remain JAK2 dependent and therefore combination therapies that target JAK2 and other components of the JAK-STAT pathway along with JAK inhibitors may provide addnl. benefits and improve clin. outcomes in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTsQA0yjOWqLVg90H21EOLACvtfcHk0ljQkbe4OH9sFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1yntLk%253D&md5=dbb7b81ecc3cc28ff370aab1f779ba38</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs12185-013-1353-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-013-1353-5%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DKoppikar%26aufirst%3DP.%26atitle%3DSensitivity%2520and%2520resistance%2520of%2520JAK2%2520inhibitors%2520to%2520myeloproliferative%2520neoplasms%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2013%26volume%3D97%26spage%3D695%26epage%3D702%26doi%3D10.1007%2Fs12185-013-1353-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span>. <i>Curr. Opin. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1097/MOH.0b013e32835d8e10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1097%2FMOH.0b013e32835d8e10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=123-129&author=F.+P.+Santosauthor=S.+Verstovsek&title=What+is+next+beyond+janus+kinase+2+inhibitors+for+primary+myelofibrosis%3F&doi=10.1097%2FMOH.0b013e32835d8e10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Although the approval of the janus kinase (JAK) inhibitor ruxolitinib for therapy of patients with myelofibrosis represents an important step in the development of targeted therapy for these patients, JAK inhibitors do not eradicate the disease, and a review of novel agents with mechanisms of action complementary to JAK2 enzymic inhibition is timely.  Recent findings: There are several compds. with different mechanisms of action undergoing preclin. and clin. testing in myelofibrosis.  Heat shock protein inhibitors and histone deacetylase inhibitors induce JAK2 degrdn. and downregulation of intracellular oncogenic signalling, and may overcome resistance to JAK2 inhibitors.  Reversal of bone marrow fibrosis is still a therapeutic challenge in this disease, and mAbs targeting transforming growth factor-Î² and lysyl oxidase like-2 may prove efficacious.  Promising compds. inhibiting signal transducer and activator of transcription 5 activity and inducing megakaryocyte polyploidization are in preclin. testing.  Summary: Although none of these new drugs have been approved for therapy of myelofibrosis, their activity is being tested in clin. trials, alone or in combination with JAK2 inhibitors.  Patients with myelofibrosis should be encouraged to participate in clin. trials testing novel compds. for this disorder, particularly if they have failed a trial of JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gqDFCRlvYrVg90H21EOLACvtfcHk0ljQkbe4OH9sFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D&md5=49159c335e02a416c0541d8b92069f4e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32835d8e10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32835d8e10%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DWhat%2520is%2520next%2520beyond%2520janus%2520kinase%25202%2520inhibitors%2520for%2520primary%2520myelofibrosis%253F%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2013%26volume%3D20%26spage%3D123%26epage%3D129%26doi%3D10.1097%2FMOH.0b013e32835d8e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choong, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaconu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defour, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeval, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span> <span> </span><span class="NLM_article-title">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1397</span>â <span class="NLM_lpage">1409</span>, <span class="refDoi">Â DOI: 10.1111/jcmm.12156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1111%2Fjcmm.12156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=24251790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFan" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1397-1409&author=M.+L.+Choongauthor=C.+Pecquetauthor=V.+Pendharkarauthor=C.+C.+Diaconuauthor=J.+W.+Yongauthor=S.+J.+Taiauthor=S.+F.+Wangauthor=J.+P.+Defourauthor=K.+Sangthongpitagauthor=J.+L.+Villevalauthor=W.+Vainchenkerauthor=S.+N.+Constantinescuauthor=M.+A.+Lee&title=Combination+treatment+for+myeloproliferative+neoplasms+using+JAK+and+pan-class+I+PI3K+inhibitors&doi=10.1111%2Fjcmm.12156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span></div><div class="casAuthors">Choong, Meng Ling; Pecquet, Christian; Pendharkar, Vishal; Diaconu, Carmen C.; Yong, Jacklyn Wei Yan; Tai, Shi Jing; Wang, Si Fang; Defour, Jean-Philippe; Sangthongpitag, Kanda; Villeval, Jean-Luc; Vainchenker, William; Constantinescu, Stefan N.; Lee, May Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1397-1409</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiol. JAK2 signalling.  We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeting nine signalling pathways and already used in clin. trials, synergized in inhibiting growth of haematopoietic cells expressing mutant and wild-type forms of JAK2 (V617F) or thrombopoietin receptor (W515L).  Out of 15 kinase inhibitors, the ZSTK474 phosphatydylinositol-3'-kinase (PI3K) inhibitor mol. showed strong synergic inhibition by Chou and Talalay anal. with JAK2 and JAK2/JAK1 inhibitors.  Other pan-class I, but not gamma or delta specific PI3K inhibitors, also synergized with JAK2 inhibitors.  Synergy was not obsd. in Bcr-Abl transformed cells.  The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen wt. in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.  It also exerted strong inhibitory effects on erythropoietin-independent erythroid colonies from MPN patients and JAK2 V617F knock-in mice, where at certain doses, a preferential inhibition of JAK2 V617F mutated progenitors was detected.  Our data support the use of a combination of JAK2 and pan-class I PI3K inhibitors in the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwYG9JAajg0rVg90H21EOLACvtfcHk0lggqojvaEuYnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFan&md5=f2fdba575d0402f6d971b1db53d41981</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12156%26sid%3Dliteratum%253Aachs%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DPecquet%26aufirst%3DC.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DDiaconu%26aufirst%3DC.%2BC.%26aulast%3DYong%26aufirst%3DJ.%2BW.%26aulast%3DTai%26aufirst%3DS.%2BJ.%26aulast%3DWang%26aufirst%3DS.%2BF.%26aulast%3DDefour%26aufirst%3DJ.%2BP.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DLee%26aufirst%3DM.%2BA.%26atitle%3DCombination%2520treatment%2520for%2520myeloproliferative%2520neoplasms%2520using%2520JAK%2520and%2520pan-class%2520I%2520PI3K%2520inhibitors%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1397%26epage%3D1409%26doi%3D10.1111%2Fjcmm.12156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waibel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralli, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidacs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virely, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins-Underwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghysdael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullighan, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1059</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2013.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.celrep.2013.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=24268771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1047-1059&author=M.+Waibelauthor=V.+S.+Solomonauthor=D.+A.+Knightauthor=R.+A.+Ralliauthor=S.+K.+Kimauthor=K.+M.+Banksauthor=E.+Vidacsauthor=C.+Virelyauthor=K.+C.+Siaauthor=L.+S.+Brackenauthor=R.+Collins-Underwoodauthor=C.+Drenbergauthor=L.+B.+Ramseyauthor=S.+C.+Meyerauthor=M.+Takiguchiauthor=R.+A.+Dickinsauthor=R.+Levineauthor=J.+Ghysdaelauthor=M.+A.+Dawsonauthor=R.+B.+Lockauthor=C.+G.+Mullighanauthor=R.+W.+Johnstone&title=Combined+targeting+of+JAK2+and+Bcl-2%2FBcl-xL+to+cure+mutant+JAK2-driven+malignancies+and+overcome+acquired+resistance+to+JAK2+inhibitors&doi=10.1016%2Fj.celrep.2013.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors</span></div><div class="casAuthors">Waibel, Michaela; Solomon, Vanessa S.; Knight, Deborah A.; Ralli, Rachael A.; Kim, Sang-Kyu; Banks, Kellie-Marie; Vidacs, Eva; Virely, Clemence; Sia, Keith C. S.; Bracken, Lauryn S.; Collins-Underwood, Racquel; Drenberg, Christina; Ramsey, Laura B.; Meyer, Sara C.; Takiguchi, Megumi; Dickins, Ross A.; Levine, Ross; Ghysdael, Jacques; Dawson, Mark A.; Lock, Richard B.; Mullighan, Charles G.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1047-1059</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To design rational therapies for JAK2-driven hematol. malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2.  In tumors driven by mutant JAK2, Stat1, Stat3, Stat5, and the Pi3k and Mek/Erk pathways were constitutively active, and gene expression profiling of TEL-JAK2 T-ALL cells revealed the upregulation of prosurvival Bcl-2 family genes.  Combining the Bcl-2/Bcl-xL inhibitor ABT-737 with JAK2 inhibitors mediated prolonged disease regressions and cures in mice bearing primary human and mouse JAK2 mutant tumors.  Moreover, combined targeting of JAK2 and Bcl-2/Bcl-xL was able to circumvent and overcome acquired resistance to single-agent JAK2 inhibitor treatment.  Thus, inhibiting the oncogenic JAK2 signaling network at two nodal points, at the initiating stage (JAK2) and the effector stage (Bcl-2/Bcl-xL), is highly effective and provides a clearly superior therapeutic benefit than targeting just one node.  Therefore, we have defined a potentially curative treatment for hematol. malignancies expressing constitutively active JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiJQ8J0GL_7Vg90H21EOLACvtfcHk0lggqojvaEuYnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN&md5=cd6ec40bd071fa0f811dee36bb882588</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DWaibel%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DV.%2BS.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DRalli%26aufirst%3DR.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DBanks%26aufirst%3DK.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DVirely%26aufirst%3DC.%26aulast%3DSia%26aufirst%3DK.%2BC.%26aulast%3DBracken%26aufirst%3DL.%2BS.%26aulast%3DCollins-Underwood%26aufirst%3DR.%26aulast%3DDrenberg%26aufirst%3DC.%26aulast%3DRamsey%26aufirst%3DL.%2BB.%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DTakiguchi%26aufirst%3DM.%26aulast%3DDickins%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DGhysdael%26aufirst%3DJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DCombined%2520targeting%2520of%2520JAK2%2520and%2520Bcl-2%252FBcl-xL%2520to%2520cure%2520mutant%2520JAK2-driven%2520malignancies%2520and%2520overcome%2520acquired%2520resistance%2520to%2520JAK2%2520inhibitors%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D5%26spage%3D1047%26epage%3D1059%26doi%3D10.1016%2Fj.celrep.2013.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptaco sa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">169</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1021/jm201112g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=169-196&author=A.+D.+Williamauthor=A.+C.+Leeauthor=K.+C.+Gohauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=C.+P.+Leeauthor=H.+Wangauthor=M.+Williamsauthor=E.+T.+Sunauthor=C.+Huauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+kinase+spectrum+selective+macrocycle+%2816E%29-14-methyl-20-oxa-5%2C7%2C14%2C26-tetraazatetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptaco+sa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2827%29%2C9%2C11%2C16%2C21%2C23-decaene+%28SB1317%2FTG02%29%2C+a+potent+inhibitor+of+cyclin+dependent+kinases+%28CDKs%29%2C+Janus+kinase+2+%28JAK2%29%2C+and+fms-like+tyrosine+kinase-3+%28FLT3%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm201112g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Goh, Kee Chuan; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Lee, Chai Ping; Wang, Haishan; Williams, Meredith; Sun, Eric T.; Hu, Changyong; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we describe the design, synthesis, and SAR of a series of unique small mol. macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3.  The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, soly., CYP450 inhibition, and microsomal stability.  This screening cascade revealed 26h (I) as a preferred compd. with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, resp.  Pharmacokinetic (PK) studies of 26h in preclin. species showed good oral exposures.  Oral efficacy was obsd. in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the obsd. PK/PD correlation.  26H (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clin. trials in advanced leukemias and multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMvOv-_pFzbVg90H21EOLACvtfcHk0lggqojvaEuYnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P&md5=50affe14bd28594735131d6b5841502a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201112g%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520kinase%2520spectrum%2520selective%2520macrocycle%2520%252816E%2529-14-methyl-20-oxa-5%252C7%252C14%252C26-tetraazatetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptaco%2520sa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-decaene%2520%2528SB1317%252FTG02%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependent%2520kinases%2520%2528CDKs%2529%252C%2520Janus%2520kinase%25202%2520%2528JAK2%2529%252C%2520and%2520fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D169%26epage%3D196%26doi%3D10.1021%2Fjm201112g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>â <span class="NLM_lpage">4658</span>, <span class="refDoi">Â DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lj-A9ezxcntVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woster, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Epigenetics: novel therapeutics targeting epigenetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">523</span>â <span class="NLM_lpage">524</span>, <span class="refDoi">Â DOI: 10.1021/jm501941q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501941q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=523-524&author=S.+J.+Conwayauthor=P.+M.+Wosterauthor=J.+K.+Shenauthor=G.+Georgauthor=S.+Wang&title=Epigenetics%3A+novel+therapeutics+targeting+epigenetics&doi=10.1021%2Fjm501941q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics: Novel Therapeutics Targeting Epigenetics</span></div><div class="casAuthors">Conway, Stuart J.; Woster, Patrick M.; Shen, Jing-Kang; Georg, Gunda; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCRBHbQISoP7Vg90H21EOLACvtfcHk0lj-A9ezxcntVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP&md5=589ff3da038c55adece6bcdbd6bbe461</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm501941q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501941q%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DS.%2BJ.%26aulast%3DWoster%26aufirst%3DP.%2BM.%26aulast%3DShen%26aufirst%3DJ.%2BK.%26aulast%3DGeorg%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DEpigenetics%253A%2520novel%2520therapeutics%2520targeting%2520epigenetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D523%26epage%3D524%26doi%3D10.1021%2Fjm501941q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ververis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licciardi, P. V.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span>. <i>Biol.: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">47</span>â <span class="NLM_lpage">60</span>, <span class="refDoi">Â DOI: 10.2147/BTT.S29965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.2147%2FBTT.S29965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23459471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=47-60&author=K.+Ververisauthor=A.+Hiongauthor=T.+C.+Karagiannisauthor=P.+V.+Licciardi&title=Histone+deacetylase+inhibitors+%28HDACIs%29%3A+multitargeted+anticancer+agents&doi=10.2147%2FBTT.S29965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span></div><div class="casAuthors">Ververis, Katherine; Hiong, Alison; Karagiannis, Tom C.; Licciardi, Paul V.</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5491</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs.  The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addn. to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter phenotype and gene expression, disturb homeostasis, and contribute to neoplastic growth.  The family of HDAC inhibitors is large and diverse.  It includes a range of naturally occurring and synthetic compds. that differ in terms of structure, function, and specificity.  HDAC inhibitors have multiple cell type-specific effects in vitro and in vivo, such as growth arrest, cell differentiation, and apoptosis in malignant cells.  HDAC inhibitors have the potential to be used as monotherapies or in combination with other anticancer therapies.  Currently, there are two HDAC inhibitors that have received approval from the US FDA for the treatment of cutaneous T-cell lymphoma: vorinostat (suberoylanilide hydroxamic acid, Zolinza) and depsipeptide (romidepsin, Istodax).  More recently, depsipeptide has also gained FDA approval for the treatment of peripheral T-cell lymphoma.  Many more clin. trials assessing the effects of various HDAC inhibitors on hematol. and solid malignancies are currently being conducted.  Despite the proven anticancer effects of particular HDAC inhibitors against certain cancers, many aspects of HDAC enzymes and HDAC inhibitors are still not fully understood.  Increasing our understanding of the effects of HDAC inhibitors, their targets and mechanisms of action will be crit. for the advancement of these drugs, esp. to facilitate the rational design of HDAC inhibitors that are effective as antineoplastic agents.  This review will discuss the use of HDAC inhibitors as multitargeted therapies for malignancy.  Further, we outline the pharmacol. and mechanisms of action of HDAC inhibitors while discussing the safety and efficacy of these compds. in clin. studies to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAm6AJlxdHLVg90H21EOLACvtfcHk0lj-A9ezxcntVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D&md5=288f04e51d214cef9edf5bc8a8c3c624</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FBTT.S29965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBTT.S29965%26sid%3Dliteratum%253Aachs%26aulast%3DVerveris%26aufirst%3DK.%26aulast%3DHiong%26aufirst%3DA.%26aulast%3DKaragiannis%26aufirst%3DT.%2BC.%26aulast%3DLicciardi%26aufirst%3DP.%2BV.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%253A%2520multitargeted%2520anticancer%2520agents%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D47%26epage%3D60%26doi%3D10.2147%2FBTT.S29965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1247</span>â <span class="NLM_lpage">1252</span>, <span class="refDoi">Â DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0ljjm1A-unDT0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenehjem, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Panobinostat for the treatment of multiple myeloma: the evidence to date</span>. <i>J. Blood Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.2147/JBM.S69140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.2147%2FJBM.S69140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26504410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=269-276&author=H.+Baileyauthor=D.+D.+Stenehjemauthor=S.+Sharma&title=Panobinostat+for+the+treatment+of+multiple+myeloma%3A+the+evidence+to+date&doi=10.2147%2FJBM.S69140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat for the treatment of multiple myeloma: the evidence to date</span></div><div class="casAuthors">Bailey, Hanna; Stenehjem, David D.; Sharma, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Blood Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-276</span>CODEN:
                <span class="NLM_cas:coden">JBMOB7</span>;
        ISSN:<span class="NLM_cas:issn">1179-2736</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow.  Survival of patients diagnosed with myeloma has significantly improved in the last decade, following the approval of novel agents.  Despite great strides achieved in the management of multiple myeloma, it is still considered an incurable disease as the majority of patients relapse after initiation of therapy.  Addnl., the duration of response generally decreases with an increasing no. of therapy lines.  The need to overcome resistance to therapy dictates research into more potent agents and those with novel mechanisms of action.  A therapeutic option for relapsed/refractory myeloma includes histone deacetylase inhibition.  Various histone deacetylase inhibitors, including the newly approved panobinostat, are currently under evaluation in this setting.  Panobinostat for multiple myeloma is used in combination with other potent therapeutic agents, such as proteasome inhibitors and steroids.  Ongoing research evaluating other panobinostat-contg. regimens will provide addnl. insight into its place in myeloma management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg66vLqHlQjrVg90H21EOLACvtfcHk0ljjm1A-unDT0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D&md5=cdff9d1bd461e6fb06e50c4708097951</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2147%2FJBM.S69140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJBM.S69140%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DH.%26aulast%3DStenehjem%26aufirst%3DD.%2BD.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DPanobinostat%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520the%2520evidence%2520to%2520date%26jtitle%3DJ.%2520Blood%2520Med.%26date%3D2015%26volume%3D6%26spage%3D269%26epage%3D276%26doi%3D10.2147%2FJBM.S69140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomathi Priya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjan, M. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of histone deacetylase as antitumor agents: a critical review</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">18</span>â <span class="NLM_lpage">42</span>, <span class="refDoi">Â DOI: 10.1016/j.bioorg.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.bioorg.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=27239721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=18-42&author=M.+Manalauthor=M.+J.+Chandrasekarauthor=J.+Gomathi+Priyaauthor=M.+J.+Nanjan&title=Inhibitors+of+histone+deacetylase+as+antitumor+agents%3A+a+critical+review&doi=10.1016%2Fj.bioorg.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of histone deacetylase as antitumor agents: A critical review</span></div><div class="casAuthors">Manal, Mohammed; Chandrasekar, M. J. N.; Gomathi Priya, Jeyapal; Nanjan, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-42</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (E.C. 3.5.1.98 - HDAC) is an amidohydrolase involved in deacetylating the histone lysine residues for chromatin remodeling and thus plays a vital role in the epigenetic regulation of gene expression.  Due to its aberrant activity and over expression in several forms of cancer, HDAC is considered as a potential anticancer drug target.  HDAC inhibitors alter the acetylation status of histone and nonhistone proteins to regulate various cellular events such as cell survival, differentiation and apoptosis in tumor cells and thus exhibit anticancer activity.  Till date, four drugs, namely Vorinostat (SAHA), Romidepsin (FK-228), Belinostat (PXD-101) and Panobinostat (LBH-589) have been granted FDA approval for cancer and several HDAC inhibitors are currently in various phases of clin. trials, either as monotherapy and/or in combination with existing/novel anticancer agents.  Regardless of this, today scientific efforts have fortified the quest for newer and novel HDAC inhibitors that show isoform selectivity.  This review focuses on the chem. of the mols. of two classes of HDAC inhibitors, namely short chain fatty acids and hydroxamic acids, investigated so far as novel therapeutic agents for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdC7-JmHyErrVg90H21EOLACvtfcHk0li3maH4YmZZzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D&md5=82e5562d9b74dfef2d6077bbceccd505</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DManal%26aufirst%3DM.%26aulast%3DChandrasekar%26aufirst%3DM.%2BJ.%26aulast%3DGomathi%2BPriya%26aufirst%3DJ.%26aulast%3DNanjan%26aufirst%3DM.%2BJ.%26atitle%3DInhibitors%2520of%2520histone%2520deacetylase%2520as%2520antitumor%2520agents%253A%2520a%2520critical%2520review%26jtitle%3DBioorg.%2520Chem.%26date%3D2016%26volume%3D67%26spage%3D18%26epage%3D42%26doi%3D10.1016%2Fj.bioorg.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget drugs: an epigenetic epiphany</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1241</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1002%2Fcmdc.201500394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26891251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1227-1241&author=A.+Ganesan&title=Multitarget+drugs%3A+an+epigenetic+epiphany&doi=10.1002%2Fcmdc.201500394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drugs: an Epigenetic Epiphany</span></div><div class="casAuthors">Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1227-1241</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Epigenetics refers to changes in a biol. phenotype that are not due to an underlying change in genotype.  In eukaryotes, epigenetics involves a set of chem. modifications of the DNA and the histone proteins in nucleosomes.  These dynamic changes are carried out by enzymes and modulate protein-protein and protein-nucleic acid interactions to det. whether specific genes are expressed or silenced.  Both the epigenetic enzymes and recognition domains are currently important drug discovery targets, particularly for the treatment of cancer.  This review summarizes the progress of epigenetic targets that have reached a clin. stage: DNA methyltransferases, histone deacetylases, lysine methyltransferases, lysine demethylases, and bromodomains; this is followed by a comprehensive survey of multitarget drugs that have included an epigenetic target as one of their mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwdZM3u9Wbc7Vg90H21EOLACvtfcHk0li3maH4YmZZzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D&md5=736284dc3f05db0032c9a304884f980d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500394%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMultitarget%2520drugs%253A%2520an%2520epigenetic%2520epiphany%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1227%26epage%3D1241%26doi%3D10.1002%2Fcmdc.201500394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>â <span class="NLM_lpage">7887</span>, <span class="refDoi">Â DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0li3maH4YmZZzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>â <span class="NLM_lpage">8971</span>, <span class="refDoi">Â DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0li3maH4YmZZzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>â <span class="NLM_lpage">2059</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0ljqMkkVRUfjWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>â <span class="NLM_lpage">8357</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0ljqMkkVRUfjWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>â <span class="NLM_lpage">8262</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0ljqMkkVRUfjWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>â <span class="NLM_lpage">7983</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0lgFmeTqJ9IUcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">243</span>, <span class="refDoi">Â DOI: 10.1021/ml500327q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500327q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-243&author=S.+Heauthor=G.+Dongauthor=Z.+Wangauthor=W.+Chenauthor=Y.+Huangauthor=Z.+Liauthor=Y.+Jiangauthor=N.+Liuauthor=J.+Yaoauthor=Z.+Miaoauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+novel+multiacting+topoisomerase+I%2FII+and+histone+deacetylase+inhibitors&doi=10.1021%2Fml500327q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wang, Zhibin; Chen, Wei; Huang, Yahui; Li, Zhengang; Jiang, Yan; Liu, Na; Yao, Jianzhong; Miao, Zhenyuan; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs remains a significant challenge in current antitumor drug discovery.  Because of the synergistic effect between topoisomerase and HDAC inhibitors, the present study reported the first-in-class triple inhibitors of topoisomerase I/II and HDAC.  On the basis of 3-amino-10-hydroxylevodiamine and SAHA, a series of hybrid mols. was successfully designed and synthesized.  In particular, compd. 8c was proven to be a potent inhibitor of topoisomerase I/II and HDAC with good antiproliferative and apoptotic activities.  This proof-of-concept study also validated the effectiveness of discovering triple topoisomerase I/II and HDAC inhibitors as novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFr6sR4u6kbVg90H21EOLACvtfcHk0lgFmeTqJ9IUcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D&md5=9630a82acaa4df7023a07aa7ed395e86</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500327q%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520multiacting%2520topoisomerase%2520I%252FII%2520and%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml500327q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-kappaB pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">577</span>, <span class="refDoi">Â DOI: 10.1021/jm401800k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401800k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=567-577&author=C.+Zhuangauthor=Z.+Miaoauthor=Y.+Wuauthor=Z.+Guoauthor=J.+Liauthor=J.+Yaoauthor=C.+Xingauthor=C.+Shengauthor=W.+Zhang&title=Double-edged+swords+as+cancer+therapeutics%3A+novel%2C+orally+active%2C+small+molecules+simultaneously+inhibit+p53-MDM2+interaction+and+the+NF-kappaB+pathway&doi=10.1021%2Fjm401800k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm401800k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401800k%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DC.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DDouble-edged%2520swords%2520as%2520cancer%2520therapeutics%253A%2520novel%252C%2520orally%2520active%252C%2520small%2520molecules%2520simultaneously%2520inhibit%2520p53-MDM2%2520interaction%2520and%2520the%2520NF-kappaB%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D567%26epage%3D577%26doi%3D10.1021%2Fjm401800k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span>; <span class="NLM_string-name">Mak, C.
C.</span>; <span class="NLM_string-name">Cao, J.</span>; <span class="NLM_string-name">Renick, J.</span>; <span class="NLM_string-name">Mcpherson, A.</span>; <span class="NLM_string-name">Zeng, B.</span>; <span class="NLM_string-name">Pathak, V. P.</span>; <span class="NLM_string-name">Lohse, D. L.</span>; <span class="NLM_string-name">Hood, J. D.</span>; <span class="NLM_string-name">Soll, R. M.</span></span> <span> </span><span class="NLM_article-title">Bi-aryl Meta-pyrimidine Inhibitors of Kinases</span>. U.S. Patent <span class="NLM_patent">8,604,042</span>, Dec. 10, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+Noronha&author=C.%0AC.+Mak&author=J.+Cao&author=J.+Renick&author=A.+Mcpherson&author=B.+Zeng&author=V.+P.+Pathak&author=D.+L.+Lohse&author=J.+D.+Hood&author=R.+M.+Soll&title=Bi-aryl+Meta-pyrimidine+Inhibitors+of+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26atitle%3DBi-aryl%2520Meta-pyrimidine%2520Inhibitors%2520of%2520Kinases%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gryder, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodji, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">505</span>â <span class="NLM_lpage">524</span>, <span class="refDoi">Â DOI: 10.4155/fmc.12.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.4155%2Ffmc.12.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22416777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=505-524&author=B.+E.+Gryderauthor=Q.+H.+Sodjiauthor=A.+K.+Oyelere&title=Targeted+cancer+therapy%3A+giving+histone+deacetylase+inhibitors+all+they+need+to+succeed&doi=10.4155%2Ffmc.12.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span></div><div class="casAuthors">Gryder, Berkley E.; Sodji, Quaovi H.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-524</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-mol. therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets.  Over 490 clin. trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis-SAHA (vorinostat, Zolinza) and FK228 (romidepsin, Istodax).  However, the current HDACis have serious limitations, including ineffectively low concns. in solid tumors and cardiac toxicity, which is hindering their progress in the clinic.  Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwrW1IVCIULVg90H21EOLACvtfcHk0lgFmeTqJ9IUcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D&md5=234080d1b0862680a68062a03afee20c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.3%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DSodji%26aufirst%3DQ.%2BH.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520giving%2520histone%2520deacetylase%2520inhibitors%2520all%2520they%2520need%2520to%2520succeed%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D505%26epage%3D524%26doi%3D10.4155%2Ffmc.12.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourke, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrugia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nero, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikanyika, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Styles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treutlein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span> <span> </span><span class="NLM_article-title">Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5887</span>â <span class="NLM_lpage">5892</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.08.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.bmcl.2009.08.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=19762238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2hurvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5887-5892&author=C.+J.+Burnsauthor=D.+G.+Bourkeauthor=L.+Andrauauthor=X.+Buauthor=S.+A.+Charmanauthor=A.+C.+Donohueauthor=E.+Fantinoauthor=M.+Farrugiaauthor=J.+T.+Feutrillauthor=M.+Joffeauthor=M.+R.+Klingauthor=M.+Kurekauthor=T.+L.+Neroauthor=T.+Nguyenauthor=J.+T.+Palmerauthor=I.+Phillipsauthor=D.+M.+Shacklefordauthor=H.+Sikanyikaauthor=M.+Stylesauthor=S.+Suauthor=H.+Treutleinauthor=J.+Zengauthor=A.+F.+Wilks&title=Phenylaminopyrimidines+as+inhibitors+of+Janus+kinases+%28JAKs%29&doi=10.1016%2Fj.bmcl.2009.08.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)</span></div><div class="casAuthors">Burns, Christopher J.; Bourke, David G.; Andrau, Laura; Bu, Xianyong; Charman, Susan A.; Donohue, Andrew C.; Fantino, Emmanuelle; Farrugia, Michelle; Feutrill, John T.; Joffe, Max; Kling, Marcel R.; Kurek, Margarita; Nero, Tracy L.; Nguyen, Thao; Palmer, James T.; Phillips, Ian; Shackleford, David M.; Sikanyika, Harrison; Styles, Michelle; Su, Stephen; Treutlein, Herbert; Zeng, Jun; Wilks, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5887-5892</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs).  Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide, I).  Details of synthesis and SAR studies of these compds. are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUtVZ62x-yaLVg90H21EOLACvtfcHk0lhbjQVeeXdlXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2hurvK&md5=e18632045687d8b56e403c2d4a7d676f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.071%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DBourke%26aufirst%3DD.%2BG.%26aulast%3DAndrau%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DX.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonohue%26aufirst%3DA.%2BC.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DFarrugia%26aufirst%3DM.%26aulast%3DFeutrill%26aufirst%3DJ.%2BT.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DKling%26aufirst%3DM.%2BR.%26aulast%3DKurek%26aufirst%3DM.%26aulast%3DNero%26aufirst%3DT.%2BL.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26aulast%3DPhillips%26aufirst%3DI.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DSikanyika%26aufirst%3DH.%26aulast%3DStyles%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DTreutlein%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DPhenylaminopyrimidines%2520as%2520inhibitors%2520of%2520Janus%2520kinases%2520%2528JAKs%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5887%26epage%3D5892%26doi%3D10.1016%2Fj.bmcl.2009.08.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, J.</span></span> <span> </span><span class="NLM_article-title">Role of heat-shock proteins in cellular function and in the biology of fungi</span>. <i>Biotechnol. Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">132635</span>, <span class="refDoi">Â DOI: 10.1155/2015/132635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1155%2F2015%2F132635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26881084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A280%3ADC%252BC28jhtVyjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=132635&author=S.+Tiwariauthor=R.+Thakurauthor=J.+Shankar&title=Role+of+heat-shock+proteins+in+cellular+function+and+in+the+biology+of+fungi&doi=10.1155%2F2015%2F132635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Heat-Shock Proteins in Cellular Function and in the Biology of Fungi</span></div><div class="casAuthors">Tiwari Shraddha; Thakur Raman; Shankar Jata</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132635</span>
        ISSN:<span class="NLM_cas:issn">2090-3138</span>.
    </div><div class="casAbstract">Stress (biotic or abiotic) is an unfavourable condition for an organism including fungus.  To overcome stress, organism expresses heat-shock proteins (Hsps) or chaperons to perform biological function.  Hsps are involved in various routine biological processes such as transcription, translation and posttranslational modifications, protein folding, and aggregation and disaggregation of proteins.  Thus, it is important to understand holistic role of Hsps in response to stress and other biological conditions in fungi.  Hsp104, Hsp70, and Hsp40 are found predominant in replication and Hsp90 is found in transcriptional and posttranscriptional process.  Hsp90 and Hsp70 in combination or alone play a major role in morphogenesis and dimorphism.  Heat stress in fungi expresses Hsp60, Hsp90, Hsp104, Hsp30, and Hsp10 proteins, whereas expression of Hsp12 protein was observed in response to cold stress.  Hsp30, Hsp70, and Hsp90 proteins showed expression in response to pH stress.  Osmotic stress is controlled by small heat-shock proteins and Hsp60.  Expression of Hsp104 is observed under high pressure conditions.  Out of these heat-shock proteins, Hsp90 has been predicted as a potential antifungal target due to its role in morphogenesis.  Thus, current review focuses on role of Hsps in fungi during morphogenesis and various stress conditions (temperature, pH, and osmotic pressure) and in antifungal drug tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRFS7HBs9MUoFEOhA_Im3cfW6udTcc2eYJ7KhDJLZkpLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhtVyjsQ%253D%253D&md5=77268ac0f1bdbeabb33c2c6a20cfc8ae</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1155%2F2015%2F132635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F132635%26sid%3Dliteratum%253Aachs%26aulast%3DTiwari%26aufirst%3DS.%26aulast%3DThakur%26aufirst%3DR.%26aulast%3DShankar%26aufirst%3DJ.%26atitle%3DRole%2520of%2520heat-shock%2520proteins%2520in%2520cellular%2520function%2520and%2520in%2520the%2520biology%2520of%2520fungi%26jtitle%3DBiotechnol.%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D132635%26doi%3D10.1155%2F2015%2F132635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlind, T. D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3532</span>â <span class="NLM_lpage">3539</span>, <span class="refDoi">Â DOI: 10.1128/AAC.46.11.3532-3539.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1128%2FAAC.46.11.3532-3539.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=12384361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1yktbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3532-3539&author=W.+L.+Smithauthor=T.+D.+Edlind&title=Histone+deacetylase+inhibitors+enhance+Candida+albicans+sensitivity+to+azoles+and+related+antifungals%3A+correlation+with+reduction+in+CDR+and+ERG+upregulation&doi=10.1128%2FAAC.46.11.3532-3539.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation</span></div><div class="casAuthors">Smith, W. Lamar; Edlind, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3532-3539</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation play important roles in eukaryotic gene regulation.  Several histone deacetylase (HDA) inhibitors have been characterized, including trichostatin A (TSA), apicidin, and sodium butyrate.  We tested their effects on Candida albicans in vitro growth, heat sensitivity, and germ tube formation; minimal effects were obsd.  However, there was a dramatic effect of TSA on C. albicans sensitivity to the azoles fluconazole, itraconazole, and miconazole.  Similar effects were obsd. with other HDA inhibitors and with the antifungals terbinafine and fenpropimorph, which target, as do azoles, enzymes in the ergosterol biosynthetic pathway.  In contrast, HDA inhibitors had minimal effect on the activities of amphotericin B, flucytosine, and echinocandin, which have unrelated targets.  Specifically, addn. of 3 Î¼g of TSA/mL lowered the itraconazole MIC for five susceptible C. albicans isolates an av. of 2.7-fold at 24 h, but this increased to > 200-fold at 48 h.  Thus, the primary effect of TSA was a redn. in azole trailing.  TSA also enhanced itraconazole activity against Candida parapsilosis and Candida tropicalis but had no effect with four less related yeast species.  To examine the mol. basis for these effects, we studied expression of ERG genes (encoding azole and terbinafine targets) and CDR/MDR1 genes (encoding multidrug transporters) in C. albicans cells treated with fluconazole or terbinafine with or without TSA.  Both antifungals induced to various levels the expression of ERG1, ERG11, CDR1, and CDR2; addn. of TSA reduced this upregulation 50 to 100%.  This most likely explains the inhibition of azole and terbinafine trailing by TSA and, more generally, provides evidence that trailing is mediated by upregulation of target enzymes and multidrug transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4DpmS0neAOrVg90H21EOLACvtfcHk0lj1f0fbw7HTlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1yktbc%253D&md5=8a372cf4fcb9077cf8b92c21b37792bf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.11.3532-3539.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.11.3532-3539.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DW.%2BL.%26aulast%3DEdlind%26aufirst%3DT.%2BD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520enhance%2520Candida%2520albicans%2520sensitivity%2520to%2520azoles%2520and%2520related%2520antifungals%253A%2520correlation%2520with%2520reduction%2520in%2520CDR%2520and%2520ERG%2520upregulation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D3532%26epage%3D3539%26doi%3D10.1128%2FAAC.46.11.3532-3539.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passariello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamara, A. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1221</span>â <span class="NLM_lpage">1225</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.bmcl.2006.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=17196388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1221-1225&author=A.+Maiauthor=D.+Rotiliauthor=S.+Massaauthor=G.+Broschauthor=G.+Simonettiauthor=C.+Passarielloauthor=A.+T.+Palamara&title=Discovery+of+uracil-based+histone+deacetylase+inhibitors+able+to+reduce+acquired+antifungal+resistance+and+trailing+growth+in+Candida+albicans&doi=10.1016%2Fj.bmcl.2006.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans</span></div><div class="casAuthors">Mai, Antonello; Rotili, Dante; Massa, Silvio; Brosch, Gerald; Simonetti, Giovanna; Passariello, Claudio; Palamara, Anna Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1221-1225</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Among fungal pathogens such as Candida albicans, acquired drug resistance has not been assocd. with plasmids or other transferable elements, but it is thought to involve primarily mutations and genetic or epigenetic phenomena.  This the authors to test some histone deacetylase inhibitors (HDACi) from their library, in combination with fluconazole, against C. albicans strains in vitro.  Among the tested compds., the two chloro-contg. uracil-hydroxamates 1c and 1d showed a strong redn. of the MIC values on Candida strains that show the trailing growth effect.  In this assay, 1c,d were more potent than SAHA, a well-known HDAC inhibitor, in reducing the Candida growth.  Compds. 1c,d as well as SAHA were able to inhibit the fluconazole-induced resistance induction in Candida cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgG2dBVCiTN7Vg90H21EOLACvtfcHk0lj1f0fbw7HTlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjsL8%253D&md5=459aca01b82b284070f9bfe6229aca3b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DBrosch%26aufirst%3DG.%26aulast%3DSimonetti%26aufirst%3DG.%26aulast%3DPassariello%26aufirst%3DC.%26aulast%3DPalamara%26aufirst%3DA.%2BT.%26atitle%3DDiscovery%2520of%2520uracil-based%2520histone%2520deacetylase%2520inhibitors%2520able%2520to%2520reduce%2520acquired%2520antifungal%2520resistance%2520and%2520trailing%2520growth%2520in%2520Candida%2520albicans%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1221%26epage%3D1225%26doi%3D10.1016%2Fj.bmcl.2006.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span> <span> </span><span class="NLM_article-title">The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1993</span>â <span class="NLM_lpage">2003</span>, <span class="refDoi">Â DOI: 10.1093/jac/dkv070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1093%2Fjac%2Fdkv070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=25825380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OltbvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=1993-2003&author=X.+Liauthor=Q.+Caiauthor=H.+Meiauthor=X.+Zhouauthor=Y.+Shenauthor=D.+Liauthor=W.+Liu&title=The+Rpd3%2FHda1+family+of+histone+deacetylases+regulates+azole+resistance+in+Candida+albicans&doi=10.1093%2Fjac%2Fdkv070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans</span></div><div class="casAuthors">Li, Xiaofang; Cai, Qing; Mei, Huan; Zhou, Xiaowei; Shen, Yongnian; Li, Dongmei; Liu, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1993-2003</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: The histone deacetylase (HDAC) has recently been linked to the morphogenesis and virulence of yeast.  However, the effects of HDAC on antifungal susceptibility are not well understood.  We sought to characterize the action of histone deacetylation on azole resistance in Candida albicans and its possible mechanism of action.  Methods: A total of 40 C. albicans strains were studied.  Azole susceptibility with or without trichostatin A (TSA) was detd. according to the CLSI microdilution method.  The null mutants of HDA1 and RPD3 (genes targeted by TSA) were also investigated using drop-plate assays and a rapid acquisition of adaptation to the azole test.  Transcriptional levels of HDAC genes and efflux genes were quantified using RT-PCR for both the basal and fluconazole-induced conditions.  Results: The inhibition of HDACs by TSA (0.25 mg/L) markedly reduced the trailing growth and the growth of most C. albicans strains.  Trailing growth for C. albicans strains was decreased from 2-fold to 256-fold at 48 h.  The deletion of HDA1 or RPD3 increased the susceptibility to azoles compared with the WT strain.  The expression of HDA1 and RPD3 was up-regulated to different levels, and returned to the level of the susceptible parental strain when stable resistance had formed during the course of acquired fluconazole resistance both in vitro and in vivo.  Efflux genes were poorly expressed in mutant strains compared with those of the WT strain.  Conclusions: Our results indicate the important role of the Rpd3/Hda1 family in the development of azole resistance in C. albicans.  Histone deacetylation may govern the expression of genes related to the early stages of adaptation to azole stress, such as efflux pump genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvglqXcJdnsbVg90H21EOLACvtfcHk0lj1f0fbw7HTlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OltbvE&md5=34cf1e334db6d83f40c498cf9218eb8f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv070%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DThe%2520Rpd3%252FHda1%2520family%2520of%2520histone%2520deacetylases%2520regulates%2520azole%2520resistance%2520in%2520Candida%2520albicans%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D1993%26epage%3D2003%26doi%3D10.1093%2Fjac%2Fdkv070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">5296</span>â <span class="NLM_lpage">5304</span>, <span class="refDoi">Â DOI: 10.1021/pr9005074</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr9005074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOqtb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=5296-5304&author=Y.+Xuauthor=Y.+Wangauthor=L.+Yanauthor=R.+M.+Liangauthor=B.+D.+Daiauthor=R.+J.+Tangauthor=P.+H.+Gaoauthor=Y.+Y.+Jiang&title=Proteomic+analysis+reveals+a+synergistic+mechanism+of+fluconazole+and+berberine+against+fluconazole-resistant+Candida+albicans%3A+endogenous+ROS+augmentation&doi=10.1021%2Fpr9005074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: Endogenous ROS augmentation</span></div><div class="casAuthors">Xu, Yi; Wang, Yan; Yan, Lan; Liang, Rong-Mei; Dai, Bao-Di; Tang, Ren-Jie; Gao, Ping-Hui; Jiang, Yuan-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5296-5304</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A previous study showed that concomitant use of berberine (BBR) and fluconazole (FLC) provided a synergistic action against FLC-resistant Candida albicans (C. albicans) clin. strains in vitro.  To clarify the mechanism underlying this action, the authors performed a comparative proteomic study in untreated control cells and cells treated with FLC and/or BBR in 2 clin. strains of C. albicans resistant to FLC.  Their analyses identified 16 differentially expressed proteins, most of which were related to energy metab. (e.g., Gap1, Adh1, and Aco1).  Functional analyses revealed that FLC + BBR treatment increased mitochondrial membrane potential, decreased intracellular ATP level, inhibited ATP synthase activity, and increased generation of endogenous reactive oxygen species (ROS) in FLC-resistant strains.  In addn., checkerboard microdilution assay showed that addn. of antioxidant ascorbic acid or reduced glutathione reduced the synergistic antifungal activity of FLC + BBR significantly.  These results suggest that mitochondrial aerobic respiration shift and endogenous ROS augmentation contribute to the synergistic action of FLC + BBR against FLC-resistant C. albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe-555LzTQqLVg90H21EOLACvtfcHk0ljOSiXsyL98UQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOqtb%252FE&md5=2240cc574a99bf927aa200b6dac3af7c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fpr9005074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr9005074%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DR.%2BM.%26aulast%3DDai%26aufirst%3DB.%2BD.%26aulast%3DTang%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DP.%2BH.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26atitle%3DProteomic%2520analysis%2520reveals%2520a%2520synergistic%2520mechanism%2520of%2520fluconazole%2520and%2520berberine%2520against%2520fluconazole-resistant%2520Candida%2520albicans%253A%2520endogenous%2520ROS%2520augmentation%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2009%26volume%3D8%26spage%3D5296%26epage%3D5304%26doi%3D10.1021%2Fpr9005074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odds, F. C.</span></span> <span> </span><span class="NLM_article-title">Synergy, antagonism, and what the chequerboard puts between them</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.1093/jac/dkg301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1093%2Fjac%2Fdkg301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=12805255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVWjsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=1&author=F.+C.+Odds&title=Synergy%2C+antagonism%2C+and+what+the+chequerboard+puts+between+them&doi=10.1093%2Fjac%2Fdkg301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy, antagonism, and what the chequerboard puts between them</span></div><div class="casAuthors">Odds, F. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVJ1xsH5KwLVg90H21EOLACvtfcHk0ljOSiXsyL98UQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVWjsr0%253D&md5=b214be21ff21422856db140f8c4a0fd0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg301%26sid%3Dliteratum%253Aachs%26aulast%3DOdds%26aufirst%3DF.%2BC.%26atitle%3DSynergy%252C%2520antagonism%252C%2520and%2520what%2520the%2520chequerboard%2520puts%2520between%2520them%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D52%26spage%3D1%26doi%3D10.1093%2Fjac%2Fdkg301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordiyenko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, J. W.</span></span> <span> </span><span class="NLM_article-title">Class I HDACs share a common mechanism of regulation by inositol phosphates</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.molcel.2013.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23791785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2013&pages=57-67&author=C.+J.+Millardauthor=P.+J.+Watsonauthor=I.+Celardoauthor=Y.+Gordiyenkoauthor=S.+M.+Cowleyauthor=C.+V.+Robinsonauthor=L.+Fairallauthor=J.+W.+Schwabe&title=Class+I+HDACs+share+a+common+mechanism+of+regulation+by+inositol+phosphates&doi=10.1016%2Fj.molcel.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates</span></div><div class="casAuthors">Millard, Christopher J.; Watson, Peter J.; Celardo, Ivana; Gordiyenko, Yuliya; Cowley, Shaun M.; Robinson, Carol V.; Fairall, Louise; Schwabe, John W. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDAC1, HDAC2, and HDAC3) are recruited by cognate corepressor proteins into specific transcriptional repression complexes that target HDAC activity to chromatin resulting in chromatin condensation and transcriptional silencing.  The authors previously reported the structure of HDAC3 in complex with the SMRT corepressor.  This structure revealed inositol-tetraphosphate [Ins(1,4,5,6)P4] at the interface of the two proteins.  It was previously unclear whether the role of Ins(1,4,5,6)P4 is to act as a structural cofactor or a regulator of HDAC3 activity.  Here the authors report the structure of HDAC1 in complex with MTA1 from the NuRD complex.  The ELM2-SANT domains from MTA1 wrap completely around HDAC1 occupying both sides of the active site such that the adjacent BAH domain is ideally positioned to recruit nucleosomes to the active site of the enzyme.  Functional assays of both the HDAC1 and HDAC3 complexes reveal that Ins(1,4,5,6)P4 is a bona fide conserved regulator of class I HDAC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYPhL0103LkLVg90H21EOLACvtfcHk0ljOSiXsyL98UQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D&md5=05a4267bf965b5a6217873217044ef2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DWatson%26aufirst%3DP.%2BJ.%26aulast%3DCelardo%26aufirst%3DI.%26aulast%3DGordiyenko%26aufirst%3DY.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DFairall%26aufirst%3DL.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%26atitle%3DClass%2520I%2520HDACs%2520share%2520a%2520common%2520mechanism%2520of%2520regulation%2520by%2520inositol%2520phosphates%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D51%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulli, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serdikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5243</span>â <span class="NLM_lpage">5254</span>, <span class="refDoi">Â DOI: 10.1021/jm300248q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300248q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5243-5254&author=B.+J.+Duganauthor=D.+E.+Gingrichauthor=E.+F.+Mesarosauthor=K.+L.+Milkiewiczauthor=M.+A.+Curryauthor=A.+L.+Zulliauthor=P.+Dobrzanskiauthor=C.+Serdikoffauthor=M.+Janauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=J.+L.+Masonauthor=L.+D.+Aimoneauthor=S.+L.+Meyerauthor=Z.+Huangauthor=K.+J.+Wells-Knechtauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=A+selective%2C+orally+bioavailable+1%2C2%2C4-triazolo%5B1%2C5-a%5Dpyridine-based+inhibitor+of+Janus+kinase+2+for+use+in+anticancer+therapy%3A+discovery+of+CEP-33779&doi=10.1021%2Fjm300248q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm300248q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300248q%26sid%3Dliteratum%253Aachs%26aulast%3DDugan%26aufirst%3DB.%2BJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DSerdikoff%26aufirst%3DC.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DJ.%2BL.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DA%2520selective%252C%2520orally%2520bioavailable%25201%252C2%252C4-triazolo%255B1%252C5-a%255Dpyridine-based%2520inhibitor%2520of%2520Janus%2520kinase%25202%2520for%2520use%2520in%2520anticancer%2520therapy%253A%2520discovery%2520of%2520CEP-33779%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5243%26epage%3D5254%26doi%3D10.1021%2Fjm300248q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>â <span class="NLM_lpage">10846</span>, <span class="refDoi">Â DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated Î±-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0ljeX-JUkj96Lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>â <span class="NLM_lpage">2589</span>, <span class="refDoi">Â DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.+C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+activity%2C+pharmacodynamic%2C+and+pharmacokinetic+properties+of+a+selective+HDAC6+inhibitor%2C+ACY-1215%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated Î±-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated Î±-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0ljeX-JUkj96Lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.%2BC.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520activity%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520selective%2520HDAC6%2520inhibitor%252C%2520ACY-1215%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malvaez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuown, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogge, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astarabadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusche, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. A.</span></span> <span> </span><span class="NLM_article-title">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2647</span>â <span class="NLM_lpage">2652</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1213364110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1073%2Fpnas.1213364110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23297220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2647-2652&author=M.+Malvaezauthor=S.+C.+McQuownauthor=G.+A.+Roggeauthor=M.+Astarabadiauthor=V.+Jacquesauthor=S.+Carreiroauthor=J.+R.+Ruscheauthor=M.+A.+Wood&title=HDAC3-selective+inhibitor+enhances+extinction+of+cocaine-seeking+behavior+in+a+persistent+manner&doi=10.1073%2Fpnas.1213364110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span></div><div class="casAuthors">Malvaez, Melissa; McQuown, Susan C.; Rogge, George A.; Astarabadi, Mariam; Jacques, Vincent; Carreiro, Samantha; Rusche, James R.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2647-2652, S2647/1-S2647/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonspecific histone deacetylase (HDAC) inhibition has been shown to facilitate the extinction of drug-seeking behavior in a manner resistant to reinstatement.  A key open question is which specific HDAC is involved in the extinction of drug-seeking behavior.  Using the selective HDAC3 inhibitor RGFP966, we investigated the role of HDAC3 in extinction and found that systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement.  We also investigated whether the facilitated extinction is related to the enhancement of extinction consolidation during extinction learning or to neg. effects on performance or reconsolidation.  These are key distinctions with regard to any compd. being used to modulate extinction, because a more rapid decrease in a defined behavior is interpreted as facilitated extinction.  Using an innovative combination of behavioral paradigms, we found that a single treatment of RGFP966 enhances extinction of a previously established cocaine-conditioned place preference, while simultaneously enhancing long-term object-location memory within subjects.  During extinction consolidation, HDAC3 inhibition promotes a distinct pattern of histone acetylation linked to gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens.  Thus, the facilitated extinction of drug-seeking cannot be explained by adverse effects on performance.  These results demonstrate that HDAC3 inhibition enhances the memory processes involved in extinction of drug-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzdD0_EQYfrVg90H21EOLACvtfcHk0lgXykQbzI_YyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D&md5=37fd432cbf96bd2c30b7d5ac9eefcf45</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213364110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213364110%26sid%3Dliteratum%253Aachs%26aulast%3DMalvaez%26aufirst%3DM.%26aulast%3DMcQuown%26aufirst%3DS.%2BC.%26aulast%3DRogge%26aufirst%3DG.%2BA.%26aulast%3DAstarabadi%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DCarreiro%26aufirst%3DS.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHDAC3-selective%2520inhibitor%2520enhances%2520extinction%2520of%2520cocaine-seeking%2520behavior%2520in%2520a%2520persistent%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D2647%26epage%3D2652%26doi%3D10.1073%2Fpnas.1213364110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inks, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4325</span>â <span class="NLM_lpage">4338</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4325-4338&author=W.+Duanauthor=J.+Liauthor=E.+S.+Inksauthor=C.+J.+Chouauthor=Y.+Jiaauthor=X.+Chuauthor=X.+Liauthor=W.+Xuauthor=Y.+Zhang&title=Design%2C+synthesis%2C+and+antitumor+evaluation+of+novel+histone+deacetylase+inhibitors+equipped+with+a+phenylsulfonylfuroxan+module+as+a+nitric+oxide+donor&doi=10.1021%2Facs.jmedchem.5b00317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00317%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antitumor%2520evaluation%2520of%2520novel%2520histone%2520deacetylase%2520inhibitors%2520equipped%2520with%2520a%2520phenylsulfonylfuroxan%2520module%2520as%2520a%2520nitric%2520oxide%2520donor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4325%26epage%3D4338%26doi%3D10.1021%2Facs.jmedchem.5b00317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span> <span> </span><span class="NLM_article-title">Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>â <span class="NLM_lpage">1354</span>, <span class="refDoi">Â DOI: 10.3892/ol.2017.6353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.3892%2Fol.2017.6353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=28789350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A280%3ADC%252BC1cflslSjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=1347-1354&author=K.+B.+Yoonauthor=S.+Y.+Choauthor=S.+J.+Anauthor=K.+R.+Parkauthor=H.+J.+Leeauthor=H.+S.+Yoonauthor=S.+M.+Leeauthor=Y.+C.+Kimauthor=S.+Y.+Han&title=Characterization+of+the+aminopyridine+derivative+KRC-180+as+a+JAK2+inhibitor&doi=10.3892%2Fol.2017.6353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor</span></div><div class="casAuthors">Yoon Kyoung Bin; An Su Jin; Park Kyeong Ryang; Lee Hyo Jeong; Yoon Hae Sung; Han Sun-Young; Cho Sung Yun; Lee Sun-Mi; Kim Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1347-1354</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase that regulates the signal transducer and activator of transcription (STAT) signaling pathway.  Deregulation of JAK2 signaling has previously been observed in hematologic malignancies, including erythroleukemia.  In the present study, an aminopyridine derivative compound, KRC-180, exhibited direct inhibition of the JAK2 protein at the catalytic site, as demonstrated using in vitro kinase activity assays and docking analyses.  In addition, KRC-180 reduced the phosphorylation of STAT3 and STAT5, downstream signaling molecules of JAK2.  The growth of HEL92.1.7 erythroleukemia cells harboring a constitutively activated form of JAK2 was suppressed by KRC-180 treatment; KRC-180 induced apoptotic cell death and cell cycle arrest.  The results of the present study indicate that KRC-180 is a JAK2 inhibitor with anti-leukemic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEwJNzZ1NYL8uCWE5mhx1RfW6udTcc2eZ-O67zZNM1gLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cflslSjtQ%253D%253D&md5=3ac5819c6274b248e040fead84e62d3d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.6353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.6353%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DK.%2BB.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DAn%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DYoon%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DHan%26aufirst%3DS.%2BY.%26atitle%3DCharacterization%2520of%2520the%2520aminopyridine%2520derivative%2520KRC-180%2520as%2520a%2520JAK2%2520inhibitor%26jtitle%3DOncol.%2520Lett.%26date%3D2017%26volume%3D14%26spage%3D1347%26epage%3D1354%26doi%3D10.3892%2Fol.2017.6353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dijck, P.</span></span> <span> </span><span class="NLM_article-title">Recent insights into Candida albicans biofilm resistance mechanisms</span>. <i>Curr. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">264</span>, <span class="refDoi">Â DOI: 10.1007/s00294-013-0400-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1007%2Fs00294-013-0400-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23974350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlarsrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=251-264&author=L.+Matheauthor=P.+Van+Dijck&title=Recent+insights+into+Candida+albicans+biofilm+resistance+mechanisms&doi=10.1007%2Fs00294-013-0400-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Recent insights into Candida albicans biofilm resistance mechanisms</span></div><div class="casAuthors">Mathe, Lotte; Van Dijck, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Current Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-264</span>CODEN:
                <span class="NLM_cas:coden">CUGED5</span>;
        ISSN:<span class="NLM_cas:issn">0172-8083</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Like other microorganisms, free-living Candida albicans is mainly present in a three-dimensional multicellular structure, which is called a biofilm, rather than in a planktonic form.  Candida albicans biofilms can be isolated from both abiotic and biotic surfaces at various locations within the host.  As the no. of abiotic implants, mainly bloodstream and urinary catheters, has been increasing, the no. of biofilm-assocd. bloodstream or urogenital tract infections is also strongly increasing resulting in a raise in mortality.  Cells within a biofilm structure show a reduced susceptibility to specific commonly used antifungals and, in addn., it has recently been shown that such cells are less sensitive to killing by components of our immune system.  In this review, we summarize the most important insights in the mechanisms underlying biofilm-assocd. antifungal drug resistance and immune evasion strategies, focusing on the most recent advances in this area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreVXKJ6shgObVg90H21EOLACvtfcHk0liamvzQRHBTNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlarsrbN&md5=3434aad13e43b2a2245f6fd163e5652b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00294-013-0400-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00294-013-0400-3%26sid%3Dliteratum%253Aachs%26aulast%3DMathe%26aufirst%3DL.%26aulast%3DVan%2BDijck%26aufirst%3DP.%26atitle%3DRecent%2520insights%2520into%2520Candida%2520albicans%2520biofilm%2520resistance%2520mechanisms%26jtitle%3DCurr.%2520Genet.%26date%3D2013%26volume%3D59%26spage%3D251%26epage%3D264%26doi%3D10.1007%2Fs00294-013-0400-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vila, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prousis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calogeropoulou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozental, S.</span></span> <span> </span><span class="NLM_article-title">Effect of alkylphospholipids on Candida albicans biofilm formation and maturation</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">113</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1093/jac/dks353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1093%2Fjac%2Fdks353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22995097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVChsbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=113-125&author=T.+V.+Vilaauthor=K.+Ishidaauthor=W.+de+Souzaauthor=K.+Prousisauthor=T.+Calogeropoulouauthor=S.+Rozental&title=Effect+of+alkylphospholipids+on+Candida+albicans+biofilm+formation+and+maturation&doi=10.1093%2Fjac%2Fdks353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of alkylphospholipids on Candida albicans biofilm formation and maturation</span></div><div class="casAuthors">Vila, Taissa V. M.; Ishida, Kelly; de Souza, Wanderley; Prousis, Kyriakos; Calogeropoulou, Theodora; Rozental, Sonia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate miltefosine and four synthetic compds. (TCAN26, TC19, TC106 and TC117) for their in vitro inhibitory activity against Candida albicans planktonic and biofilm cells and investigate whether these compds. are able to inhibit the biofilm formation and to reduce the viability of mature C. albicans biofilm cells.  The XTT redn. assay and transmission and SEM were employed to det. the inhibitory effects of the test compds. in comparison with amphotericin B and fluconazole against both planktonic cells and sessile cells in biofilms.  C. albicans planktonic cells were susceptible to miltefosine, TCAN26 and TC19, all alkylphospholipid compds.  Miltefosine and TCAN26 present a fungicidal activity with similar values of MIC and min. fungicidal concn. (MFC), ranging from 2 to 8 mg/L.  Cell treatment with sub-inhibitory concns. of alkylphospholipids induced several ultrastructural alterations.  In relation to biofilms, miltefosine reduced formation (38%-71%) and mature biofilms viability (32%-44%), at concns. of 64 mg/L.  TCAN26 also reduced biofilm formation (24%-30%) and mature biofilm viability (15%-20%), at concns. of 64 mg/L.  Although amphotericin B reduced biofilm formation similarly to miltefosine (51%-74%), its activity was lower on mature biofilms (24%-30%).  Miltefosine antibiofilm activity was significantly higher than amphotericin B, on both formation and mature biofilms (P<0.05 and P<0.0001, resp.).  Fluconazole was the least effective compd. tested.  Promising antibiofilm activity was displayed by miltefosine and other alkylphosphocholine compds., which could be considered a putative option for future treatment of candidemia assocd. with biofilm formation, although further evaluation in in vivo systems is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJcArT64BgNrVg90H21EOLACvtfcHk0liamvzQRHBTNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVChsbbI&md5=019b83a645e547244a36263464b84d4a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdks353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdks353%26sid%3Dliteratum%253Aachs%26aulast%3DVila%26aufirst%3DT.%2BV.%26aulast%3DIshida%26aufirst%3DK.%26aulast%3Dde%2BSouza%26aufirst%3DW.%26aulast%3DProusis%26aufirst%3DK.%26aulast%3DCalogeropoulou%26aufirst%3DT.%26aulast%3DRozental%26aufirst%3DS.%26atitle%3DEffect%2520of%2520alkylphospholipids%2520on%2520Candida%2520albicans%2520biofilm%2520formation%2520and%2520maturation%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2013%26volume%3D68%26spage%3D113%26epage%3D125%26doi%3D10.1093%2Fjac%2Fdks353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">The discovery of novel antifungal scaffolds by structural simplification of the natural product sampangine</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">14648</span>â <span class="NLM_lpage">14651</span>, <span class="refDoi">Â DOI: 10.1039/C5CC05699C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1039%2FC5CC05699C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26289663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSnu7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=14648-14651&author=Z.+Jiangauthor=N.+Liuauthor=D.+Huauthor=G.+Dongauthor=Z.+Miaoauthor=J.+Yaoauthor=H.+Heauthor=Y.+Jiangauthor=W.+Zhangauthor=Y.+Wangauthor=C.+Sheng&title=The+discovery+of+novel+antifungal+scaffolds+by+structural+simplification+of+the+natural+product+sampangine&doi=10.1039%2FC5CC05699C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of novel antifungal scaffolds by structural simplification of the natural product sampangine</span></div><div class="casAuthors">Jiang, Zhigan; Liu, Na; Hu, Dandan; Dong, Guoqiang; Miao, Zhenyuan; Yao, Jianzhong; He, Haiying; Jiang, Yuanying; Zhang, Wannian; Wang, Yan; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">78</span>),
    <span class="NLM_cas:pages">14648-14651</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Natural products are important sources of therapeutic drugs.  However, it is a challenge to simplify the structure of natural products without decreasing the biol. activity.  Here we provide the first example of the successful simplification of an antifungal natural product.  Starting from sampangine, two novel simplified scaffolds with excellent antifungal activity were discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDQRLoWYoyu7Vg90H21EOLACvtfcHk0liamvzQRHBTNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSnu7vO&md5=82161572e5e8a6dcd2db7bb3e2f5e7e3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC5CC05699C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC05699C%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520of%2520novel%2520antifungal%2520scaffolds%2520by%2520structural%2520simplification%2520of%2520the%2520natural%2520product%2520sampangine%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D14648%26epage%3D14651%26doi%3D10.1039%2FC5CC05699C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppuluri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tristan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wormley, F. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Ribot, J. L.</span></span> <span> </span><span class="NLM_article-title">A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1494</span>â <span class="NLM_lpage">1500</span>, <span class="refDoi">Â DOI: 10.1038/nprot.2008.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fnprot.2008.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=18772877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsL7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1494-1500&author=C.+G.+Pierceauthor=P.+Uppuluriauthor=A.+R.+Tristanauthor=F.+L.+Wormleyauthor=E.+Mowatauthor=G.+Ramageauthor=J.+L.+Lopez-Ribot&title=A+simple+and+reproducible+96-well+plate-based+method+for+the+formation+of+fungal+biofilms+and+its+application+to+antifungal+susceptibility+testing&doi=10.1038%2Fnprot.2008.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing</span></div><div class="casAuthors">Pierce, Christopher G.; Uppuluri, Priya; Tristan, Amanda R.; Wormley, Floyd L, Jr.; Mowat, Eilidh; Ramage, Gordon; Lopez-Ribot, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1494-1500</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The incidence of fungal infections has increased significantly over the past decades.  Very often these infections are assocd. with biofilm formation on implanted biomaterials and/or host surfaces.  This has important clin. implications, as fungal biofilms display properties that are dramatically different from planktonic (free-living) populations, including increased resistance to antifungal agents.  Here the authors describe a rapid and highly reproducible 96-well microtiter-based method for the formation of fungal biofilms, which is easily adaptable for antifungal susceptibility testing.  This model is based on the ability of metabolically active sessile cells to reduce a tetrazolium salt (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide) to water-sol. orange formazan compds., the intensity of which can then be detd. using a microtiter-plate reader.  The entire procedure takes approx. 2 d to complete.  This technique simplifies biofilm formation and quantification, making it more reliable and comparable among different labs., a necessary step toward the standardization of antifungal susceptibility testing of biofilms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1U1dGFsZzB7Vg90H21EOLACvtfcHk0liamvzQRHBTNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsL7L&md5=68b5e3690b61f93cbe05d6736b3a5460</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2008.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2008.141%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DC.%2BG.%26aulast%3DUppuluri%26aufirst%3DP.%26aulast%3DTristan%26aufirst%3DA.%2BR.%26aulast%3DWormley%26aufirst%3DF.%2BL.%26aulast%3DMowat%26aufirst%3DE.%26aulast%3DRamage%26aufirst%3DG.%26aulast%3DLopez-Ribot%26aufirst%3DJ.%2BL.%26atitle%3DA%2520simple%2520and%2520reproducible%252096-well%2520plate-based%2520method%2520for%2520the%2520formation%2520of%2520fungal%2520biofilms%2520and%2520its%2520application%2520to%2520antifungal%2520susceptibility%2520testing%26jtitle%3DNat.%2520Protoc.%26date%3D2008%26volume%3D3%26spage%3D1494%26epage%3D1500%26doi%3D10.1038%2Fnprot.2008.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">16228</span>, <span class="refDoi">Â DOI: 10.1038/srep16228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fsrep16228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26538086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyht7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=16228&author=X.+Liauthor=H.+Guoauthor=H.+Duanauthor=Y.+Yangauthor=J.+Mengauthor=J.+Liuauthor=C.+Wangauthor=H.+Xu&title=Improving+chemotherapeutic+efficiency+in+acute+myeloid+leukemia+treatments+by+chemically+synthesized+peptide+interfering+with+CXCR4%2FCXCL12+axis&doi=10.1038%2Fsrep16228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis</span></div><div class="casAuthors">Li, Xiaojin; Guo, Hua; Duan, Hongyang; Yang, Yanlian; Meng, Jie; Liu, Jian; Wang, Chen; Xu, Haiyan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16228</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bone marrow stroma can protect acute myeloid leukemia (AML) cells against chemotherapeutic agents and provide anti-apoptosis and chemoresistance signals through secreting chemokine CXCL12 to activate its receptor CXCR4 on AML cells, resulting in minimal residual leukemia and relapse.  Therefore disrupting the CXCR4/CXCL12 axis with antagonists is of great significance for improving chemosensitivity and decreasing relapse rate.  In a previous study, we reported a novel synthetic peptide E5 with its remarkable effect on inhibiting CXCR4/CXCL12-mediated adhesion and migration of AML cells.  Here we presented E5's capacity of enhancing the therapeutic efficiency of various chemotherapeutics on AML in vitro and in vivo.  Results showed that E5 can diminish bone marrow stromal cell-provided protection to leukemia cells, significantly increasing the apoptosis induced by various chemotherapeutics in multiple AML cell lines.  In an AML mouse xenograft model, E5 induced 1.84-fold increase of circulating AML cells out of protective stroma niche.  Combined with vincristine or cyclophosphamide, E5 inhibited infiltration of AML cells into bone marrow, liver and spleen, as well as prolonged the lifespan of AML mice compared with mice treated with chemotherapy alone.  In addn., E5 presented no toxicity in vivo according to the histol. anal. and routine clin. parameters of serum anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCtpZKoFF0Y7Vg90H21EOLACvtfcHk0ljkCeyQJAr9sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyht7nI&md5=1ef094355b4298ad8bf3fe1adf4ba10f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fsrep16228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep16228%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DImproving%2520chemotherapeutic%2520efficiency%2520in%2520acute%2520myeloid%2520leukemia%2520treatments%2520by%2520chemically%2520synthesized%2520peptide%2520interfering%2520with%2520CXCR4%252FCXCL12%2520axis%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D16228%26doi%3D10.1038%2Fsrep16228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Z.</span></span> <span> </span><span class="NLM_article-title">LG-362B targets PML-RARalpha and blocks ATRA resistance of acute promyelocytic leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1465</span>â <span class="NLM_lpage">1474</span>, <span class="refDoi">Â DOI: 10.1038/leu.2016.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fleu.2016.50" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1465-1474&author=X.+Wangauthor=Q.+Linauthor=F.+Lvauthor=N.+Liuauthor=Y.+Xuauthor=M.+Liuauthor=Y.+Chenauthor=Z.+Yi&title=LG-362B+targets+PML-RARalpha+and+blocks+ATRA+resistance+of+acute+promyelocytic+leukemia&doi=10.1038%2Fleu.2016.50"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.50%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYi%26aufirst%3DZ.%26atitle%3DLG-362B%2520targets%2520PML-RARalpha%2520and%2520blocks%2520ATRA%2520resistance%2520of%2520acute%2520promyelocytic%2520leukemia%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D1465%26epage%3D1474%26doi%3D10.1038%2Fleu.2016.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1096</span>â <span class="NLM_lpage">1099</span>, <span class="refDoi">Â DOI: 10.1128/AAC.50.3.1096-1099.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1128%2FAAC.50.3.1096-1099.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=16495278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFamurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1096-1099&author=H.+Quanauthor=Y.+Y.+Caoauthor=Z.+Xuauthor=J.+X.+Zhaoauthor=P.+H.+Gaoauthor=X.+F.+Qinauthor=Y.+Y.+Jiang&title=Potent+in+vitro+synergism+of+fluconazole+and+berberine+chloride+against+clinical+isolates+of+Candida+albicans+resistant+to+fluconazole&doi=10.1128%2FAAC.50.3.1096-1099.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole</span></div><div class="casAuthors">Quan, Hua; Cao, Ying-Ying; Xu, Zheng; Zhao, Jing-Xia; Gao, Ping-Hui; Qin, Xiao-Feng; Jiang, Yuan-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1096-1099</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In vitro interaction of fluconazole and berberine chloride was investigated against 40 fluconazole-resistant clin. isolates of Candida albicans.  Synergism in fungistatic activity was found with the checkerboard microdilution assay.  The findings of agar diffusion tests and time-kill curves confirmed the synergistic interaction, but no antagonistic action was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGiBzNAvJqirVg90H21EOLACvtfcHk0ljkCeyQJAr9sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFamurw%253D&md5=9a0007a890ccae954ec4d625ef7dc595</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FAAC.50.3.1096-1099.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.50.3.1096-1099.2006%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DY.%2BY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DJ.%2BX.%26aulast%3DGao%26aufirst%3DP.%2BH.%26aulast%3DQin%26aufirst%3DX.%2BF.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26atitle%3DPotent%2520in%2520vitro%2520synergism%2520of%2520fluconazole%2520and%2520berberine%2520chloride%2520against%2520clinical%2520isolates%2520of%2520Candida%2520albicans%2520resistant%2520to%2520fluconazole%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D1096%26epage%3D1099%26doi%3D10.1128%2FAAC.50.3.1096-1099.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 46 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wanzhen Yang, Jie Tu, Changjin Ji, Zhuang Li, Guiyan Han, Na Liu, Jian Li, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Piperidol Derivatives for Combinational Treatment of Azole-Resistant Candidiasis. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (3)
                                     , 650-660. <a href="https://doi.org/10.1021/acsinfecdis.0c00849" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00849</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00849%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DDiscovery%252Bof%252BPiperidol%252BDerivatives%252Bfor%252BCombinational%252BTreatment%252Bof%252BAzole-Resistant%252BCandidiasis%26aulast%3DYang%26aufirst%3DWanzhen%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D02122020%26date%3D16022021%26volume%3D7%26issue%3D3%26spage%3D650%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Shuai Tang, Xuyi Liu, Yingluo Liu, Qifu Xu, Xiaomin Wang, Abdusaid Saidahmatov, Chunpu Li, Jiang Wang, Yu Zhou, Yingjie Zhang, Meiyu Geng, Min Huang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-based%252BDerivatives%252Bas%252BPotent%252BJAK%25252FHDAC%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRefractory%252BSolid%252BTumors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2021%26date%3D2020%26date%3D07122020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, Mussa Yussuf Khamis, Yi-Han Li, Li-Ying Ma, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Min Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1362-1391. <a href="https://doi.org/10.1021/acs.jmedchem.0c01782" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01782%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BReview%252Bof%252BProgress%252Bin%252BHistone%252BDeacetylase%252B6%252BInhibitors%252BResearch%25253A%252BStructural%252BSpecificity%252Band%252BFunctional%252BDiversity%26aulast%3DZhang%26aufirst%3DXin-Hui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D01022021%26volume%3D64%26issue%3D3%26spage%3D1362%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhuang Li, Jie Tu, Guiyan Han, Na Liu, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 1116-1126. <a href="https://doi.org/10.1021/acs.jmedchem.0c01763" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01763</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01763%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BCarboline%252BFungal%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BInhibitors%252Bfor%252BCombinational%252BTreatment%252Bof%252BAzole-Resistant%252BCandidiasis%26aulast%3DLi%26aufirst%3DZhuang%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D07102020%26date%3D27122020%26volume%3D64%26issue%3D2%26spage%3D1116%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, <span class="NLM_string-name hlFld-ContribAuthor">Guiyun Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8977-9002. <a href="https://doi.org/10.1021/acs.jmedchem.0c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-Target%252BInhibitors%252BBased%252Bon%252BHDACs%25253A%252BNovel%252BAntitumor%252BAgents%252Bfor%252BCancer%252BTherapy%26aulast%3DLiu%26aufirst%3DTingting%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23032020%26date%3D30042020%26date%3D22042020%26volume%3D63%26issue%3D17%26spage%3D8977%26epage%3D9002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guiyan Han, Na Liu, Chenglan Li, Jie Tu, Zhuang Li, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Fungal Lanosterol 14Î±-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5341-5359. <a href="https://doi.org/10.1021/acs.jmedchem.0c00102" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00102%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BFungal%252BLanosterol%252B14%2525CE%2525B1-Demethylase%252B%252528CYP51%252529%25252FHistone%252BDeacetylase%252BDual%252BInhibitors%252Bto%252BTreat%252BAzole-Resistant%252BCandidiasis%26aulast%3DHan%26aufirst%3DGuiyan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D09052020%26date%3D29042020%26volume%3D63%26issue%3D10%26spage%3D5341%26epage%3D5359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi Zhou, Xiaoting Liu, Junxin Xue, Lulu Liu, Tao Liang, Wen Li, Xinying Yang, Xuben Hou, <span class="NLM_string-name hlFld-ContribAuthor">Hao Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4701-4715. <a href="https://doi.org/10.1021/acs.jmedchem.9b02161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02161%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPeptide%252BBoronate%252BDerivatives%252Bas%252BHistone%252BDeacetylase%252Band%252BProteasome%252BDual%252BInhibitors%252Bfor%252BOvercoming%252BBortezomib%252BResistance%252Bof%252BMultiple%252BMyeloma%26aulast%3DZhou%26aufirst%3DYi%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D24122019%26date%3D23042020%26date%3D08042020%26volume%3D63%26issue%3D9%26spage%3D4701%26epage%3D4715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Changjin Ji, Na Liu, Jie Tu, Zhuang Li, Guiyan Han, Jian Li, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Repurposing of Haloperidol: Discovery of New Benzocyclane Derivatives as Potent Antifungal Agents against Cryptococcosis and Candidiasis. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (5)
                                     , 768-786. <a href="https://doi.org/10.1021/acsinfecdis.9b00197" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00197%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DDrug%252BRepurposing%252Bof%252BHaloperidol%25253A%252BDiscovery%252Bof%252BNew%252BBenzocyclane%252BDerivatives%252Bas%252BPotent%252BAntifungal%252BAgents%252Bagainst%252BCryptococcosis%252Band%252BCandidiasis%26aulast%3DJi%26aufirst%3DChangjin%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D24052019%26date%3D08102019%26date%3D24092019%26volume%3D6%26issue%3D5%26spage%3D768%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Minjian Yang, Bingzhong Tao, Chengjuan Chen, Wenqiang Jia, Shaolei Sun, Tiantai Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojian Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5002-5012. <a href="https://doi.org/10.1021/acs.jcim.9b00798" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMachine%252BLearning%252BModels%252BBased%252Bon%252BMolecular%252BFingerprints%252Band%252Ban%252BExtreme%252BGradient%252BBoosting%252BMethod%252BLead%252Bto%252Bthe%252BDiscovery%252Bof%252BJAK2%252BInhibitors%26aulast%3DYang%26aufirst%3DMinjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15092019%26date%3D04122019%26date%3D20112019%26volume%3D59%26issue%3D12%26spage%3D5002%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junting Zhou, Xueyang Jiang, Siyu He, Hongli Jiang, Feng Feng, Wenyuan Liu, Wei Qu, <span class="NLM_string-name hlFld-ContribAuthor">Haopeng Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8881-8914. <a href="https://doi.org/10.1021/acs.jmedchem.9b00017" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Bof%252BMultitarget-Directed%252BLigands%25253A%252BStrategies%252Band%252BEmerging%252BParadigms%26aulast%3DZhou%26aufirst%3DJunting%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04012019%26date%3D28052019%26date%3D13052019%26volume%3D62%26issue%3D20%26spage%3D8881%26epage%3D8914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhuang Li, Na Liu, Jie Tu, Changjin Ji, Guiyan Han, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Simplified Sampangine Derivatives with Potent Antifungal Activities against Cryptococcal Meningitis. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2019,</strong> <em>5 </em>
                                    (8)
                                     , 1376-1384. <a href="https://doi.org/10.1021/acsinfecdis.9b00086" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00086%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DDiscovery%252Bof%252BSimplified%252BSampangine%252BDerivatives%252Bwith%252BPotent%252BAntifungal%252BActivities%252Bagainst%252BCryptococcal%252BMeningitis%26aulast%3DLi%26aufirst%3DZhuang%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02032019%26date%3D22052019%26date%3D09052019%26volume%3D5%26issue%3D8%26spage%3D1376%26epage%3D1384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shengzheng Wang, Guoqiang Dong, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Simplification of Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (6)
                                     , 4180-4220. <a href="https://doi.org/10.1021/acs.chemrev.8b00504" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00504%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DStructural%252BSimplification%252Bof%252BNatural%252BProducts%26aulast%3DWang%26aufirst%3DShengzheng%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D09082018%26date%3D07022019%26volume%3D119%26issue%3D6%26spage%3D4180%26epage%3D4220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianbao  Zhu</span>, <span class="hlFld-ContribAuthor ">Xi  Chen</span>, <span class="hlFld-ContribAuthor ">Chenglan  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Tu</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Defeng  Xu</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Lanosterol 14Î±-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113524. <a href="https://doi.org/10.1016/j.ejmech.2021.113524" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113524</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113524%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLanosterol%252B14%2525CE%2525B1-demethylase%252B%252528CYP51%252529%25252Fhistone%252Bdeacetylase%252B%252528HDAC%252529%252Bdual%252Binhibitors%252Bfor%252Btreatment%252Bof%252BCandida%252Btropicalis%252Band%252BCryptococcus%252Bneoformans%252Binfections%26aulast%3DZhu%26aufirst%3DTianbao%26date%3D2021%26volume%3D221%26spage%3D113524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Xie</span>, <span class="hlFld-ContribAuthor ">Huidan  Tan</span>, <span class="hlFld-ContribAuthor ">Minru  Liao</span>, <span class="hlFld-ContribAuthor ">Shiou  Zhu</span>, <span class="hlFld-ContribAuthor ">Ling-Li  Zheng</span>, <span class="hlFld-ContribAuthor ">Haixia  Huang</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>13 </em>, 105702. <a href="https://doi.org/10.1016/j.phrs.2021.105702" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105702%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DTargeting%252Bcancer%252Bepigenetic%252Bpathways%252Bwith%252Bsmall-molecule%252Bcompounds%25253A%252BTherapeutic%252Befficacy%252Band%252Bcombination%252Btherapies%26aulast%3DWang%26aufirst%3DYi%26date%3D2021%26volume%3D13%26spage%3D105702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eclair Venturini  Filho</span>, <span class="hlFld-ContribAuthor ">Erick M.C.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sergio  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sandro J.  Greco</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidines: Recent synthetic procedures and anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>209 </em>, 132256. <a href="https://doi.org/10.1016/j.tet.2021.132256" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132256%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAminopyrimidines%25253A%252BRecent%252Bsynthetic%252Bprocedures%252Band%252Banticancer%252Bactivities%26aulast%3DFilho%26aufirst%3DEclair%2BVenturini%26date%3D2021%26volume%3D209%26spage%3D132256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Yuan</span>, <span class="hlFld-ContribAuthor ">Jie  Tu</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, <span class="hlFld-ContribAuthor ">Xi  Chen</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Microbiology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fmicb.2021.680382" title="DOI URL">https://doi.org/10.3389/fmicb.2021.680382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmicb.2021.680382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmicb.2021.680382%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Microbiology%26atitle%3DEffects%252Bof%252BHsp90%252BInhibitor%252BGanetespib%252Bon%252BInhibition%252Bof%252BAzole-Resistant%252BCandida%252Balbicans%26aulast%3DYuan%26aufirst%3DRui%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming-Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Yu-Sha  Luo</span>, <span class="hlFld-ContribAuthor ">Gui-Yan  Han</span>, <span class="hlFld-ContribAuthor ">Zhi-Qiang  Ma</span>, <span class="hlFld-ContribAuthor ">Fei  Huang</span>, <span class="hlFld-ContribAuthor ">Yuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhen-Yuan  Miao</span>, <span class="hlFld-ContribAuthor ">Wan-Nian  Zhang</span>, <span class="hlFld-ContribAuthor ">Chun-Quan  Sheng</span>, <span class="hlFld-ContribAuthor ">Jian-Zhong  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113363. <a href="https://doi.org/10.1016/j.ejmech.2021.113363" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113363%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bdual-mode%252Bantitumor%252Bchlorin-based%252Bderivatives%252Bas%252Bpotent%252Bphotosensitizers%252Band%252Bhistone%252Bdeacetylase%252Binhibitors%252Bfor%252Bphotodynamic%252Btherapy%252Band%252Bchemotherapy%26aulast%3DZhang%26aufirst%3DXing-Jie%26date%3D2021%26volume%3D217%26spage%3D113363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zonglin  Ma</span>, <span class="hlFld-ContribAuthor ">Yahui  Huang</span>, <span class="hlFld-ContribAuthor ">Kun  Wan</span>, <span class="hlFld-ContribAuthor ">Fugui  Zhu</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, <span class="hlFld-ContribAuthor ">Shuqiang  Chen</span>, <span class="hlFld-ContribAuthor ">Dan  Liu</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Structural simplification of evodiamine: Discovery of novel tetrahydro-Î²-carboline derivatives as potent antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>40 </em>, 127954. <a href="https://doi.org/10.1016/j.bmcl.2021.127954" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127954</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127954%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructural%252Bsimplification%252Bof%252Bevodiamine%25253A%252BDiscovery%252Bof%252Bnovel%252Btetrahydro-%2525CE%2525B2-carboline%252Bderivatives%252Bas%252Bpotent%252Bantitumor%252Bagents%26aulast%3DMa%26aufirst%3DZonglin%26date%3D2021%26volume%3D40%26spage%3D127954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David G.  Covell</span>, . </span><span class="cited-content_cbyCitation_article-title">Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , e0243336. <a href="https://doi.org/10.1371/journal.pone.0243336" title="DOI URL">https://doi.org/10.1371/journal.pone.0243336</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0243336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0243336%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DBioinformatic%252Banalysis%252Blinking%252Bgenomic%252Bdefects%252Bto%252Bchemosensitivity%252Band%252Bmechanism%252Bof%252Baction%26aulast%3DCovell%26aufirst%3DDavid%2BG.%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D4%26spage%3De0243336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arshdeep  Singh</span>, <span class="hlFld-ContribAuthor ">Ting-Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Navdeep  Kaur</span>, <span class="hlFld-ContribAuthor ">Kai-Cheng  Hsu</span>, <span class="hlFld-ContribAuthor ">Yun  Yen</span>, <span class="hlFld-ContribAuthor ">Tony Eight  Lin</span>, <span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Sung-Bau  Lee</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113169. <a href="https://doi.org/10.1016/j.ejmech.2021.113169" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113169%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCAP%252Brigidification%252Bof%252BMS-275%252Band%252Bchidamide%252Bleads%252Bto%252Benhanced%252Bantiproliferative%252Beffects%252Bmediated%252Bthrough%252BHDAC1%25252C%252B2%252Band%252Btubulin%252Bpolymerization%252Binhibition%26aulast%3DSingh%26aufirst%3DArshdeep%26date%3D2021%26volume%3D215%26spage%3D113169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandria M.  Chan</span>, <span class="hlFld-ContribAuthor ">Steven  Fletcher</span>. </span><span class="cited-content_cbyCitation_article-title">Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     , 178-196. <a href="https://doi.org/10.1039/D0MD00286K" title="DOI URL">https://doi.org/10.1039/D0MD00286K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00286K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00286K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DShifting%252Bthe%252Bparadigm%252Bin%252Btreating%252Bmulti-factorial%252Bdiseases%25253A%252Bpolypharmacological%252Bco-inhibitors%252Bof%252BHDAC6%26aulast%3DChan%26aufirst%3DAlexandria%2BM.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2%26spage%3D178%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Qiuzi  Dai</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Zhao</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor evaluations of nucleoside base hydroxamic acid derivatives as DNMT and HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>59 </em><a href="https://doi.org/10.1016/j.cclet.2021.02.004" title="DOI URL">https://doi.org/10.1016/j.cclet.2021.02.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2021.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2021.02.004%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bevaluations%252Bof%252Bnucleoside%252Bbase%252Bhydroxamic%252Bacid%252Bderivatives%252Bas%252BDNMT%252Band%252BHDAC%252Bdual%252Binhibitors%26aulast%3DSun%26aufirst%3DQinsheng%26date%3D2021%26volume%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of âclassicalâ HDAC inhibitors to âhybridâ HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiang  Liu</span>, <span class="hlFld-ContribAuthor ">Bolun  Ai</span>, <span class="hlFld-ContribAuthor ">Xiangyi  Kong</span>, <span class="hlFld-ContribAuthor ">Xiangyu  Wang</span>, <span class="hlFld-ContribAuthor ">Yihang  Qi</span>, <span class="hlFld-ContribAuthor ">Zhongzhao  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Fang</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2021,</strong> <em>90 </em>, 107186. <a href="https://doi.org/10.1016/j.intimp.2020.107186" title="DOI URL">https://doi.org/10.1016/j.intimp.2020.107186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2020.107186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2020.107186%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DJAK2%252Bexpression%252Bis%252Bcorrelated%252Bwith%252Bthe%252Bmolecular%252Band%252Bclinical%252Bfeatures%252Bof%252Bbreast%252Bcancer%252Bas%252Ba%252Bfavorable%252Bprognostic%252Bfactor%26aulast%3DLiu%26aufirst%3DQiang%26date%3D2021%26volume%3D90%26spage%3D107186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Mologni</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>, <span class="hlFld-ContribAuthor ">Sara  Redaelli</span>, <span class="hlFld-ContribAuthor ">Alfonso  Zambon</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Kinase Targeting in Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 119. <a href="https://doi.org/10.3390/cancers13010119" title="DOI URL">https://doi.org/10.3390/cancers13010119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13010119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13010119%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDual%252BKinase%252BTargeting%252Bin%252BLeukemia%26aulast%3DMologni%26aufirst%3DLuca%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D1%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">FrÃ©dÃ©ric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaopeng  Peng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Peihua  Kuang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112831. <a href="https://doi.org/10.1016/j.ejmech.2020.112831" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bon%252BHDAC%252Binhibitors%252Bwith%252Bdual%252Btargeting%252Bcapabilities%252Bfor%252Bcancer%252Btreatment%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2020%26volume%3D208%26spage%3D112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yufeng  Xiao</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in small molecular modulators targeting histone deacetylase 6. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2020,</strong> <em>2 </em>
                                    (4)
                                     , FDD53. <a href="https://doi.org/10.4155/fdd-2020-0023" title="DOI URL">https://doi.org/10.4155/fdd-2020-0023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2020-0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2020-0023%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DRecent%252Badvances%252Bin%252Bsmall%252Bmolecular%252Bmodulators%252Btargeting%252Bhistone%252Bdeacetylase%252B6%26aulast%3DXiao%26aufirst%3DYufeng%26date%3D2020%26volume%3D2%26issue%3D4%26spage%3DFDD53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Hu</span>, <span class="hlFld-ContribAuthor ">Fei  Chen</span>, <span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 103970. <a href="https://doi.org/10.1016/j.bioorg.2020.103970" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103970</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103970%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bdual%252Bc-Met%25252FHDAC%252Binhibitors%252Bas%252Ba%252Bpromising%252Bstrategy%252Bfor%252Bcancer%252Btherapy%26aulast%3DHu%26aufirst%3DHao%26date%3D2020%26volume%3D101%26spage%3D103970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Morgen</span>, <span class="hlFld-ContribAuthor ">Raphael R.  Steimbach</span>, <span class="hlFld-ContribAuthor ">Magalie  GÃ©raldy</span>, <span class="hlFld-ContribAuthor ">Lars  Hellweg</span>, <span class="hlFld-ContribAuthor ">Peter  Sehr</span>, <span class="hlFld-ContribAuthor ">Johannes  Ridinger</span>, <span class="hlFld-ContribAuthor ">Olaf  Witt</span>, <span class="hlFld-ContribAuthor ">Ina  Oehme</span>, <span class="hlFld-ContribAuthor ">Corey J.  HerbstâGervasoni</span>, <span class="hlFld-ContribAuthor ">Jeremy D.  Osko</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Porter</span>, <span class="hlFld-ContribAuthor ">David W.  Christianson</span>, <span class="hlFld-ContribAuthor ">Nikolas  Gunkel</span>, <span class="hlFld-ContribAuthor ">Aubry K.  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (13)
                                     , 1163-1174. <a href="https://doi.org/10.1002/cmdc.202000149" title="DOI URL">https://doi.org/10.1002/cmdc.202000149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000149%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BDihydroxamic%252BAcids%252Bas%252BHDAC6%25252F8%25252F10%252BInhibitors%26aulast%3DMorgen%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D13%26spage%3D1163%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 263-274. <a href="https://doi.org/10.1080/13543776.2020.1725470" title="DOI URL">https://doi.org/10.1080/13543776.2020.1725470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DHistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%252Bin%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhao%26aufirst%3DChunlong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Regina  MartÃ­nez</span>, <span class="hlFld-ContribAuthor ">Bruno  Di Geronimo</span>, <span class="hlFld-ContribAuthor ">Miryam  Pastor</span>, <span class="hlFld-ContribAuthor ">JosÃ© MarÃ­a  Zapico</span>, <span class="hlFld-ContribAuthor ">Claire  Coderch</span>, <span class="hlFld-ContribAuthor ">Rostyslav  Panchuk</span>, <span class="hlFld-ContribAuthor ">Nadia  Skorokhyd</span>, <span class="hlFld-ContribAuthor ">Maciej  Maslyk</span>, <span class="hlFld-ContribAuthor ">Ana  Ramos</span>, <span class="hlFld-ContribAuthor ">Beatriz  de Pascual-Teresa</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (7)
                                     , 1497. <a href="https://doi.org/10.3390/molecules25071497" title="DOI URL">https://doi.org/10.3390/molecules25071497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25071497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25071497%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMultitarget%252BAnticancer%252BAgents%252BBased%252Bon%252BHistone%252BDeacetylase%252Band%252BProtein%252BKinase%252BCK2%252BInhibitors%26aulast%3DMart%25C3%25ADnez%26aufirst%3DRegina%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D7%26spage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Shun  Yang</span>, <span class="hlFld-ContribAuthor ">Mi-Mi  Su</span>, <span class="hlFld-ContribAuthor ">Jian-Fei  Xu</span>, <span class="hlFld-ContribAuthor ">Qi-Xing  Liu</span>, <span class="hlFld-ContribAuthor ">Li-Fei  Bai</span>, <span class="hlFld-ContribAuthor ">Xiao-Wei  Hu</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel oxoindolin derivatives as atypical dual inhibitors for DNA Gyrase and FabH. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>93 </em>, 103309. <a href="https://doi.org/10.1016/j.bioorg.2019.103309" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103309%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Boxoindolin%252Bderivatives%252Bas%252Batypical%252Bdual%252Binhibitors%252Bfor%252BDNA%252BGyrase%252Band%252BFabH%26aulast%3DYang%26aufirst%3DYu-Shun%26date%3D2019%26volume%3D93%26spage%3D103309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solventâexposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingxiu  Li</span>, <span class="hlFld-ContribAuthor ">Tianyu  Ye</span>, <span class="hlFld-ContribAuthor ">Le  Xu</span>, <span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Yong  Luo</span>, <span class="hlFld-ContribAuthor ">Chu  Wang</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Ke  Chen</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111590. <a href="https://doi.org/10.1016/j.ejmech.2019.111590" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111590%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-piperazinyl-2-aminopyrimidine%252Bderivatives%252Bas%252Bdual%252Binhibitors%252Bof%252BJAK2%252Band%252BFLT3%26aulast%3DLi%26aufirst%3DYingxiu%26date%3D2019%26volume%3D181%26spage%3D111590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengzheng  Wang</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Structural simplification: an efficient strategy in lead optimization. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2019,</strong> <em>9 </em>
                                    (5)
                                     , 880-901. <a href="https://doi.org/10.1016/j.apsb.2019.05.004" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DStructural%252Bsimplification%25253A%252Ban%252Befficient%252Bstrategy%252Bin%252Blead%252Boptimization%26aulast%3DWang%26aufirst%3DShengzheng%26date%3D2019%26volume%3D9%26issue%3D5%26spage%3D880%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuewu  Liang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (15)
                                     , 1849-1852. <a href="https://doi.org/10.4155/fmc-2019-0168" title="DOI URL">https://doi.org/10.4155/fmc-2019-0168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0168%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DNovel-targeted%252Btherapy%252Bfor%252Bhematological%252Bmalignancies%252Bwith%252BJAK%252Band%252BHDAC%252Bdual%252Binhibitors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2019%26volume%3D11%26issue%3D15%26spage%3D1849%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Nihar  Kinarivala</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 842-874. <a href="https://doi.org/10.2174/1871520619666190118120708" title="DOI URL">https://doi.org/10.2174/1871520619666190118120708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DMulti-Targeting%252BAnticancer%252BAgents%25253A%252BRational%252BApproaches%25252C%252BSynthetic%252BRoutes%252Band%252BStructure%252BActivity%252BRelationship%26aulast%3DSingh%26aufirst%3DHarbinder%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D842%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuang  Li</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Jie  Tu</span>, <span class="hlFld-ContribAuthor ">Changjin  Ji</span>, <span class="hlFld-ContribAuthor ">Guiyan  Han</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel simplified isoxazole derivatives of sampangine as potent anti-cryptococcal agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (5)
                                     , 832-840. <a href="https://doi.org/10.1016/j.bmc.2019.01.029" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.01.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.01.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bsimplified%252Bisoxazole%252Bderivatives%252Bof%252Bsampangine%252Bas%252Bpotent%252Banti-cryptococcal%252Bagents%26aulast%3DLi%26aufirst%3DZhuang%26date%3D2019%26volume%3D27%26issue%3D5%26spage%3D832%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samantha L.  Goldman</span>, <span class="hlFld-ContribAuthor ">Ciaran  Hassan</span>, <span class="hlFld-ContribAuthor ">Mihir  Khunte</span>, <span class="hlFld-ContribAuthor ">Arielle  Soldatenko</span>, <span class="hlFld-ContribAuthor ">Yunji  Jong</span>, <span class="hlFld-ContribAuthor ">Ebrahim  Afshinnekoo</span>, <span class="hlFld-ContribAuthor ">Christopher E.  Mason</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Genetics</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fgene.2019.00133" title="DOI URL">https://doi.org/10.3389/fgene.2019.00133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fgene.2019.00133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffgene.2019.00133%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Genetics%26atitle%3DEpigenetic%252BModifications%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BPrognosis%25252C%252BTreatment%25252C%252Band%252BHeterogeneity%26aulast%3DGoldman%26aufirst%3DSamantha%2BL.%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Chemical structures and pharmacophore of JAK2 inhibitors; (B) chemical structure and pharmacophore of HDAC inhibitors; (C) design of JAK2-HDAC dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Toluene/<i>n-</i>PrOH, 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 100 Â°C, 55%; (b) <b>6</b>, TsOHÂ·H<sub>2</sub>O, 120 Â°C, 3 Days, 82%; (c) NH<sub>2</sub>OK, Anhydrous CH<sub>3</sub>OH, 4 h, 56%; (d) LiOH, THF/H<sub>2</sub>O, Reflux, 4 h, 85%; (e) <i>o</i>-Phenylenediamine, HATU, DIPEA, DMF, RT, 4 h, 63%; (f) Various Amino-Esters, HATU, DIPEA, DMF, RT, 4 h, 58%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Toluene/<i>n-</i>PrOH, 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 100 Â°C, 51%; (b) <b>6</b>, TsOHÂ·H<sub>2</sub>O, 120 Â°C, 3 Days, 77%; (c) NH<sub>2</sub>OK, Anhydrous CH<sub>3</sub>OH, 4 h, 48%; (d) LiOH, THF/H<sub>2</sub>O, Reflux, 4 h, 82%; (e) <i>o</i>-Phenylenediamine, HATU, DIPEA, DMF, RT, 4 h, 56%; (f) Various Amino-Esters, HATU, DIPEA, DMF, RT, 4 h, 57%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reagents and Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Toluene/<i>n-</i>PrOH, 2 M aq Na<sub>2</sub>CO<sub>3</sub>, 100 Â°C, 48%; (b) 4-Morpholinoaniline, TsOHÂ·H<sub>2</sub>O, 120 Â°C, 3 Days, 73%; (c) NH<sub>2</sub>OK, Anhydrous CH<sub>3</sub>OH, 4 h, 62%; (d) LiOH, THF/H<sub>2</sub>O, Reflux, 4 h, 86%; (e) <i>o</i>-Phenylenediamine, HATU, DIPEA, DMF, RT, 4 h, 51%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed binding mode of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> in the active site of HDAC1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>, <b>AâC</b>) and in the ATP-binding site of JAK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AQC">4AQC</a>, <b>DâF</b>). The carbons of <b>20a</b>, <b>20h</b>, and <b>24</b> are colored in yellow, pink and orange, respectively. Oxygen atoms are colored in red and nitrogen atoms in blue. Hydrogen bonds are indicated with dashed lines. The figure was generated using PyMol (<a href="http://www.pymol.org/" class="extLink">http://www.pymol.org/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell apoptosis induced by compounds <b>20a</b>, <b>20h</b>, and <b>24</b>. HEL cells were incubated with the indicated concentrations of <b>1</b>, <b>20a</b>, <b>20h</b>, and <b>24</b> for 48 h. Cells treated with DMSO were used for comparison. Data were represented as mean Â± standard deviation from three independent experiments. A single asterisks indicates <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001, as determined with a Studentâs <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cell cycle analysis after 48 h of treatment. HEL cells treated with <b>20a</b>, <b>20h</b>, and <b>24</b> at different concentrations for 48 h were assayed by flow cytometry after staining with PI. Data were represented as mean Â± standard deviation from three independent experiments. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001, as determined with Studentâs <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> on the levels of acetyl-H3, acetyl-H4, and STAT5 phosphorylation in HEL cells. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 versus the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Synergistic doseâresponse relationships of the drug combination. Growth curves of <i>C. albicans</i> 0304103 cells incubated with 1 Î¼g/mL of FLC and different concentration of compounds (A) <b>20a</b>, (B) <b>20h</b>, and (C) <b>24</b> for 24 h. Growth curves of <i>C. albicans</i> 0304103 cells treated with 32 Î¼g/mL of compounds (D) <b>20a</b>, (E) <b>20h</b>, and (F) <b>24</b> and different concentration of FLC for 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of FLC-resistant <i>C. albicans</i> biofilm formation by (A) DMSO and compounds (B) <b>20a</b>, (C) <b>20h</b>, and (D) <b>24</b> using the XTT reduction assay. The results were presented as a percentage compared with the control biofilms formed without compound treatment. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 versus the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compounds <b>20a</b>, <b>20h</b>, and <b>24</b> suppress tumor growth and improve survival of leukemic mice in vivo. (A) The efficacy of compounds <b>20a</b>, <b>20h</b>, and <b>24</b> in the HEL xenograft model. Data were represented as mean Â± standard deviation. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 versus the control group, as determined with Studentâs <i>t</i> test. (B) Tumor weight of dissected HEL tumor tissues. (C) The KaplanâMeier curves of leukemic mice in control (vehicle), <b>1</b>, <b>2</b>, <b>20a</b>, <b>20h</b>, and <b>24</b> treatment groups. Single asterisks indicate <i>P</i> < 0.05, double asterisks indicate <i>P</i> < 0.01, and triple asterisks indicate <i>P</i> < 0.001 by log-rank test for significance. (D) The spleen weight of the killed leukemic mice. Single asterisks indicate <i>P</i> < 0.05 and double asterisks indicate <i>P</i> < 0.01, as determined with Studentâs <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Therapeutic efficacy of compounds and FLC in FLC-resistant <i>C. albicans</i> disseminated infection model. Mice were infected with <i>C. albicans</i> isolate 0304103 and treated with vehicle, (A) compounds <b>1</b> and <b>2</b>, (B) <b>20a</b>, (C) <b>20h</b>, (D) <b>24</b>, or FLC or a combination. Triple asterisks indicate <i>P</i> < 0.001 vs the FLC group by log-rank test for significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/medium/jm-2018-003937_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmacokinetics of compound <b>20a</b> in rats. (A) Mean (Â± standard deviation) plasma concentrationâtime profiles of compound <b>20a</b> in SD rats. (B) PK parameters of compound <b>20a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-14/acs.jmedchem.8b00393/20180719/images/large/jm-2018-003937_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00393&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offidani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invernizzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lint, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentini, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girmenia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosari, A.</span></span> <span> </span><span class="NLM_article-title">The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1068</span>â <span class="NLM_lpage">1075</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=1068-1075&author=L.+Paganoauthor=M.+Cairaauthor=A.+Candoniauthor=M.+Offidaniauthor=L.+Fianchiauthor=B.+Martinoauthor=D.+Pastoreauthor=M.+Picardiauthor=A.+Boniniauthor=A.+Chierichiniauthor=R.+Fanciauthor=C.+Caramattiauthor=R.+Invernizziauthor=D.+Matteiauthor=M.+E.+Mitraauthor=L.+Melilloauthor=F.+Aversaauthor=M.+T.+Van+Lintauthor=P.+Falcucciauthor=C.+G.+Valentiniauthor=C.+Girmeniaauthor=A.+Nosari&title=The+epidemiology+of+fungal+infections+in+patients+with+hematologic+malignancies%3A+the+SEIFEM-2004+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DL.%26aulast%3DCaira%26aufirst%3DM.%26aulast%3DCandoni%26aufirst%3DA.%26aulast%3DOffidani%26aufirst%3DM.%26aulast%3DFianchi%26aufirst%3DL.%26aulast%3DMartino%26aufirst%3DB.%26aulast%3DPastore%26aufirst%3DD.%26aulast%3DPicardi%26aufirst%3DM.%26aulast%3DBonini%26aufirst%3DA.%26aulast%3DChierichini%26aufirst%3DA.%26aulast%3DFanci%26aufirst%3DR.%26aulast%3DCaramatti%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DR.%26aulast%3DMattei%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DM.%2BE.%26aulast%3DMelillo%26aufirst%3DL.%26aulast%3DAversa%26aufirst%3DF.%26aulast%3DVan%2BLint%26aufirst%3DM.%2BT.%26aulast%3DFalcucci%26aufirst%3DP.%26aulast%3DValentini%26aufirst%3DC.%2BG.%26aulast%3DGirmenia%26aufirst%3DC.%26aulast%3DNosari%26aufirst%3DA.%26atitle%3DThe%2520epidemiology%2520of%2520fungal%2520infections%2520in%2520patients%2520with%2520hematologic%2520malignancies%253A%2520the%2520SEIFEM-2004%2520study%26jtitle%3DHaematologica%26date%3D2006%26volume%3D91%26spage%3D1068%26epage%3D1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pophali, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, M. M.</span></span> <span> </span><span class="NLM_article-title">The role of new tyrosine kinase inhibitors in chronic myeloid leukemia</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">40</span>â <span class="NLM_lpage">50</span>, <span class="refDoi">Â DOI: 10.1097/PPO.0000000000000165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1097%2FPPO.0000000000000165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26841016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit12msrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=40-50&author=P.+A.+Pophaliauthor=M.+M.+Patnaik&title=The+role+of+new+tyrosine+kinase+inhibitors+in+chronic+myeloid+leukemia&doi=10.1097%2FPPO.0000000000000165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia</span></div><div class="casAuthors">Pophali, Priyanka A.; Patnaik, Mrinal M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-50</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia.  Imatinib produces acceptable responses in approx. 60% of patients, with approx. 20% discontinuing therapy because of intolerance and approx. 20% developing drug resistance.  The advent of newer TKIs, such as nilotinib, dasatinib, bosutinib, and ponatinib, has provided multiple options for patients.  These agents are more potent, have unique adverse effect profiles, and are more likely to achieve relevant milestones, such as early mol. responses (3-6 mo) and optimal mol. responses (12 mo).  The acquisition of BCR-ABL kinase domain mutations is also reportedly lower with these drugs.  Thus far, none of the randomized phase III clin. trials have shown a clin. significant survival difference between frontline imatinib vs. newer TKIs.  Cost and safety issues with the newer TKIs, such as vascular disease with nilotinib and ponatinib and pulmonary hypertension with dasatinib, have dampened the enthusiasm of using these drugs as frontline options.  While the utility of new TKIs in the setting of imatinib failure or intolerance is clear, their use as frontline agents should factor in the age of the patient, addnl. comorbidities, risk stratification (Sokal score), and cost.  Combination therapies and newer agents with potential to eradicate quiescent chronic myeloid leukemia stem cells offers future hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouJ68ImNbrpbVg90H21EOLACvtfcHk0ljSa78Fx681Fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit12msrs%253D&md5=ad246db34c96901d74a5f33cdefdf88f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000165%26sid%3Dliteratum%253Aachs%26aulast%3DPophali%26aufirst%3DP.%2BA.%26aulast%3DPatnaik%26aufirst%3DM.%2BM.%26atitle%3DThe%2520role%2520of%2520new%2520tyrosine%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520J.%26date%3D2016%26volume%3D22%26spage%3D40%26epage%3D50%26doi%3D10.1097%2FPPO.0000000000000165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J.</span></span> <span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>â <span class="NLM_lpage">244</span>, <span class="refDoi">Â DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0ljSa78Fx681Fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>â <span class="NLM_lpage">550</span>, <span class="refDoi">Â DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0li_4D9saEsbNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>â <span class="NLM_lpage">911</span>, <span class="refDoi">Â DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0li_4D9saEsbNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>â <span class="NLM_lpage">5038</span>, <span class="refDoi">Â DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0li_4D9saEsbNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kontzias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotlyar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâShea, J. J.</span></span> <span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">464</span>â <span class="NLM_lpage">470</span>, <span class="refDoi">Â DOI: 10.1016/j.coph.2012.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease&doi=10.1016%2Fj.coph.2012.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0lgFiDrHU_lt8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470%26doi%3D10.1016%2Fj.coph.2012.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span> <span> </span><span class="NLM_article-title">JAK/STAT signaling in hematological malignancies</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2601</span>â <span class="NLM_lpage">2613</span>, <span class="refDoi">Â DOI: 10.1038/onc.2012.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fonc.2012.347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22869151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=2601-2613&author=W.+Vainchenkerauthor=S.+N.+Constantinescu&title=JAK%2FSTAT+signaling+in+hematological+malignancies&doi=10.1038%2Fonc.2012.347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">JAK/STAT signaling in hematological malignancies</span></div><div class="casAuthors">Vainchenker, W.; Constantinescu, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2601-2613</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is crit. in blood formation and immune response.  Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are crit. for the formation of blood lineages.  Several cancers, including blood malignancies, have been assocd. with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation.  More recently, human myeloproliferative neoplasms were discovered to be assocd. with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2.  Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematol. malignancies.  This has been obsd. in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.  Here we discuss the nature and resp. contribution of mutations dysregulating the JAK/STAT pathway in hematol. malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage.  JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematol. diseases might benefit from treatment with these inhibitors in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwfhpAymyJbVg90H21EOLACvtfcHk0lgFiDrHU_lt8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrtr%252FN&md5=f491a126765e10fbfbb73f6e04fd64e6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.347%26sid%3Dliteratum%253Aachs%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26atitle%3DJAK%252FSTAT%2520signaling%2520in%2520hematological%2520malignancies%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D2601%26epage%3D2613%26doi%3D10.1038%2Fonc.2012.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushal, S.</span></span> <span> </span><span class="NLM_article-title">Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1074</span>â <span class="NLM_lpage">1086</span>, <span class="refDoi">Â DOI: 10.1016/j.clinthera.2014.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.clinthera.2014.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=25047498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=1074-1086&author=K.+Kaurauthor=S.+Kalraauthor=S.+Kaushal&title=Systematic+review+of+tofacitinib%3A+a+new+drug+for+the+management+of+rheumatoid+arthritis&doi=10.1016%2Fj.clinthera.2014.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis</span></div><div class="casAuthors">Kaur, Kirandeep; Kalra, Sonesh; Kaushal, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1074-1086</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The goal of this study was to review and summarize the efficacy and safety of use of tofacitinib for treating rheumatoid arthritis (RA).  A systematic literature review was conducted to identify English-language articles published through May 2013 within PubMed, ClinicalTrials.gov, and Cochrane Library reporting results from Phase II and Phase III tofacitinib randomized clin. trials.  Tofacitinib must have been used as monotherapy or in combination therapy with disease-modifying antirheumatic drugs (DMARDs) in the treatment of RA.  Study outcomes had to include at least 1 of the following: American College of Rheumatol. (ACR) 20%, 50%, or 70% response rates; tender/swollen joint count; health assessment questionnaire of disability; radiog. outcomes; and drug persistence.  Eight studies (4 Phase II and 4 Phase III trials) were included in the review.  Patients with active RA and who were nonresponders to a biol. agent or the nonbiol. DMARD methotrexate were included in these studies.  The results of the Phase II trials show that tofacitinib at doses â¥3 mg BID was efficacious among the nonresponders.  The results of the Phase III trials, comparing tofacitinib 5 and 10 mg with placebo, show that tofacitinib led to a significant improvement in ACR20 response (P < 0.0001), Health Assessment Questionnaire-Disability Index (P < 0.0001) scores, and ACR50 response (P < 0.0001) after 3 mo.  The efficacy of tofacitinib was numerically similar to adalimumab.  The most common adverse events were infections, infestations, increases in LDL-C and HDL-C levels, and a decrease in neutrophil counts.  Tofacitinib is an efficacious drug for the management of moderate to severe RA among patients with an inadequate response to methotrexate and tumor necrosis factor inhibitors.  Long-term studies can help in understanding the risk/benefit profile of tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNhogMT16YO7Vg90H21EOLACvtfcHk0lgFiDrHU_lt8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI&md5=8ffd0a6e85f9b9880cc80462337ddc7f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2014.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2014.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DS.%26atitle%3DSystematic%2520review%2520of%2520tofacitinib%253A%2520a%2520new%2520drug%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DClin.%2520Ther.%26date%3D2014%26volume%3D36%26spage%3D1074%26epage%3D1086%26doi%3D10.1016%2Fj.clinthera.2014.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plosker, G. L.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a review of its use in patients with myelofibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">308</span>, <span class="refDoi">Â DOI: 10.1007/s40265-015-0351-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1007%2Fs40265-015-0351-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=25601187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=297-308&author=G.+L.+Plosker&title=Ruxolitinib%3A+a+review+of+its+use+in+patients+with+myelofibrosis&doi=10.1007%2Fs40265-015-0351-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis</span></div><div class="casAuthors">Plosker, Greg L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (Jakavi, Jakafi) is an orally administered inhibitor of Janus kinases (JAK) 1 and 2 used in the management of patients with myelofibrosis.  Clin. trials with ruxolitinib, notably the phase III COMFORT-I and -II studies and their extensions, have demonstrated marked and durable clin. benefits in terms of redns. in splenomegaly and disease-related symptoms in patients with intermediate-2 or high-risk myelofibrosis.  Ruxolitinib was also assocd. with improvements in health-related quality of life and functioning.  Despite the crossover of patients in control groups to ruxolitinib, results of the COMFORT studies and their extensions indicate a survival advantage for patients randomized to ruxolitinib.  The beneficial effects of ruxolitinib were obsd. across subgroups of myelofibrosis patients, including those not harbouring the JAK2V617F mutation.  Improvements in splenomegaly and disease-related symptoms were also obsd. in a trial in Japanese/Asian patients with myelofibrosis and in myelofibrosis patients with a low baseline platelet count.  Dose-related anemia and thrombocytopenia were common in clin. trials with ruxolitinib, but rarely led to discontinuation of therapy and were managed with dosage modifications and/or transfusions of packed red blood cells.  In addn. to the USA and EU, ruxolitinib is now approved in a no. of other countries, including Japan, and remains the only approved drug for the treatment of myelofibrosis, although various other agents are undergoing investigation.  Appropriate monitoring and dosage titrn. are important to achieve optimal clin. benefits of ruxolitinib.  Further research, including studies evaluating ruxolitinib-based combination therapy, may also help to optimize treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjqinnNMi_PLVg90H21EOLACvtfcHk0liDj3H_ZYwUpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisrg%253D&md5=58970b22ffdaab2e4a3d8ee7dffdb72f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0351-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0351-8%26sid%3Dliteratum%253Aachs%26aulast%3DPlosker%26aufirst%3DG.%2BL.%26atitle%3DRuxolitinib%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520myelofibrosis%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D297%26epage%3D308%26doi%3D10.1007%2Fs40265-015-0351-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK kinase in solid tumors: emerging opportunities and challenges</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">939</span>â <span class="NLM_lpage">951</span>, <span class="refDoi">Â DOI: 10.1038/onc.2015.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fonc.2015.150" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=939-951&author=M.+Buchertauthor=C.+J.+Burnsauthor=M.+Ernst&title=Targeting+JAK+kinase+in+solid+tumors%3A+emerging+opportunities+and+challenges&doi=10.1038%2Fonc.2015.150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.150%26sid%3Dliteratum%253Aachs%26aulast%3DBuchert%26aufirst%3DM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DErnst%26aufirst%3DM.%26atitle%3DTargeting%2520JAK%2520kinase%2520in%2520solid%2520tumors%253A%2520emerging%2520opportunities%2520and%2520challenges%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26spage%3D939%26epage%3D951%26doi%3D10.1038%2Fonc.2015.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms</span>. <i>Hematol. Oncol. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">627</span>â <span class="NLM_lpage">642</span>, <span class="refDoi">Â DOI: 10.1016/j.hoc.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.hoc.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=28673392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=627-642&author=S.+C.+Meyer&title=Mechanisms+of+resistance+to+JAK2+inhibitors+in+myeloproliferative+neoplasms&doi=10.1016%2Fj.hoc.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms</span></div><div class="casAuthors">Meyer Sara C</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-642</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Myeloproliferative neoplasms are driven by activated JAK2 signaling due to somatic mutations in JAK2, the thrombopoietin receptor MPL or the chaperone calreticulin in hematopoietic stem/progenitor cells.  JAK2 inhibitors have been developed, but despite clinical benefits, they do not signficantly reduce the mutant clone.  Loss of response to JAK2 inhibitors occurs and several mechanisms of resistance, genetic and functional, have been identified.  Resistance mutations have not been reported in MPN patients suggesting incomplete target inhibition.  Alternative targeting of JAK2 by HSP90 inhibitors or type II JAK2 inhibition overcomes resistance to current JAK2 inhibitors.  Additional combined therapy approaches are currently being evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsWLFM_lbR1VmfW6udTcc2eY54XiXRabsKbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCmsw%253D%253D&md5=195db657c3d8a32ffc83932047d37595</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520JAK2%2520inhibitors%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D31%26spage%3D627%26epage%3D642%26doi%3D10.1016%2Fj.hoc.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppikar, P.</span></span> <span> </span><span class="NLM_article-title">Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms</span>. <i>Int. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">695</span>â <span class="NLM_lpage">702</span>, <span class="refDoi">Â DOI: 10.1007/s12185-013-1353-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1007%2Fs12185-013-1353-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23670175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1yntLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=695-702&author=N.+Bhagwatauthor=R.+L.+Levineauthor=P.+Koppikar&title=Sensitivity+and+resistance+of+JAK2+inhibitors+to+myeloproliferative+neoplasms&doi=10.1007%2Fs12185-013-1353-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms</span></div><div class="casAuthors">Bhagwat, Neha; Levine, Ross L.; Koppikar, Priya</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-702</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  The discovery of activating mutations in JAK2 and MPL in a majority of patients with myeloproliferative neoplasms (MPN) has led to the rapid clin. development of several JAK kinase inhibitors.  Of these, the JAK1/2 inhibitor, ruxolitinib (INCB018424, Incyte Corporation) was recently approved for the treatment of patients with myelofibrosis (MF).  JAK inhibitors have effectively reduced splenomegaly and high cytokine levels in patients leading to improvements in quality of life.  However, they have not been successful in eliminating the mutant clone in a majority of patients.  In vitro studies using satn. mutagenesis screens have revealed several mutations in JAK2 that confer resistance to JAK inhibitors.  Nevertheless, these mutations have not been identified so far in JAK inhibitor-treated patients.  A recent study from our lab. demonstrated that chronic JAK kinase inhibition leads to JAK inhibitor persistence via transphosphorylation of JAK2 through other JAK kinase family members.  This phenomenon is seen in cell lines, mouse models and patient samples.  The JAK inhibitor persistent cells, however, still remain JAK2 dependent and therefore combination therapies that target JAK2 and other components of the JAK-STAT pathway along with JAK inhibitors may provide addnl. benefits and improve clin. outcomes in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTsQA0yjOWqLVg90H21EOLACvtfcHk0liDj3H_ZYwUpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1yntLk%253D&md5=dbb7b81ecc3cc28ff370aab1f779ba38</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs12185-013-1353-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-013-1353-5%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DKoppikar%26aufirst%3DP.%26atitle%3DSensitivity%2520and%2520resistance%2520of%2520JAK2%2520inhibitors%2520to%2520myeloproliferative%2520neoplasms%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2013%26volume%3D97%26spage%3D695%26epage%3D702%26doi%3D10.1007%2Fs12185-013-1353-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span>. <i>Curr. Opin. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1097/MOH.0b013e32835d8e10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1097%2FMOH.0b013e32835d8e10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=123-129&author=F.+P.+Santosauthor=S.+Verstovsek&title=What+is+next+beyond+janus+kinase+2+inhibitors+for+primary+myelofibrosis%3F&doi=10.1097%2FMOH.0b013e32835d8e10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Although the approval of the janus kinase (JAK) inhibitor ruxolitinib for therapy of patients with myelofibrosis represents an important step in the development of targeted therapy for these patients, JAK inhibitors do not eradicate the disease, and a review of novel agents with mechanisms of action complementary to JAK2 enzymic inhibition is timely.  Recent findings: There are several compds. with different mechanisms of action undergoing preclin. and clin. testing in myelofibrosis.  Heat shock protein inhibitors and histone deacetylase inhibitors induce JAK2 degrdn. and downregulation of intracellular oncogenic signalling, and may overcome resistance to JAK2 inhibitors.  Reversal of bone marrow fibrosis is still a therapeutic challenge in this disease, and mAbs targeting transforming growth factor-Î² and lysyl oxidase like-2 may prove efficacious.  Promising compds. inhibiting signal transducer and activator of transcription 5 activity and inducing megakaryocyte polyploidization are in preclin. testing.  Summary: Although none of these new drugs have been approved for therapy of myelofibrosis, their activity is being tested in clin. trials, alone or in combination with JAK2 inhibitors.  Patients with myelofibrosis should be encouraged to participate in clin. trials testing novel compds. for this disorder, particularly if they have failed a trial of JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gqDFCRlvYrVg90H21EOLACvtfcHk0liUYJGCIlJ8Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D&md5=49159c335e02a416c0541d8b92069f4e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32835d8e10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32835d8e10%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DWhat%2520is%2520next%2520beyond%2520janus%2520kinase%25202%2520inhibitors%2520for%2520primary%2520myelofibrosis%253F%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2013%26volume%3D20%26spage%3D123%26epage%3D129%26doi%3D10.1097%2FMOH.0b013e32835d8e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choong, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaconu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defour, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeval, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vainchenker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span> <span> </span><span class="NLM_article-title">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1397</span>â <span class="NLM_lpage">1409</span>, <span class="refDoi">Â DOI: 10.1111/jcmm.12156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1111%2Fjcmm.12156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=24251790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFan" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1397-1409&author=M.+L.+Choongauthor=C.+Pecquetauthor=V.+Pendharkarauthor=C.+C.+Diaconuauthor=J.+W.+Yongauthor=S.+J.+Taiauthor=S.+F.+Wangauthor=J.+P.+Defourauthor=K.+Sangthongpitagauthor=J.+L.+Villevalauthor=W.+Vainchenkerauthor=S.+N.+Constantinescuauthor=M.+A.+Lee&title=Combination+treatment+for+myeloproliferative+neoplasms+using+JAK+and+pan-class+I+PI3K+inhibitors&doi=10.1111%2Fjcmm.12156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span></div><div class="casAuthors">Choong, Meng Ling; Pecquet, Christian; Pendharkar, Vishal; Diaconu, Carmen C.; Yong, Jacklyn Wei Yan; Tai, Shi Jing; Wang, Si Fang; Defour, Jean-Philippe; Sangthongpitag, Kanda; Villeval, Jean-Luc; Vainchenker, William; Constantinescu, Stefan N.; Lee, May Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1397-1409</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiol. JAK2 signalling.  We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeting nine signalling pathways and already used in clin. trials, synergized in inhibiting growth of haematopoietic cells expressing mutant and wild-type forms of JAK2 (V617F) or thrombopoietin receptor (W515L).  Out of 15 kinase inhibitors, the ZSTK474 phosphatydylinositol-3'-kinase (PI3K) inhibitor mol. showed strong synergic inhibition by Chou and Talalay anal. with JAK2 and JAK2/JAK1 inhibitors.  Other pan-class I, but not gamma or delta specific PI3K inhibitors, also synergized with JAK2 inhibitors.  Synergy was not obsd. in Bcr-Abl transformed cells.  The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen wt. in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.  It also exerted strong inhibitory effects on erythropoietin-independent erythroid colonies from MPN patients and JAK2 V617F knock-in mice, where at certain doses, a preferential inhibition of JAK2 V617F mutated progenitors was detected.  Our data support the use of a combination of JAK2 and pan-class I PI3K inhibitors in the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwYG9JAajg0rVg90H21EOLACvtfcHk0liUYJGCIlJ8Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFan&md5=f2fdba575d0402f6d971b1db53d41981</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12156%26sid%3Dliteratum%253Aachs%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DPecquet%26aufirst%3DC.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DDiaconu%26aufirst%3DC.%2BC.%26aulast%3DYong%26aufirst%3DJ.%2BW.%26aulast%3DTai%26aufirst%3DS.%2BJ.%26aulast%3DWang%26aufirst%3DS.%2BF.%26aulast%3DDefour%26aufirst%3DJ.%2BP.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DLee%26aufirst%3DM.%2BA.%26atitle%3DCombination%2520treatment%2520for%2520myeloproliferative%2520neoplasms%2520using%2520JAK%2520and%2520pan-class%2520I%2520PI3K%2520inhibitors%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1397%26epage%3D1409%26doi%3D10.1111%2Fjcmm.12156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waibel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralli, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidacs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virely, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins-Underwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takiguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghysdael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullighan, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1047</span>â <span class="NLM_lpage">1059</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2013.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.celrep.2013.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=24268771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1047-1059&author=M.+Waibelauthor=V.+S.+Solomonauthor=D.+A.+Knightauthor=R.+A.+Ralliauthor=S.+K.+Kimauthor=K.+M.+Banksauthor=E.+Vidacsauthor=C.+Virelyauthor=K.+C.+Siaauthor=L.+S.+Brackenauthor=R.+Collins-Underwoodauthor=C.+Drenbergauthor=L.+B.+Ramseyauthor=S.+C.+Meyerauthor=M.+Takiguchiauthor=R.+A.+Dickinsauthor=R.+Levineauthor=J.+Ghysdaelauthor=M.+A.+Dawsonauthor=R.+B.+Lockauthor=C.+G.+Mullighanauthor=R.+W.+Johnstone&title=Combined+targeting+of+JAK2+and+Bcl-2%2FBcl-xL+to+cure+mutant+JAK2-driven+malignancies+and+overcome+acquired+resistance+to+JAK2+inhibitors&doi=10.1016%2Fj.celrep.2013.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors</span></div><div class="casAuthors">Waibel, Michaela; Solomon, Vanessa S.; Knight, Deborah A.; Ralli, Rachael A.; Kim, Sang-Kyu; Banks, Kellie-Marie; Vidacs, Eva; Virely, Clemence; Sia, Keith C. S.; Bracken, Lauryn S.; Collins-Underwood, Racquel; Drenberg, Christina; Ramsey, Laura B.; Meyer, Sara C.; Takiguchi, Megumi; Dickins, Ross A.; Levine, Ross; Ghysdael, Jacques; Dawson, Mark A.; Lock, Richard B.; Mullighan, Charles G.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1047-1059</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To design rational therapies for JAK2-driven hematol. malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2.  In tumors driven by mutant JAK2, Stat1, Stat3, Stat5, and the Pi3k and Mek/Erk pathways were constitutively active, and gene expression profiling of TEL-JAK2 T-ALL cells revealed the upregulation of prosurvival Bcl-2 family genes.  Combining the Bcl-2/Bcl-xL inhibitor ABT-737 with JAK2 inhibitors mediated prolonged disease regressions and cures in mice bearing primary human and mouse JAK2 mutant tumors.  Moreover, combined targeting of JAK2 and Bcl-2/Bcl-xL was able to circumvent and overcome acquired resistance to single-agent JAK2 inhibitor treatment.  Thus, inhibiting the oncogenic JAK2 signaling network at two nodal points, at the initiating stage (JAK2) and the effector stage (Bcl-2/Bcl-xL), is highly effective and provides a clearly superior therapeutic benefit than targeting just one node.  Therefore, we have defined a potentially curative treatment for hematol. malignancies expressing constitutively active JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiJQ8J0GL_7Vg90H21EOLACvtfcHk0liUYJGCIlJ8Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN&md5=cd6ec40bd071fa0f811dee36bb882588</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DWaibel%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DV.%2BS.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DRalli%26aufirst%3DR.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DBanks%26aufirst%3DK.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DVirely%26aufirst%3DC.%26aulast%3DSia%26aufirst%3DK.%2BC.%26aulast%3DBracken%26aufirst%3DL.%2BS.%26aulast%3DCollins-Underwood%26aufirst%3DR.%26aulast%3DDrenberg%26aufirst%3DC.%26aulast%3DRamsey%26aufirst%3DL.%2BB.%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DTakiguchi%26aufirst%3DM.%26aulast%3DDickins%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DGhysdael%26aufirst%3DJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DCombined%2520targeting%2520of%2520JAK2%2520and%2520Bcl-2%252FBcl-xL%2520to%2520cure%2520mutant%2520JAK2-driven%2520malignancies%2520and%2520overcome%2520acquired%2520resistance%2520to%2520JAK2%2520inhibitors%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D5%26spage%3D1047%26epage%3D1059%26doi%3D10.1016%2Fj.celrep.2013.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptaco sa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">169</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1021/jm201112g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=169-196&author=A.+D.+Williamauthor=A.+C.+Leeauthor=K.+C.+Gohauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=C.+P.+Leeauthor=H.+Wangauthor=M.+Williamsauthor=E.+T.+Sunauthor=C.+Huauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+kinase+spectrum+selective+macrocycle+%2816E%29-14-methyl-20-oxa-5%2C7%2C14%2C26-tetraazatetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptaco+sa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2827%29%2C9%2C11%2C16%2C21%2C23-decaene+%28SB1317%2FTG02%29%2C+a+potent+inhibitor+of+cyclin+dependent+kinases+%28CDKs%29%2C+Janus+kinase+2+%28JAK2%29%2C+and+fms-like+tyrosine+kinase-3+%28FLT3%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm201112g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Goh, Kee Chuan; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Lee, Chai Ping; Wang, Haishan; Williams, Meredith; Sun, Eric T.; Hu, Changyong; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we describe the design, synthesis, and SAR of a series of unique small mol. macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3.  The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, soly., CYP450 inhibition, and microsomal stability.  This screening cascade revealed 26h (I) as a preferred compd. with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, resp.  Pharmacokinetic (PK) studies of 26h in preclin. species showed good oral exposures.  Oral efficacy was obsd. in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the obsd. PK/PD correlation.  26H (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clin. trials in advanced leukemias and multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMvOv-_pFzbVg90H21EOLACvtfcHk0li8tf29Kndx6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P&md5=50affe14bd28594735131d6b5841502a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201112g%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520kinase%2520spectrum%2520selective%2520macrocycle%2520%252816E%2529-14-methyl-20-oxa-5%252C7%252C14%252C26-tetraazatetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptaco%2520sa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-decaene%2520%2528SB1317%252FTG02%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependent%2520kinases%2520%2528CDKs%2529%252C%2520Janus%2520kinase%25202%2520%2528JAK2%2529%252C%2520and%2520fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D169%26epage%3D196%26doi%3D10.1021%2Fjm201112g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>â <span class="NLM_lpage">4658</span>, <span class="refDoi">Â DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0li8tf29Kndx6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conway, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woster, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Epigenetics: novel therapeutics targeting epigenetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">523</span>â <span class="NLM_lpage">524</span>, <span class="refDoi">Â DOI: 10.1021/jm501941q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501941q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=523-524&author=S.+J.+Conwayauthor=P.+M.+Wosterauthor=J.+K.+Shenauthor=G.+Georgauthor=S.+Wang&title=Epigenetics%3A+novel+therapeutics+targeting+epigenetics&doi=10.1021%2Fjm501941q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics: Novel Therapeutics Targeting Epigenetics</span></div><div class="casAuthors">Conway, Stuart J.; Woster, Patrick M.; Shen, Jing-Kang; Georg, Gunda; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCRBHbQISoP7Vg90H21EOLACvtfcHk0ljeezNdjXTjAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOgs7rP&md5=589ff3da038c55adece6bcdbd6bbe461</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm501941q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501941q%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DS.%2BJ.%26aulast%3DWoster%26aufirst%3DP.%2BM.%26aulast%3DShen%26aufirst%3DJ.%2BK.%26aulast%3DGeorg%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DEpigenetics%253A%2520novel%2520therapeutics%2520targeting%2520epigenetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D523%26epage%3D524%26doi%3D10.1021%2Fjm501941q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ververis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licciardi, P. V.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span>. <i>Biol.: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">47</span>â <span class="NLM_lpage">60</span>, <span class="refDoi">Â DOI: 10.2147/BTT.S29965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.2147%2FBTT.S29965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23459471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=47-60&author=K.+Ververisauthor=A.+Hiongauthor=T.+C.+Karagiannisauthor=P.+V.+Licciardi&title=Histone+deacetylase+inhibitors+%28HDACIs%29%3A+multitargeted+anticancer+agents&doi=10.2147%2FBTT.S29965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</span></div><div class="casAuthors">Ververis, Katherine; Hiong, Alison; Karagiannis, Tom C.; Licciardi, Paul V.</div><div class="citationInfo"><span class="NLM_cas:title">Biologics: Targets & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">BTTICT</span>;
        ISSN:<span class="NLM_cas:issn">1177-5491</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs.  The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addn. to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter phenotype and gene expression, disturb homeostasis, and contribute to neoplastic growth.  The family of HDAC inhibitors is large and diverse.  It includes a range of naturally occurring and synthetic compds. that differ in terms of structure, function, and specificity.  HDAC inhibitors have multiple cell type-specific effects in vitro and in vivo, such as growth arrest, cell differentiation, and apoptosis in malignant cells.  HDAC inhibitors have the potential to be used as monotherapies or in combination with other anticancer therapies.  Currently, there are two HDAC inhibitors that have received approval from the US FDA for the treatment of cutaneous T-cell lymphoma: vorinostat (suberoylanilide hydroxamic acid, Zolinza) and depsipeptide (romidepsin, Istodax).  More recently, depsipeptide has also gained FDA approval for the treatment of peripheral T-cell lymphoma.  Many more clin. trials assessing the effects of various HDAC inhibitors on hematol. and solid malignancies are currently being conducted.  Despite the proven anticancer effects of particular HDAC inhibitors against certain cancers, many aspects of HDAC enzymes and HDAC inhibitors are still not fully understood.  Increasing our understanding of the effects of HDAC inhibitors, their targets and mechanisms of action will be crit. for the advancement of these drugs, esp. to facilitate the rational design of HDAC inhibitors that are effective as antineoplastic agents.  This review will discuss the use of HDAC inhibitors as multitargeted therapies for malignancy.  Further, we outline the pharmacol. and mechanisms of action of HDAC inhibitors while discussing the safety and efficacy of these compds. in clin. studies to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAm6AJlxdHLVg90H21EOLACvtfcHk0ljeezNdjXTjAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFCms70%253D&md5=288f04e51d214cef9edf5bc8a8c3c624</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2147%2FBTT.S29965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBTT.S29965%26sid%3Dliteratum%253Aachs%26aulast%3DVerveris%26aufirst%3DK.%26aulast%3DHiong%26aufirst%3DA.%26aulast%3DKaragiannis%26aufirst%3DT.%2BC.%26aulast%3DLicciardi%26aufirst%3DP.%2BV.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%253A%2520multitargeted%2520anticancer%2520agents%26jtitle%3DBiol.%253A%2520Targets%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D47%26epage%3D60%26doi%3D10.2147%2FBTT.S29965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1247</span>â <span class="NLM_lpage">1252</span>, <span class="refDoi">Â DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0ljeezNdjXTjAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenehjem, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Panobinostat for the treatment of multiple myeloma: the evidence to date</span>. <i>J. Blood Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.2147/JBM.S69140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.2147%2FJBM.S69140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26504410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=269-276&author=H.+Baileyauthor=D.+D.+Stenehjemauthor=S.+Sharma&title=Panobinostat+for+the+treatment+of+multiple+myeloma%3A+the+evidence+to+date&doi=10.2147%2FJBM.S69140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat for the treatment of multiple myeloma: the evidence to date</span></div><div class="casAuthors">Bailey, Hanna; Stenehjem, David D.; Sharma, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Blood Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-276</span>CODEN:
                <span class="NLM_cas:coden">JBMOB7</span>;
        ISSN:<span class="NLM_cas:issn">1179-2736</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow.  Survival of patients diagnosed with myeloma has significantly improved in the last decade, following the approval of novel agents.  Despite great strides achieved in the management of multiple myeloma, it is still considered an incurable disease as the majority of patients relapse after initiation of therapy.  Addnl., the duration of response generally decreases with an increasing no. of therapy lines.  The need to overcome resistance to therapy dictates research into more potent agents and those with novel mechanisms of action.  A therapeutic option for relapsed/refractory myeloma includes histone deacetylase inhibition.  Various histone deacetylase inhibitors, including the newly approved panobinostat, are currently under evaluation in this setting.  Panobinostat for multiple myeloma is used in combination with other potent therapeutic agents, such as proteasome inhibitors and steroids.  Ongoing research evaluating other panobinostat-contg. regimens will provide addnl. insight into its place in myeloma management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg66vLqHlQjrVg90H21EOLACvtfcHk0lj2YxEiNgr2ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1ejt74%253D&md5=cdff9d1bd461e6fb06e50c4708097951</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2147%2FJBM.S69140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJBM.S69140%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DH.%26aulast%3DStenehjem%26aufirst%3DD.%2BD.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DPanobinostat%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520the%2520evidence%2520to%2520date%26jtitle%3DJ.%2520Blood%2520Med.%26date%3D2015%26volume%3D6%26spage%3D269%26epage%3D276%26doi%3D10.2147%2FJBM.S69140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomathi Priya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjan, M. J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of histone deacetylase as antitumor agents: a critical review</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">18</span>â <span class="NLM_lpage">42</span>, <span class="refDoi">Â DOI: 10.1016/j.bioorg.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.bioorg.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=27239721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=18-42&author=M.+Manalauthor=M.+J.+Chandrasekarauthor=J.+Gomathi+Priyaauthor=M.+J.+Nanjan&title=Inhibitors+of+histone+deacetylase+as+antitumor+agents%3A+a+critical+review&doi=10.1016%2Fj.bioorg.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of histone deacetylase as antitumor agents: A critical review</span></div><div class="casAuthors">Manal, Mohammed; Chandrasekar, M. J. N.; Gomathi Priya, Jeyapal; Nanjan, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-42</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (E.C. 3.5.1.98 - HDAC) is an amidohydrolase involved in deacetylating the histone lysine residues for chromatin remodeling and thus plays a vital role in the epigenetic regulation of gene expression.  Due to its aberrant activity and over expression in several forms of cancer, HDAC is considered as a potential anticancer drug target.  HDAC inhibitors alter the acetylation status of histone and nonhistone proteins to regulate various cellular events such as cell survival, differentiation and apoptosis in tumor cells and thus exhibit anticancer activity.  Till date, four drugs, namely Vorinostat (SAHA), Romidepsin (FK-228), Belinostat (PXD-101) and Panobinostat (LBH-589) have been granted FDA approval for cancer and several HDAC inhibitors are currently in various phases of clin. trials, either as monotherapy and/or in combination with existing/novel anticancer agents.  Regardless of this, today scientific efforts have fortified the quest for newer and novel HDAC inhibitors that show isoform selectivity.  This review focuses on the chem. of the mols. of two classes of HDAC inhibitors, namely short chain fatty acids and hydroxamic acids, investigated so far as novel therapeutic agents for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdC7-JmHyErrVg90H21EOLACvtfcHk0lj2YxEiNgr2ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xoslaltbc%253D&md5=82e5562d9b74dfef2d6077bbceccd505</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DManal%26aufirst%3DM.%26aulast%3DChandrasekar%26aufirst%3DM.%2BJ.%26aulast%3DGomathi%2BPriya%26aufirst%3DJ.%26aulast%3DNanjan%26aufirst%3DM.%2BJ.%26atitle%3DInhibitors%2520of%2520histone%2520deacetylase%2520as%2520antitumor%2520agents%253A%2520a%2520critical%2520review%26jtitle%3DBioorg.%2520Chem.%26date%3D2016%26volume%3D67%26spage%3D18%26epage%3D42%26doi%3D10.1016%2Fj.bioorg.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget drugs: an epigenetic epiphany</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1241</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1002%2Fcmdc.201500394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26891251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1227-1241&author=A.+Ganesan&title=Multitarget+drugs%3A+an+epigenetic+epiphany&doi=10.1002%2Fcmdc.201500394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drugs: an Epigenetic Epiphany</span></div><div class="casAuthors">Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1227-1241</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Epigenetics refers to changes in a biol. phenotype that are not due to an underlying change in genotype.  In eukaryotes, epigenetics involves a set of chem. modifications of the DNA and the histone proteins in nucleosomes.  These dynamic changes are carried out by enzymes and modulate protein-protein and protein-nucleic acid interactions to det. whether specific genes are expressed or silenced.  Both the epigenetic enzymes and recognition domains are currently important drug discovery targets, particularly for the treatment of cancer.  This review summarizes the progress of epigenetic targets that have reached a clin. stage: DNA methyltransferases, histone deacetylases, lysine methyltransferases, lysine demethylases, and bromodomains; this is followed by a comprehensive survey of multitarget drugs that have included an epigenetic target as one of their mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwdZM3u9Wbc7Vg90H21EOLACvtfcHk0lj2YxEiNgr2ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D&md5=736284dc3f05db0032c9a304884f980d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500394%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMultitarget%2520drugs%253A%2520an%2520epigenetic%2520epiphany%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1227%26epage%3D1241%26doi%3D10.1002%2Fcmdc.201500394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>â <span class="NLM_lpage">7887</span>, <span class="refDoi">Â DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lj2YxEiNgr2ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>â <span class="NLM_lpage">8971</span>, <span class="refDoi">Â DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lgIyUl3XpksGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>â <span class="NLM_lpage">2059</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0lgIyUl3XpksGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>â <span class="NLM_lpage">8357</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lgIyUl3XpksGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>â <span class="NLM_lpage">8262</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0liNfMlSeeABbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>â <span class="NLM_lpage">7983</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0liNfMlSeeABbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">243</span>, <span class="refDoi">Â DOI: 10.1021/ml500327q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500327q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-243&author=S.+Heauthor=G.+Dongauthor=Z.+Wangauthor=W.+Chenauthor=Y.+Huangauthor=Z.+Liauthor=Y.+Jiangauthor=N.+Liuauthor=J.+Yaoauthor=Z.+Miaoauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+novel+multiacting+topoisomerase+I%2FII+and+histone+deacetylase+inhibitors&doi=10.1021%2Fml500327q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wang, Zhibin; Chen, Wei; Huang, Yahui; Li, Zhengang; Jiang, Yan; Liu, Na; Yao, Jianzhong; Miao, Zhenyuan; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs remains a significant challenge in current antitumor drug discovery.  Because of the synergistic effect between topoisomerase and HDAC inhibitors, the present study reported the first-in-class triple inhibitors of topoisomerase I/II and HDAC.  On the basis of 3-amino-10-hydroxylevodiamine and SAHA, a series of hybrid mols. was successfully designed and synthesized.  In particular, compd. 8c was proven to be a potent inhibitor of topoisomerase I/II and HDAC with good antiproliferative and apoptotic activities.  This proof-of-concept study also validated the effectiveness of discovering triple topoisomerase I/II and HDAC inhibitors as novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFr6sR4u6kbVg90H21EOLACvtfcHk0liNfMlSeeABbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D&md5=9630a82acaa4df7023a07aa7ed395e86</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500327q%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520multiacting%2520topoisomerase%2520I%252FII%2520and%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml500327q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-kappaB pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">577</span>, <span class="refDoi">Â DOI: 10.1021/jm401800k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401800k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=567-577&author=C.+Zhuangauthor=Z.+Miaoauthor=Y.+Wuauthor=Z.+Guoauthor=J.+Liauthor=J.+Yaoauthor=C.+Xingauthor=C.+Shengauthor=W.+Zhang&title=Double-edged+swords+as+cancer+therapeutics%3A+novel%2C+orally+active%2C+small+molecules+simultaneously+inhibit+p53-MDM2+interaction+and+the+NF-kappaB+pathway&doi=10.1021%2Fjm401800k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm401800k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401800k%26sid%3Dliteratum%253Aachs%26aulast%3DZhuang%26aufirst%3DC.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DSheng%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DDouble-edged%2520swords%2520as%2520cancer%2520therapeutics%253A%2520novel%252C%2520orally%2520active%252C%2520small%2520molecules%2520simultaneously%2520inhibit%2520p53-MDM2%2520interaction%2520and%2520the%2520NF-kappaB%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D567%26epage%3D577%26doi%3D10.1021%2Fjm401800k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span>; <span class="NLM_string-name">Mak, C.
C.</span>; <span class="NLM_string-name">Cao, J.</span>; <span class="NLM_string-name">Renick, J.</span>; <span class="NLM_string-name">Mcpherson, A.</span>; <span class="NLM_string-name">Zeng, B.</span>; <span class="NLM_string-name">Pathak, V. P.</span>; <span class="NLM_string-name">Lohse, D. L.</span>; <span class="NLM_string-name">Hood, J. D.</span>; <span class="NLM_string-name">Soll, R. M.</span></span> <span> </span><span class="NLM_article-title">Bi-aryl Meta-pyrimidine Inhibitors of Kinases</span>. U.S. Patent <span class="NLM_patent">8,604,042</span>, Dec. 10, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+Noronha&author=C.%0AC.+Mak&author=J.+Cao&author=J.+Renick&author=A.+Mcpherson&author=B.+Zeng&author=V.+P.+Pathak&author=D.+L.+Lohse&author=J.+D.+Hood&author=R.+M.+Soll&title=Bi-aryl+Meta-pyrimidine+Inhibitors+of+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26atitle%3DBi-aryl%2520Meta-pyrimidine%2520Inhibitors%2520of%2520Kinases%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gryder, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodji, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">505</span>â <span class="NLM_lpage">524</span>, <span class="refDoi">Â DOI: 10.4155/fmc.12.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.4155%2Ffmc.12.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22416777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=505-524&author=B.+E.+Gryderauthor=Q.+H.+Sodjiauthor=A.+K.+Oyelere&title=Targeted+cancer+therapy%3A+giving+histone+deacetylase+inhibitors+all+they+need+to+succeed&doi=10.4155%2Ffmc.12.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span></div><div class="casAuthors">Gryder, Berkley E.; Sodji, Quaovi H.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-524</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-mol. therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets.  Over 490 clin. trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis-SAHA (vorinostat, Zolinza) and FK228 (romidepsin, Istodax).  However, the current HDACis have serious limitations, including ineffectively low concns. in solid tumors and cardiac toxicity, which is hindering their progress in the clinic.  Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwrW1IVCIULVg90H21EOLACvtfcHk0lh73WU4WL1z_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D&md5=234080d1b0862680a68062a03afee20c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.3%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DSodji%26aufirst%3DQ.%2BH.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520giving%2520histone%2520deacetylase%2520inhibitors%2520all%2520they%2520need%2520to%2520succeed%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D505%26epage%3D524%26doi%3D10.4155%2Ffmc.12.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourke, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrugia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feutrill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nero, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikanyika, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Styles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treutlein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, A. F.</span></span> <span> </span><span class="NLM_article-title">Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5887</span>â <span class="NLM_lpage">5892</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.08.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.bmcl.2009.08.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=19762238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2hurvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5887-5892&author=C.+J.+Burnsauthor=D.+G.+Bourkeauthor=L.+Andrauauthor=X.+Buauthor=S.+A.+Charmanauthor=A.+C.+Donohueauthor=E.+Fantinoauthor=M.+Farrugiaauthor=J.+T.+Feutrillauthor=M.+Joffeauthor=M.+R.+Klingauthor=M.+Kurekauthor=T.+L.+Neroauthor=T.+Nguyenauthor=J.+T.+Palmerauthor=I.+Phillipsauthor=D.+M.+Shacklefordauthor=H.+Sikanyikaauthor=M.+Stylesauthor=S.+Suauthor=H.+Treutleinauthor=J.+Zengauthor=A.+F.+Wilks&title=Phenylaminopyrimidines+as+inhibitors+of+Janus+kinases+%28JAKs%29&doi=10.1016%2Fj.bmcl.2009.08.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)</span></div><div class="casAuthors">Burns, Christopher J.; Bourke, David G.; Andrau, Laura; Bu, Xianyong; Charman, Susan A.; Donohue, Andrew C.; Fantino, Emmanuelle; Farrugia, Michelle; Feutrill, John T.; Joffe, Max; Kling, Marcel R.; Kurek, Margarita; Nero, Tracy L.; Nguyen, Thao; Palmer, James T.; Phillips, Ian; Shackleford, David M.; Sikanyika, Harrison; Styles, Michelle; Su, Stephen; Treutlein, Herbert; Zeng, Jun; Wilks, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5887-5892</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs).  Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide, I).  Details of synthesis and SAR studies of these compds. are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUtVZ62x-yaLVg90H21EOLACvtfcHk0lh73WU4WL1z_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2hurvK&md5=e18632045687d8b56e403c2d4a7d676f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.071%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DBourke%26aufirst%3DD.%2BG.%26aulast%3DAndrau%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DX.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonohue%26aufirst%3DA.%2BC.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DFarrugia%26aufirst%3DM.%26aulast%3DFeutrill%26aufirst%3DJ.%2BT.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DKling%26aufirst%3DM.%2BR.%26aulast%3DKurek%26aufirst%3DM.%26aulast%3DNero%26aufirst%3DT.%2BL.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26aulast%3DPhillips%26aufirst%3DI.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DSikanyika%26aufirst%3DH.%26aulast%3DStyles%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DTreutlein%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DPhenylaminopyrimidines%2520as%2520inhibitors%2520of%2520Janus%2520kinases%2520%2528JAKs%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5887%26epage%3D5892%26doi%3D10.1016%2Fj.bmcl.2009.08.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, J.</span></span> <span> </span><span class="NLM_article-title">Role of heat-shock proteins in cellular function and in the biology of fungi</span>. <i>Biotechnol. Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">132635</span>, <span class="refDoi">Â DOI: 10.1155/2015/132635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1155%2F2015%2F132635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26881084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A280%3ADC%252BC28jhtVyjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=132635&author=S.+Tiwariauthor=R.+Thakurauthor=J.+Shankar&title=Role+of+heat-shock+proteins+in+cellular+function+and+in+the+biology+of+fungi&doi=10.1155%2F2015%2F132635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Heat-Shock Proteins in Cellular Function and in the Biology of Fungi</span></div><div class="casAuthors">Tiwari Shraddha; Thakur Raman; Shankar Jata</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132635</span>
        ISSN:<span class="NLM_cas:issn">2090-3138</span>.
    </div><div class="casAbstract">Stress (biotic or abiotic) is an unfavourable condition for an organism including fungus.  To overcome stress, organism expresses heat-shock proteins (Hsps) or chaperons to perform biological function.  Hsps are involved in various routine biological processes such as transcription, translation and posttranslational modifications, protein folding, and aggregation and disaggregation of proteins.  Thus, it is important to understand holistic role of Hsps in response to stress and other biological conditions in fungi.  Hsp104, Hsp70, and Hsp40 are found predominant in replication and Hsp90 is found in transcriptional and posttranscriptional process.  Hsp90 and Hsp70 in combination or alone play a major role in morphogenesis and dimorphism.  Heat stress in fungi expresses Hsp60, Hsp90, Hsp104, Hsp30, and Hsp10 proteins, whereas expression of Hsp12 protein was observed in response to cold stress.  Hsp30, Hsp70, and Hsp90 proteins showed expression in response to pH stress.  Osmotic stress is controlled by small heat-shock proteins and Hsp60.  Expression of Hsp104 is observed under high pressure conditions.  Out of these heat-shock proteins, Hsp90 has been predicted as a potential antifungal target due to its role in morphogenesis.  Thus, current review focuses on role of Hsps in fungi during morphogenesis and various stress conditions (temperature, pH, and osmotic pressure) and in antifungal drug tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRFS7HBs9MUoFEOhA_Im3cfW6udTcc2eZc90XlhO6FRbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhtVyjsQ%253D%253D&md5=77268ac0f1bdbeabb33c2c6a20cfc8ae</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1155%2F2015%2F132635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F132635%26sid%3Dliteratum%253Aachs%26aulast%3DTiwari%26aufirst%3DS.%26aulast%3DThakur%26aufirst%3DR.%26aulast%3DShankar%26aufirst%3DJ.%26atitle%3DRole%2520of%2520heat-shock%2520proteins%2520in%2520cellular%2520function%2520and%2520in%2520the%2520biology%2520of%2520fungi%26jtitle%3DBiotechnol.%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D132635%26doi%3D10.1155%2F2015%2F132635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlind, T. D.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3532</span>â <span class="NLM_lpage">3539</span>, <span class="refDoi">Â DOI: 10.1128/AAC.46.11.3532-3539.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1128%2FAAC.46.11.3532-3539.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=12384361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1yktbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3532-3539&author=W.+L.+Smithauthor=T.+D.+Edlind&title=Histone+deacetylase+inhibitors+enhance+Candida+albicans+sensitivity+to+azoles+and+related+antifungals%3A+correlation+with+reduction+in+CDR+and+ERG+upregulation&doi=10.1128%2FAAC.46.11.3532-3539.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation</span></div><div class="casAuthors">Smith, W. Lamar; Edlind, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3532-3539</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation play important roles in eukaryotic gene regulation.  Several histone deacetylase (HDA) inhibitors have been characterized, including trichostatin A (TSA), apicidin, and sodium butyrate.  We tested their effects on Candida albicans in vitro growth, heat sensitivity, and germ tube formation; minimal effects were obsd.  However, there was a dramatic effect of TSA on C. albicans sensitivity to the azoles fluconazole, itraconazole, and miconazole.  Similar effects were obsd. with other HDA inhibitors and with the antifungals terbinafine and fenpropimorph, which target, as do azoles, enzymes in the ergosterol biosynthetic pathway.  In contrast, HDA inhibitors had minimal effect on the activities of amphotericin B, flucytosine, and echinocandin, which have unrelated targets.  Specifically, addn. of 3 Î¼g of TSA/mL lowered the itraconazole MIC for five susceptible C. albicans isolates an av. of 2.7-fold at 24 h, but this increased to > 200-fold at 48 h.  Thus, the primary effect of TSA was a redn. in azole trailing.  TSA also enhanced itraconazole activity against Candida parapsilosis and Candida tropicalis but had no effect with four less related yeast species.  To examine the mol. basis for these effects, we studied expression of ERG genes (encoding azole and terbinafine targets) and CDR/MDR1 genes (encoding multidrug transporters) in C. albicans cells treated with fluconazole or terbinafine with or without TSA.  Both antifungals induced to various levels the expression of ERG1, ERG11, CDR1, and CDR2; addn. of TSA reduced this upregulation 50 to 100%.  This most likely explains the inhibition of azole and terbinafine trailing by TSA and, more generally, provides evidence that trailing is mediated by upregulation of target enzymes and multidrug transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4DpmS0neAOrVg90H21EOLACvtfcHk0lh7M2zi-lcRCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1yktbc%253D&md5=8a372cf4fcb9077cf8b92c21b37792bf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.11.3532-3539.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.11.3532-3539.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DW.%2BL.%26aulast%3DEdlind%26aufirst%3DT.%2BD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520enhance%2520Candida%2520albicans%2520sensitivity%2520to%2520azoles%2520and%2520related%2520antifungals%253A%2520correlation%2520with%2520reduction%2520in%2520CDR%2520and%2520ERG%2520upregulation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D3532%26epage%3D3539%26doi%3D10.1128%2FAAC.46.11.3532-3539.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passariello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamara, A. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1221</span>â <span class="NLM_lpage">1225</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.bmcl.2006.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=17196388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1221-1225&author=A.+Maiauthor=D.+Rotiliauthor=S.+Massaauthor=G.+Broschauthor=G.+Simonettiauthor=C.+Passarielloauthor=A.+T.+Palamara&title=Discovery+of+uracil-based+histone+deacetylase+inhibitors+able+to+reduce+acquired+antifungal+resistance+and+trailing+growth+in+Candida+albicans&doi=10.1016%2Fj.bmcl.2006.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans</span></div><div class="casAuthors">Mai, Antonello; Rotili, Dante; Massa, Silvio; Brosch, Gerald; Simonetti, Giovanna; Passariello, Claudio; Palamara, Anna Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1221-1225</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Among fungal pathogens such as Candida albicans, acquired drug resistance has not been assocd. with plasmids or other transferable elements, but it is thought to involve primarily mutations and genetic or epigenetic phenomena.  This the authors to test some histone deacetylase inhibitors (HDACi) from their library, in combination with fluconazole, against C. albicans strains in vitro.  Among the tested compds., the two chloro-contg. uracil-hydroxamates 1c and 1d showed a strong redn. of the MIC values on Candida strains that show the trailing growth effect.  In this assay, 1c,d were more potent than SAHA, a well-known HDAC inhibitor, in reducing the Candida growth.  Compds. 1c,d as well as SAHA were able to inhibit the fluconazole-induced resistance induction in Candida cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgG2dBVCiTN7Vg90H21EOLACvtfcHk0lh7M2zi-lcRCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjsL8%253D&md5=459aca01b82b284070f9bfe6229aca3b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DBrosch%26aufirst%3DG.%26aulast%3DSimonetti%26aufirst%3DG.%26aulast%3DPassariello%26aufirst%3DC.%26aulast%3DPalamara%26aufirst%3DA.%2BT.%26atitle%3DDiscovery%2520of%2520uracil-based%2520histone%2520deacetylase%2520inhibitors%2520able%2520to%2520reduce%2520acquired%2520antifungal%2520resistance%2520and%2520trailing%2520growth%2520in%2520Candida%2520albicans%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1221%26epage%3D1225%26doi%3D10.1016%2Fj.bmcl.2006.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span> <span> </span><span class="NLM_article-title">The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1993</span>â <span class="NLM_lpage">2003</span>, <span class="refDoi">Â DOI: 10.1093/jac/dkv070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1093%2Fjac%2Fdkv070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=25825380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OltbvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=1993-2003&author=X.+Liauthor=Q.+Caiauthor=H.+Meiauthor=X.+Zhouauthor=Y.+Shenauthor=D.+Liauthor=W.+Liu&title=The+Rpd3%2FHda1+family+of+histone+deacetylases+regulates+azole+resistance+in+Candida+albicans&doi=10.1093%2Fjac%2Fdkv070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans</span></div><div class="casAuthors">Li, Xiaofang; Cai, Qing; Mei, Huan; Zhou, Xiaowei; Shen, Yongnian; Li, Dongmei; Liu, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1993-2003</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: The histone deacetylase (HDAC) has recently been linked to the morphogenesis and virulence of yeast.  However, the effects of HDAC on antifungal susceptibility are not well understood.  We sought to characterize the action of histone deacetylation on azole resistance in Candida albicans and its possible mechanism of action.  Methods: A total of 40 C. albicans strains were studied.  Azole susceptibility with or without trichostatin A (TSA) was detd. according to the CLSI microdilution method.  The null mutants of HDA1 and RPD3 (genes targeted by TSA) were also investigated using drop-plate assays and a rapid acquisition of adaptation to the azole test.  Transcriptional levels of HDAC genes and efflux genes were quantified using RT-PCR for both the basal and fluconazole-induced conditions.  Results: The inhibition of HDACs by TSA (0.25 mg/L) markedly reduced the trailing growth and the growth of most C. albicans strains.  Trailing growth for C. albicans strains was decreased from 2-fold to 256-fold at 48 h.  The deletion of HDA1 or RPD3 increased the susceptibility to azoles compared with the WT strain.  The expression of HDA1 and RPD3 was up-regulated to different levels, and returned to the level of the susceptible parental strain when stable resistance had formed during the course of acquired fluconazole resistance both in vitro and in vivo.  Efflux genes were poorly expressed in mutant strains compared with those of the WT strain.  Conclusions: Our results indicate the important role of the Rpd3/Hda1 family in the development of azole resistance in C. albicans.  Histone deacetylation may govern the expression of genes related to the early stages of adaptation to azole stress, such as efflux pump genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvglqXcJdnsbVg90H21EOLACvtfcHk0lh7M2zi-lcRCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OltbvE&md5=34cf1e334db6d83f40c498cf9218eb8f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv070%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DThe%2520Rpd3%252FHda1%2520family%2520of%2520histone%2520deacetylases%2520regulates%2520azole%2520resistance%2520in%2520Candida%2520albicans%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2015%26volume%3D70%26spage%3D1993%26epage%3D2003%26doi%3D10.1093%2Fjac%2Fdkv070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">5296</span>â <span class="NLM_lpage">5304</span>, <span class="refDoi">Â DOI: 10.1021/pr9005074</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr9005074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOqtb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=5296-5304&author=Y.+Xuauthor=Y.+Wangauthor=L.+Yanauthor=R.+M.+Liangauthor=B.+D.+Daiauthor=R.+J.+Tangauthor=P.+H.+Gaoauthor=Y.+Y.+Jiang&title=Proteomic+analysis+reveals+a+synergistic+mechanism+of+fluconazole+and+berberine+against+fluconazole-resistant+Candida+albicans%3A+endogenous+ROS+augmentation&doi=10.1021%2Fpr9005074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: Endogenous ROS augmentation</span></div><div class="casAuthors">Xu, Yi; Wang, Yan; Yan, Lan; Liang, Rong-Mei; Dai, Bao-Di; Tang, Ren-Jie; Gao, Ping-Hui; Jiang, Yuan-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5296-5304</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A previous study showed that concomitant use of berberine (BBR) and fluconazole (FLC) provided a synergistic action against FLC-resistant Candida albicans (C. albicans) clin. strains in vitro.  To clarify the mechanism underlying this action, the authors performed a comparative proteomic study in untreated control cells and cells treated with FLC and/or BBR in 2 clin. strains of C. albicans resistant to FLC.  Their analyses identified 16 differentially expressed proteins, most of which were related to energy metab. (e.g., Gap1, Adh1, and Aco1).  Functional analyses revealed that FLC + BBR treatment increased mitochondrial membrane potential, decreased intracellular ATP level, inhibited ATP synthase activity, and increased generation of endogenous reactive oxygen species (ROS) in FLC-resistant strains.  In addn., checkerboard microdilution assay showed that addn. of antioxidant ascorbic acid or reduced glutathione reduced the synergistic antifungal activity of FLC + BBR significantly.  These results suggest that mitochondrial aerobic respiration shift and endogenous ROS augmentation contribute to the synergistic action of FLC + BBR against FLC-resistant C. albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe-555LzTQqLVg90H21EOLACvtfcHk0lhcF3fH07YljA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOqtb%252FE&md5=2240cc574a99bf927aa200b6dac3af7c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fpr9005074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr9005074%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DR.%2BM.%26aulast%3DDai%26aufirst%3DB.%2BD.%26aulast%3DTang%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DP.%2BH.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26atitle%3DProteomic%2520analysis%2520reveals%2520a%2520synergistic%2520mechanism%2520of%2520fluconazole%2520and%2520berberine%2520against%2520fluconazole-resistant%2520Candida%2520albicans%253A%2520endogenous%2520ROS%2520augmentation%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2009%26volume%3D8%26spage%3D5296%26epage%3D5304%26doi%3D10.1021%2Fpr9005074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odds, F. C.</span></span> <span> </span><span class="NLM_article-title">Synergy, antagonism, and what the chequerboard puts between them</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.1093/jac/dkg301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1093%2Fjac%2Fdkg301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=12805255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVWjsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=1&author=F.+C.+Odds&title=Synergy%2C+antagonism%2C+and+what+the+chequerboard+puts+between+them&doi=10.1093%2Fjac%2Fdkg301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy, antagonism, and what the chequerboard puts between them</span></div><div class="casAuthors">Odds, F. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVJ1xsH5KwLVg90H21EOLACvtfcHk0lhcF3fH07YljA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVWjsr0%253D&md5=b214be21ff21422856db140f8c4a0fd0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg301%26sid%3Dliteratum%253Aachs%26aulast%3DOdds%26aufirst%3DF.%2BC.%26atitle%3DSynergy%252C%2520antagonism%252C%2520and%2520what%2520the%2520chequerboard%2520puts%2520between%2520them%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D52%26spage%3D1%26doi%3D10.1093%2Fjac%2Fdkg301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordiyenko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, J. W.</span></span> <span> </span><span class="NLM_article-title">Class I HDACs share a common mechanism of regulation by inositol phosphates</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2013.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1016%2Fj.molcel.2013.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23791785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2013&pages=57-67&author=C.+J.+Millardauthor=P.+J.+Watsonauthor=I.+Celardoauthor=Y.+Gordiyenkoauthor=S.+M.+Cowleyauthor=C.+V.+Robinsonauthor=L.+Fairallauthor=J.+W.+Schwabe&title=Class+I+HDACs+share+a+common+mechanism+of+regulation+by+inositol+phosphates&doi=10.1016%2Fj.molcel.2013.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates</span></div><div class="casAuthors">Millard, Christopher J.; Watson, Peter J.; Celardo, Ivana; Gordiyenko, Yuliya; Cowley, Shaun M.; Robinson, Carol V.; Fairall, Louise; Schwabe, John W. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDAC1, HDAC2, and HDAC3) are recruited by cognate corepressor proteins into specific transcriptional repression complexes that target HDAC activity to chromatin resulting in chromatin condensation and transcriptional silencing.  The authors previously reported the structure of HDAC3 in complex with the SMRT corepressor.  This structure revealed inositol-tetraphosphate [Ins(1,4,5,6)P4] at the interface of the two proteins.  It was previously unclear whether the role of Ins(1,4,5,6)P4 is to act as a structural cofactor or a regulator of HDAC3 activity.  Here the authors report the structure of HDAC1 in complex with MTA1 from the NuRD complex.  The ELM2-SANT domains from MTA1 wrap completely around HDAC1 occupying both sides of the active site such that the adjacent BAH domain is ideally positioned to recruit nucleosomes to the active site of the enzyme.  Functional assays of both the HDAC1 and HDAC3 complexes reveal that Ins(1,4,5,6)P4 is a bona fide conserved regulator of class I HDAC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYPhL0103LkLVg90H21EOLACvtfcHk0lhcF3fH07YljA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVygu74%253D&md5=05a4267bf965b5a6217873217044ef2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DWatson%26aufirst%3DP.%2BJ.%26aulast%3DCelardo%26aufirst%3DI.%26aulast%3DGordiyenko%26aufirst%3DY.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DRobinson%26aufirst%3DC.%2BV.%26aulast%3DFairall%26aufirst%3DL.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%26atitle%3DClass%2520I%2520HDACs%2520share%2520a%2520common%2520mechanism%2520of%2520regulation%2520by%2520inositol%2520phosphates%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D51%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.molcel.2013.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulli, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrzanski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serdikoff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells-Knecht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5243</span>â <span class="NLM_lpage">5254</span>, <span class="refDoi">Â DOI: 10.1021/jm300248q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300248q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5243-5254&author=B.+J.+Duganauthor=D.+E.+Gingrichauthor=E.+F.+Mesarosauthor=K.+L.+Milkiewiczauthor=M.+A.+Curryauthor=A.+L.+Zulliauthor=P.+Dobrzanskiauthor=C.+Serdikoffauthor=M.+Janauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=J.+L.+Masonauthor=L.+D.+Aimoneauthor=S.+L.+Meyerauthor=Z.+Huangauthor=K.+J.+Wells-Knechtauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=A+selective%2C+orally+bioavailable+1%2C2%2C4-triazolo%5B1%2C5-a%5Dpyridine-based+inhibitor+of+Janus+kinase+2+for+use+in+anticancer+therapy%3A+discovery+of+CEP-33779&doi=10.1021%2Fjm300248q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm300248q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300248q%26sid%3Dliteratum%253Aachs%26aulast%3DDugan%26aufirst%3DB.%2BJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DZulli%26aufirst%3DA.%2BL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DSerdikoff%26aufirst%3DC.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DMason%26aufirst%3DJ.%2BL.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWells-Knecht%26aufirst%3DK.%2BJ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DA%2520selective%252C%2520orally%2520bioavailable%25201%252C2%252C4-triazolo%255B1%252C5-a%255Dpyridine-based%2520inhibitor%2520of%2520Janus%2520kinase%25202%2520for%2520use%2520in%2520anticancer%2520therapy%253A%2520discovery%2520of%2520CEP-33779%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5243%26epage%3D5254%26doi%3D10.1021%2Fjm300248q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>â <span class="NLM_lpage">10846</span>, <span class="refDoi">Â DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated Î±-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lhT2vFj-Uj82w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>â <span class="NLM_lpage">2589</span>, <span class="refDoi">Â DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.+C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+activity%2C+pharmacodynamic%2C+and+pharmacokinetic+properties+of+a+selective+HDAC6+inhibitor%2C+ACY-1215%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated Î±-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated Î±-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0lhT2vFj-Uj82w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.%2BC.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520activity%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520selective%2520HDAC6%2520inhibitor%252C%2520ACY-1215%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malvaez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuown, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogge, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astarabadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusche, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. A.</span></span> <span> </span><span class="NLM_article-title">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2647</span>â <span class="NLM_lpage">2652</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1213364110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1073%2Fpnas.1213364110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23297220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2647-2652&author=M.+Malvaezauthor=S.+C.+McQuownauthor=G.+A.+Roggeauthor=M.+Astarabadiauthor=V.+Jacquesauthor=S.+Carreiroauthor=J.+R.+Ruscheauthor=M.+A.+Wood&title=HDAC3-selective+inhibitor+enhances+extinction+of+cocaine-seeking+behavior+in+a+persistent+manner&doi=10.1073%2Fpnas.1213364110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span></div><div class="casAuthors">Malvaez, Melissa; McQuown, Susan C.; Rogge, George A.; Astarabadi, Mariam; Jacques, Vincent; Carreiro, Samantha; Rusche, James R.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2647-2652, S2647/1-S2647/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonspecific histone deacetylase (HDAC) inhibition has been shown to facilitate the extinction of drug-seeking behavior in a manner resistant to reinstatement.  A key open question is which specific HDAC is involved in the extinction of drug-seeking behavior.  Using the selective HDAC3 inhibitor RGFP966, we investigated the role of HDAC3 in extinction and found that systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement.  We also investigated whether the facilitated extinction is related to the enhancement of extinction consolidation during extinction learning or to neg. effects on performance or reconsolidation.  These are key distinctions with regard to any compd. being used to modulate extinction, because a more rapid decrease in a defined behavior is interpreted as facilitated extinction.  Using an innovative combination of behavioral paradigms, we found that a single treatment of RGFP966 enhances extinction of a previously established cocaine-conditioned place preference, while simultaneously enhancing long-term object-location memory within subjects.  During extinction consolidation, HDAC3 inhibition promotes a distinct pattern of histone acetylation linked to gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens.  Thus, the facilitated extinction of drug-seeking cannot be explained by adverse effects on performance.  These results demonstrate that HDAC3 inhibition enhances the memory processes involved in extinction of drug-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzdD0_EQYfrVg90H21EOLACvtfcHk0lhT2vFj-Uj82w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D&md5=37fd432cbf96bd2c30b7d5ac9eefcf45</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213364110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213364110%26sid%3Dliteratum%253Aachs%26aulast%3DMalvaez%26aufirst%3DM.%26aulast%3DMcQuown%26aufirst%3DS.%2BC.%26aulast%3DRogge%26aufirst%3DG.%2BA.%26aulast%3DAstarabadi%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DCarreiro%26aufirst%3DS.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHDAC3-selective%2520inhibitor%2520enhances%2520extinction%2520of%2520cocaine-seeking%2520behavior%2520in%2520a%2520persistent%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D2647%26epage%3D2652%26doi%3D10.1073%2Fpnas.1213364110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inks, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4325</span>â <span class="NLM_lpage">4338</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00317</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00317" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4325-4338&author=W.+Duanauthor=J.+Liauthor=E.+S.+Inksauthor=C.+J.+Chouauthor=Y.+Jiaauthor=X.+Chuauthor=X.+Liauthor=W.+Xuauthor=Y.+Zhang&title=Design%2C+synthesis%2C+and+antitumor+evaluation+of+novel+histone+deacetylase+inhibitors+equipped+with+a+phenylsulfonylfuroxan+module+as+a+nitric+oxide+donor&doi=10.1021%2Facs.jmedchem.5b00317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00317%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antitumor%2520evaluation%2520of%2520novel%2520histone%2520deacetylase%2520inhibitors%2520equipped%2520with%2520a%2520phenylsulfonylfuroxan%2520module%2520as%2520a%2520nitric%2520oxide%2520donor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4325%26epage%3D4338%26doi%3D10.1021%2Facs.jmedchem.5b00317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. Y.</span></span> <span> </span><span class="NLM_article-title">Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>â <span class="NLM_lpage">1354</span>, <span class="refDoi">Â DOI: 10.3892/ol.2017.6353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.3892%2Fol.2017.6353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=28789350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A280%3ADC%252BC1cflslSjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=1347-1354&author=K.+B.+Yoonauthor=S.+Y.+Choauthor=S.+J.+Anauthor=K.+R.+Parkauthor=H.+J.+Leeauthor=H.+S.+Yoonauthor=S.+M.+Leeauthor=Y.+C.+Kimauthor=S.+Y.+Han&title=Characterization+of+the+aminopyridine+derivative+KRC-180+as+a+JAK2+inhibitor&doi=10.3892%2Fol.2017.6353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor</span></div><div class="casAuthors">Yoon Kyoung Bin; An Su Jin; Park Kyeong Ryang; Lee Hyo Jeong; Yoon Hae Sung; Han Sun-Young; Cho Sung Yun; Lee Sun-Mi; Kim Yong-Chul</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1347-1354</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase that regulates the signal transducer and activator of transcription (STAT) signaling pathway.  Deregulation of JAK2 signaling has previously been observed in hematologic malignancies, including erythroleukemia.  In the present study, an aminopyridine derivative compound, KRC-180, exhibited direct inhibition of the JAK2 protein at the catalytic site, as demonstrated using in vitro kinase activity assays and docking analyses.  In addition, KRC-180 reduced the phosphorylation of STAT3 and STAT5, downstream signaling molecules of JAK2.  The growth of HEL92.1.7 erythroleukemia cells harboring a constitutively activated form of JAK2 was suppressed by KRC-180 treatment; KRC-180 induced apoptotic cell death and cell cycle arrest.  The results of the present study indicate that KRC-180 is a JAK2 inhibitor with anti-leukemic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEwJNzZ1NYL8uCWE5mhx1RfW6udTcc2ebZDb8ArYOFcbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cflslSjtQ%253D%253D&md5=3ac5819c6274b248e040fead84e62d3d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3892%2Fol.2017.6353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2017.6353%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DK.%2BB.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DAn%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DYoon%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DHan%26aufirst%3DS.%2BY.%26atitle%3DCharacterization%2520of%2520the%2520aminopyridine%2520derivative%2520KRC-180%2520as%2520a%2520JAK2%2520inhibitor%26jtitle%3DOncol.%2520Lett.%26date%3D2017%26volume%3D14%26spage%3D1347%26epage%3D1354%26doi%3D10.3892%2Fol.2017.6353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dijck, P.</span></span> <span> </span><span class="NLM_article-title">Recent insights into Candida albicans biofilm resistance mechanisms</span>. <i>Curr. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">264</span>, <span class="refDoi">Â DOI: 10.1007/s00294-013-0400-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1007%2Fs00294-013-0400-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=23974350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlarsrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2013&pages=251-264&author=L.+Matheauthor=P.+Van+Dijck&title=Recent+insights+into+Candida+albicans+biofilm+resistance+mechanisms&doi=10.1007%2Fs00294-013-0400-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Recent insights into Candida albicans biofilm resistance mechanisms</span></div><div class="casAuthors">Mathe, Lotte; Van Dijck, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Current Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-264</span>CODEN:
                <span class="NLM_cas:coden">CUGED5</span>;
        ISSN:<span class="NLM_cas:issn">0172-8083</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Like other microorganisms, free-living Candida albicans is mainly present in a three-dimensional multicellular structure, which is called a biofilm, rather than in a planktonic form.  Candida albicans biofilms can be isolated from both abiotic and biotic surfaces at various locations within the host.  As the no. of abiotic implants, mainly bloodstream and urinary catheters, has been increasing, the no. of biofilm-assocd. bloodstream or urogenital tract infections is also strongly increasing resulting in a raise in mortality.  Cells within a biofilm structure show a reduced susceptibility to specific commonly used antifungals and, in addn., it has recently been shown that such cells are less sensitive to killing by components of our immune system.  In this review, we summarize the most important insights in the mechanisms underlying biofilm-assocd. antifungal drug resistance and immune evasion strategies, focusing on the most recent advances in this area of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreVXKJ6shgObVg90H21EOLACvtfcHk0lgZUAUC6wz3Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlarsrbN&md5=3434aad13e43b2a2245f6fd163e5652b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00294-013-0400-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00294-013-0400-3%26sid%3Dliteratum%253Aachs%26aulast%3DMathe%26aufirst%3DL.%26aulast%3DVan%2BDijck%26aufirst%3DP.%26atitle%3DRecent%2520insights%2520into%2520Candida%2520albicans%2520biofilm%2520resistance%2520mechanisms%26jtitle%3DCurr.%2520Genet.%26date%3D2013%26volume%3D59%26spage%3D251%26epage%3D264%26doi%3D10.1007%2Fs00294-013-0400-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vila, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prousis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calogeropoulou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozental, S.</span></span> <span> </span><span class="NLM_article-title">Effect of alkylphospholipids on Candida albicans biofilm formation and maturation</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">113</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1093/jac/dks353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1093%2Fjac%2Fdks353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=22995097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVChsbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=113-125&author=T.+V.+Vilaauthor=K.+Ishidaauthor=W.+de+Souzaauthor=K.+Prousisauthor=T.+Calogeropoulouauthor=S.+Rozental&title=Effect+of+alkylphospholipids+on+Candida+albicans+biofilm+formation+and+maturation&doi=10.1093%2Fjac%2Fdks353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of alkylphospholipids on Candida albicans biofilm formation and maturation</span></div><div class="casAuthors">Vila, Taissa V. M.; Ishida, Kelly; de Souza, Wanderley; Prousis, Kyriakos; Calogeropoulou, Theodora; Rozental, Sonia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate miltefosine and four synthetic compds. (TCAN26, TC19, TC106 and TC117) for their in vitro inhibitory activity against Candida albicans planktonic and biofilm cells and investigate whether these compds. are able to inhibit the biofilm formation and to reduce the viability of mature C. albicans biofilm cells.  The XTT redn. assay and transmission and SEM were employed to det. the inhibitory effects of the test compds. in comparison with amphotericin B and fluconazole against both planktonic cells and sessile cells in biofilms.  C. albicans planktonic cells were susceptible to miltefosine, TCAN26 and TC19, all alkylphospholipid compds.  Miltefosine and TCAN26 present a fungicidal activity with similar values of MIC and min. fungicidal concn. (MFC), ranging from 2 to 8 mg/L.  Cell treatment with sub-inhibitory concns. of alkylphospholipids induced several ultrastructural alterations.  In relation to biofilms, miltefosine reduced formation (38%-71%) and mature biofilms viability (32%-44%), at concns. of 64 mg/L.  TCAN26 also reduced biofilm formation (24%-30%) and mature biofilm viability (15%-20%), at concns. of 64 mg/L.  Although amphotericin B reduced biofilm formation similarly to miltefosine (51%-74%), its activity was lower on mature biofilms (24%-30%).  Miltefosine antibiofilm activity was significantly higher than amphotericin B, on both formation and mature biofilms (P<0.05 and P<0.0001, resp.).  Fluconazole was the least effective compd. tested.  Promising antibiofilm activity was displayed by miltefosine and other alkylphosphocholine compds., which could be considered a putative option for future treatment of candidemia assocd. with biofilm formation, although further evaluation in in vivo systems is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJcArT64BgNrVg90H21EOLACvtfcHk0lgZUAUC6wz3Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVChsbbI&md5=019b83a645e547244a36263464b84d4a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdks353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdks353%26sid%3Dliteratum%253Aachs%26aulast%3DVila%26aufirst%3DT.%2BV.%26aulast%3DIshida%26aufirst%3DK.%26aulast%3Dde%2BSouza%26aufirst%3DW.%26aulast%3DProusis%26aufirst%3DK.%26aulast%3DCalogeropoulou%26aufirst%3DT.%26aulast%3DRozental%26aufirst%3DS.%26atitle%3DEffect%2520of%2520alkylphospholipids%2520on%2520Candida%2520albicans%2520biofilm%2520formation%2520and%2520maturation%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2013%26volume%3D68%26spage%3D113%26epage%3D125%26doi%3D10.1093%2Fjac%2Fdks353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">The discovery of novel antifungal scaffolds by structural simplification of the natural product sampangine</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">14648</span>â <span class="NLM_lpage">14651</span>, <span class="refDoi">Â DOI: 10.1039/C5CC05699C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1039%2FC5CC05699C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26289663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSnu7vO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=14648-14651&author=Z.+Jiangauthor=N.+Liuauthor=D.+Huauthor=G.+Dongauthor=Z.+Miaoauthor=J.+Yaoauthor=H.+Heauthor=Y.+Jiangauthor=W.+Zhangauthor=Y.+Wangauthor=C.+Sheng&title=The+discovery+of+novel+antifungal+scaffolds+by+structural+simplification+of+the+natural+product+sampangine&doi=10.1039%2FC5CC05699C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of novel antifungal scaffolds by structural simplification of the natural product sampangine</span></div><div class="casAuthors">Jiang, Zhigan; Liu, Na; Hu, Dandan; Dong, Guoqiang; Miao, Zhenyuan; Yao, Jianzhong; He, Haiying; Jiang, Yuanying; Zhang, Wannian; Wang, Yan; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">78</span>),
    <span class="NLM_cas:pages">14648-14651</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Natural products are important sources of therapeutic drugs.  However, it is a challenge to simplify the structure of natural products without decreasing the biol. activity.  Here we provide the first example of the successful simplification of an antifungal natural product.  Starting from sampangine, two novel simplified scaffolds with excellent antifungal activity were discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDQRLoWYoyu7Vg90H21EOLACvtfcHk0ljjJXAOg36ETQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSnu7vO&md5=82161572e5e8a6dcd2db7bb3e2f5e7e3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC5CC05699C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC05699C%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520of%2520novel%2520antifungal%2520scaffolds%2520by%2520structural%2520simplification%2520of%2520the%2520natural%2520product%2520sampangine%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D14648%26epage%3D14651%26doi%3D10.1039%2FC5CC05699C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppuluri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tristan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wormley, F. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Ribot, J. L.</span></span> <span> </span><span class="NLM_article-title">A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1494</span>â <span class="NLM_lpage">1500</span>, <span class="refDoi">Â DOI: 10.1038/nprot.2008.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fnprot.2008.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=18772877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsL7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1494-1500&author=C.+G.+Pierceauthor=P.+Uppuluriauthor=A.+R.+Tristanauthor=F.+L.+Wormleyauthor=E.+Mowatauthor=G.+Ramageauthor=J.+L.+Lopez-Ribot&title=A+simple+and+reproducible+96-well+plate-based+method+for+the+formation+of+fungal+biofilms+and+its+application+to+antifungal+susceptibility+testing&doi=10.1038%2Fnprot.2008.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing</span></div><div class="casAuthors">Pierce, Christopher G.; Uppuluri, Priya; Tristan, Amanda R.; Wormley, Floyd L, Jr.; Mowat, Eilidh; Ramage, Gordon; Lopez-Ribot, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1494-1500</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The incidence of fungal infections has increased significantly over the past decades.  Very often these infections are assocd. with biofilm formation on implanted biomaterials and/or host surfaces.  This has important clin. implications, as fungal biofilms display properties that are dramatically different from planktonic (free-living) populations, including increased resistance to antifungal agents.  Here the authors describe a rapid and highly reproducible 96-well microtiter-based method for the formation of fungal biofilms, which is easily adaptable for antifungal susceptibility testing.  This model is based on the ability of metabolically active sessile cells to reduce a tetrazolium salt (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide) to water-sol. orange formazan compds., the intensity of which can then be detd. using a microtiter-plate reader.  The entire procedure takes approx. 2 d to complete.  This technique simplifies biofilm formation and quantification, making it more reliable and comparable among different labs., a necessary step toward the standardization of antifungal susceptibility testing of biofilms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1U1dGFsZzB7Vg90H21EOLACvtfcHk0ljjJXAOg36ETQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsL7L&md5=68b5e3690b61f93cbe05d6736b3a5460</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2008.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2008.141%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DC.%2BG.%26aulast%3DUppuluri%26aufirst%3DP.%26aulast%3DTristan%26aufirst%3DA.%2BR.%26aulast%3DWormley%26aufirst%3DF.%2BL.%26aulast%3DMowat%26aufirst%3DE.%26aulast%3DRamage%26aufirst%3DG.%26aulast%3DLopez-Ribot%26aufirst%3DJ.%2BL.%26atitle%3DA%2520simple%2520and%2520reproducible%252096-well%2520plate-based%2520method%2520for%2520the%2520formation%2520of%2520fungal%2520biofilms%2520and%2520its%2520application%2520to%2520antifungal%2520susceptibility%2520testing%26jtitle%3DNat.%2520Protoc.%26date%3D2008%26volume%3D3%26spage%3D1494%26epage%3D1500%26doi%3D10.1038%2Fnprot.2008.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">16228</span>, <span class="refDoi">Â DOI: 10.1038/srep16228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fsrep16228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=26538086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyht7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=16228&author=X.+Liauthor=H.+Guoauthor=H.+Duanauthor=Y.+Yangauthor=J.+Mengauthor=J.+Liuauthor=C.+Wangauthor=H.+Xu&title=Improving+chemotherapeutic+efficiency+in+acute+myeloid+leukemia+treatments+by+chemically+synthesized+peptide+interfering+with+CXCR4%2FCXCL12+axis&doi=10.1038%2Fsrep16228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis</span></div><div class="casAuthors">Li, Xiaojin; Guo, Hua; Duan, Hongyang; Yang, Yanlian; Meng, Jie; Liu, Jian; Wang, Chen; Xu, Haiyan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16228</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bone marrow stroma can protect acute myeloid leukemia (AML) cells against chemotherapeutic agents and provide anti-apoptosis and chemoresistance signals through secreting chemokine CXCL12 to activate its receptor CXCR4 on AML cells, resulting in minimal residual leukemia and relapse.  Therefore disrupting the CXCR4/CXCL12 axis with antagonists is of great significance for improving chemosensitivity and decreasing relapse rate.  In a previous study, we reported a novel synthetic peptide E5 with its remarkable effect on inhibiting CXCR4/CXCL12-mediated adhesion and migration of AML cells.  Here we presented E5's capacity of enhancing the therapeutic efficiency of various chemotherapeutics on AML in vitro and in vivo.  Results showed that E5 can diminish bone marrow stromal cell-provided protection to leukemia cells, significantly increasing the apoptosis induced by various chemotherapeutics in multiple AML cell lines.  In an AML mouse xenograft model, E5 induced 1.84-fold increase of circulating AML cells out of protective stroma niche.  Combined with vincristine or cyclophosphamide, E5 inhibited infiltration of AML cells into bone marrow, liver and spleen, as well as prolonged the lifespan of AML mice compared with mice treated with chemotherapy alone.  In addn., E5 presented no toxicity in vivo according to the histol. anal. and routine clin. parameters of serum anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCtpZKoFF0Y7Vg90H21EOLACvtfcHk0ljjJXAOg36ETQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyht7nI&md5=1ef094355b4298ad8bf3fe1adf4ba10f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fsrep16228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep16228%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DImproving%2520chemotherapeutic%2520efficiency%2520in%2520acute%2520myeloid%2520leukemia%2520treatments%2520by%2520chemically%2520synthesized%2520peptide%2520interfering%2520with%2520CXCR4%252FCXCL12%2520axis%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D16228%26doi%3D10.1038%2Fsrep16228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Z.</span></span> <span> </span><span class="NLM_article-title">LG-362B targets PML-RARalpha and blocks ATRA resistance of acute promyelocytic leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1465</span>â <span class="NLM_lpage">1474</span>, <span class="refDoi">Â DOI: 10.1038/leu.2016.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1038%2Fleu.2016.50" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1465-1474&author=X.+Wangauthor=Q.+Linauthor=F.+Lvauthor=N.+Liuauthor=Y.+Xuauthor=M.+Liuauthor=Y.+Chenauthor=Z.+Yi&title=LG-362B+targets+PML-RARalpha+and+blocks+ATRA+resistance+of+acute+promyelocytic+leukemia&doi=10.1038%2Fleu.2016.50"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.50%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYi%26aufirst%3DZ.%26atitle%3DLG-362B%2520targets%2520PML-RARalpha%2520and%2520blocks%2520ATRA%2520resistance%2520of%2520acute%2520promyelocytic%2520leukemia%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D1465%26epage%3D1474%26doi%3D10.1038%2Fleu.2016.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1096</span>â <span class="NLM_lpage">1099</span>, <span class="refDoi">Â DOI: 10.1128/AAC.50.3.1096-1099.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=10.1128%2FAAC.50.3.1096-1099.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=16495278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFamurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1096-1099&author=H.+Quanauthor=Y.+Y.+Caoauthor=Z.+Xuauthor=J.+X.+Zhaoauthor=P.+H.+Gaoauthor=X.+F.+Qinauthor=Y.+Y.+Jiang&title=Potent+in+vitro+synergism+of+fluconazole+and+berberine+chloride+against+clinical+isolates+of+Candida+albicans+resistant+to+fluconazole&doi=10.1128%2FAAC.50.3.1096-1099.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole</span></div><div class="casAuthors">Quan, Hua; Cao, Ying-Ying; Xu, Zheng; Zhao, Jing-Xia; Gao, Ping-Hui; Qin, Xiao-Feng; Jiang, Yuan-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1096-1099</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In vitro interaction of fluconazole and berberine chloride was investigated against 40 fluconazole-resistant clin. isolates of Candida albicans.  Synergism in fungistatic activity was found with the checkerboard microdilution assay.  The findings of agar diffusion tests and time-kill curves confirmed the synergistic interaction, but no antagonistic action was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGiBzNAvJqirVg90H21EOLACvtfcHk0lgcpG-YfiZ2nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFamurw%253D&md5=9a0007a890ccae954ec4d625ef7dc595</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FAAC.50.3.1096-1099.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.50.3.1096-1099.2006%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DY.%2BY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DJ.%2BX.%26aulast%3DGao%26aufirst%3DP.%2BH.%26aulast%3DQin%26aufirst%3DX.%2BF.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26atitle%3DPotent%2520in%2520vitro%2520synergism%2520of%2520fluconazole%2520and%2520berberine%2520chloride%2520against%2520clinical%2520isolates%2520of%2520Candida%2520albicans%2520resistant%2520to%2520fluconazole%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D1096%26epage%3D1099%26doi%3D10.1128%2FAAC.50.3.1096-1099.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX','PDB','4BKX'); return false;">PDB: 4BKX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AQC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AQC','PDB','4AQC'); return false;">PDB: 4AQC</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i59"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00393">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18580"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00393">10.1021/acs.jmedchem.8b00393</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figures showing the proposed binding mode, the change of body weight, a picture of dissected spleens, experimental structures, cell cycle analysis, selective HDAC inhibitors, therapeutic efficacy, and HPLC spectra. Tables showing inhibitory analysis, anti-cancer activities, antifungal activities, and synergistic effects. Experimental protocols, structural characterization, molecular docking, determination of metabolic stability, and pharmacokinetic studies. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the target compounds. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_001.pdf">jm8b00393_si_001.pdf (1.27 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00393/suppl_file/jm8b00393_si_002.csv">jm8b00393_si_002.csv (1.66 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-14%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00393%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00393" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667979c1db0323f8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
